"name","brand_name","application_number","Action_Date","submission_class_code_description","New_Ind_in_Skin_Ca_Y_N","Indication_brief","Dz","N","substance_name","generic_name","manufacturer_name","marketing_status","reference_drug","product_number","dosage_form","route","strength","submission_number","submission_status","submission_type","submission_status_date","review_priority","submission_class_code","Subjects_Enrolled","Drug_Approval","BLA_NDA","Indication","Notes","Trial","Endpoint","END","Endpoint_shortened","EndpointNum","EE Var","EE Raw","Effect_Estimate","Major Efficacy Outcome Measure","Hazard_Ratio","Response_Rate","lb_95CI_proposed","lb_95CI","ub_95CI","Tool","Toolshort","ToolNum","Subm_Class_Skin_Confirmed_yes_no","NTE_Skin_confirmed","SingleArmNum_N_Y","RR_used_n_y","Placebo_Controlled_Trial","Comparator_Study_Placebo_Observation_or_Active_Comparator_N_Y","Regular_Approval","Accelerated_Approval","RANum","Mechanism","Mechanism_long","Mechanistic_Class","DESI_Drug","Other"
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2011-08-19,"Type 1 - New Molecular Entity",NA,"HL and sALCL","HL and sALCL",NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","1","AP","ORIG",2011-08-19,"PRIORITY","TYPE 1",NA,NA,NA,"The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2011-08-19,"Efficacy",NA,NA,NA,NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","6","AP","SUPPL",2011-08-19,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2012-01-13,"Labeling",NA,NA,NA,NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","11","AP","SUPPL",2012-01-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2012-01-13,"Labeling",NA,NA,NA,NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","5","AP","SUPPL",2012-01-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2013-08-19,"Labeling",NA,NA,NA,NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","45","AP","SUPPL",2013-08-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2014-11-23,"Labeling",NA,NA,NA,NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","56","AP","SUPPL",2014-11-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2014-11-23,"Labeling",NA,NA,NA,NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","78","AP","SUPPL",2014-11-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2015-08-17,"Efficacy",NA,"HL post auto-HSCT","HL",NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","80","AP","SUPPL",2015-08-17,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation based on the final study report from Study SGN35-005",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2015-08-17,"Labeling",NA,NA,NA,NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","81","AP","SUPPL",2015-08-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2016-03-04,"Labeling",NA,NA,NA,NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","84","AP","SUPPL",2016-03-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2016-09-28,"Labeling",NA,NA,NA,NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","88","AP","SUPPL",2016-09-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2017-11-09,"Efficacy","Yes","CD30+ MF and pcALCL in the second line","CTCL","128","BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","94","AP","SUPPL",2017-11-09,"PRIORITY","EFFICACY","128|
(T=66|
C=62)","Brentuximab vedotin (ADCETRIS™)","BLA125388","A new indication for adult patients with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides who have received prior systemic therapy","Did of breakthrough not confirmed, but around 11/10/19","A randomized, open-label, multicenter clinical trial ADCETRIS vs. mtx or bexarotene","Objective Response Rate(Durable ≥4 mo(ORR4))(Prim)
CR rate/PFS (Sec)","DRR","Durable Response Rate",8,"DRR4 Diff","56.3% vs. 12.5%","43.8","RR: 56.3%",NA,"RR: 56.3%",NA,NA,NA,"Global Response Criteria","GRS","9","Yes",0,0,"1",0,1,"Yes","No","1","CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2018-03-20,"Efficacy",NA,"untreated HL","HL",NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","97","AP","SUPPL",2018-03-20,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma, in combination with chemotherapy",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2018-11-16,"Efficacy",NA,"PTCL and sALCL","PTCL",NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","99","AP","SUPPL",2018-11-16,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including
angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"BRENTUXIMAB VEDOTIN","ADCETRIS","BLA125388",2019-10-15,"Labeling",NA,NA,NA,NA,"BRENTUXIMAB VEDOTIN","BRENTUXIMAB VEDOTIN","SEAGEN INC.","Prescription","No","001","INJECTABLE","INJECTION","50MG/VIAL","100","AP","SUPPL",2019-10-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CD30 Ab","CD30 Targeted Antibody","Targeted Therapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",1997-02-27,"Type 1 - New Molecular Entity",NA,"Genital Warts",NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","1","AP","ORIG",1997-02-27,"STANDARD","TYPE 1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",1997-11-07,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","2","AP","SUPPL",1997-11-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",1997-12-08,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","3","AP","SUPPL",1997-12-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",1998-02-20,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","4","AP","SUPPL",1998-02-20,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2000-03-07,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","6","AP","SUPPL",2000-03-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2000-03-07,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","7","AP","SUPPL",2000-03-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2000-09-27,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","8","AP","SUPPL",2000-09-27,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2001-03-28,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","9","AP","SUPPL",2001-03-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2001-12-08,"Labeling",NA,"Genital Warts",NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","1","AP","SUPPL",2001-12-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2002-09-03,"Labeling",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","11","AP","SUPPL",2002-09-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2002-09-03,"Labeling",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","12","AP","SUPPL",2002-09-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2002-12-15,"Labeling",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","10","AP","SUPPL",2002-12-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2004-03-02,"Efficacy","Yes","Nonhypertrophic Actinic Keratoses on the Face or Scalp","AK","436","IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","15","AP","SUPPL",2004-03-02,"STANDARD","EFFICACY","436|
(T=215|
C=221)","Imiquimod 5% Cream (ALDARA™)","NDA020723","Aldara Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults.",NA,"In two double-blind, vehicle-controlled clinical studies, 436 patients with actinic keratosis (AK) were treated with Aldara Cream or vehicle cream 2 times per week for 16 weeks","Complete Clearance Rate at 8 weeks post treatment","CCR","Complete Clearance Rate",5,"RR diff","CRR 45.1% (97/215) vs. 3.2% (7/221)","41.9","CRR: 46% (Study A) |
CCR: 44% (Study B)",NA,"CRR: 46% (Study A) |
CCR: 44% (Study B)",NA,NA,NA,"Investigator Assessment of 25 cm2 area","Clinical","1","Yes",0,0,"1",1,1,"Yes","No","1","TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2004-07-14,"Efficacy","Yes","Superficial Basal Cell Carcinoma","BCC","364","IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","16","AP","SUPPL",2004-07-14,"UNKNOWN","EFFICACY","364|
(T=185|
C=179)","Imiquimod 5% Cream (ALDARA™)","NDA020723","Aldara Cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured. The histological diagnosis of superficial basal cell carcinoma should be established prior to treatment, since safety and effectiveness of Aldara Cream have not been established for other types of basal cell carcinomas, including nodular, morpheaform (fibrosing or sclerosing) types.","Although there is a link to a ""review"" it does not provide the documents, only the labeling info","In two double-blind, vehicle-controlled clinical studies, 364 patients with primary superficial
basal cell carcinoma (sBCC) were treated with Aldara Cream or vehicle cream 5X/week for 6
weeks","Complete Clearance Rate at 12 weeks post treatment","CCR","Complete Clearance Rate",5,"RR diff","CRR: 75% (139/185) vs. 2% (3/177) TYPO!!! Should be 179 but irrelevant since I am splitting apart","73","CCR: 70% (Study C) |
CCR: 80% (Study D)",NA,"CCR: 70% (Study C) |
CCR: 80% (Study D)",NA,NA,NA,"Composite Endpoint(clinical and histologic)","Composite","6","Yes",0,0,"1",1,1,"Yes","No","1","TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2005-08-09,"Labeling",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","18","AP","SUPPL",2005-08-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2007-03-22,"Efficacy",NA,"Updated safety data in pediatric population",NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","20","AP","SUPPL",2007-03-22,"PRIORITY","EFFICACY",NA,NA,NA,"This new drug application provides for the addition of pediatric safety data in the INDICATIONS and USAGE and USE IN SPECIFIC POPULATIONS:",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2010-10-14,"Labeling",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","22","AP","SUPPL",2010-10-14,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2014-11-26,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","25","AP","SUPPL",2014-11-26,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ALDARA","NDA020723",2015-02-03,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","Bausch Health US LLC","Prescription","Yes","001","CREAM","TOPICAL","5%","26","AP","SUPPL",2015-02-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","AMELUZ","NDA208081",2016-05-10,"Type 3 - New Dosage Form","Yes","Actinic keratoses of mild-to-moderate severity on the face and scalp","AK","299","AMINOLEVULINIC ACID HYDROCHLORIDE","AMINOLEVULINIC ACID HYDROCHLORIDE","Biofrontera Inc.","Prescription","Yes","001","GEL","TOPICAL","10%","1","AP","ORIG",2016-05-10,"STANDARD","TYPE 3","299|
(T=212|
C=87)","Aminolevulinic HCL 10% Gel (AMELUZ®)","NDA208081","AMELUZ gel, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED lamp, is indicated for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp",NA,"Three randomized, multicenter trials (Trials 1, 2, and 3). Trials 2 and 3 were vehicle-controlled and double-blind","Complete Clearance Rate at 12 Weeks","CCR","Complete Response Rate",5,NA,"Trial 1 - 106/125 (85%) |
Trial 2 - 27/32 (84%) |
Trial 3 - 50/55 (91%)",NA,"CCR: 85% (Trial 1) |
CCR: 84% (Trial 2) |
CCR: 91% (Trial 3)",NA,"CCR: 85% (Trial 1) |
CCR: 84% (Trial 2) |
CCR: 91% (Trial 3)",NA,NA,NA,"Investigator Assessment","Clinical","1",NA,NA,0,"1",1,1,"Yes","No","1","Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","AMELUZ","NDA208081",2017-09-06,"Labeling",NA,NA,NA,NA,"AMINOLEVULINIC ACID HYDROCHLORIDE","AMINOLEVULINIC ACID HYDROCHLORIDE","Biofrontera Inc.","Prescription","Yes","001","GEL","TOPICAL","10%","2","AP","SUPPL",2017-09-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","AMELUZ","NDA208081",2021-05-25,"Labeling",NA,NA,NA,NA,"AMINOLEVULINIC ACID HYDROCHLORIDE","AMINOLEVULINIC ACID HYDROCHLORIDE","Biofrontera Inc.","Prescription","Yes","001","GEL","TOPICAL","10%","11","AP","SUPPL",2021-05-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",1957-12-03,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","1","AP","ORIG",1957-12-03,"PRIORITY","TYPE 1",NA,"Triamcinolone (ARISTOCORT®)","NDA011161","Mycosis Fungoides","DESI Drug; efficacy not confirmed",NA,NA,"Missing",NA,NA,NA,"PI unavailable",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Tablet"
"TRIAMCINOLONE","ARISTOCORT","NDA011161",1979-08-06,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","40","AP","SUPPL",1979-08-06,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",1981-04-27,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","42","AP","SUPPL",1981-04-27,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",1982-06-11,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","43","AP","SUPPL",1982-06-11,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",1986-09-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","46","AP","SUPPL",1986-09-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",1986-11-29,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","45","AP","SUPPL",1986-11-29,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",1993-09-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","49","AP","SUPPL",1993-09-07,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",1994-03-30,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","48","AP","SUPPL",1994-03-30,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",1994-10-18,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","50","AP","SUPPL",1994-10-18,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",1999-09-17,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","51","AP","SUPPL",1999-09-17,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",2009-03-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","39","AP","SUPPL",2009-03-13,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",2009-03-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","44","AP","SUPPL",2009-03-13,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE","ARISTOCORT","NDA011161",2009-03-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","009","TABLET","ORAL","2MG, 4MG, 1MG, 16MG, 8MG","47","AP","SUPPL",2009-03-13,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",1959-03-12,"Type 2 - New Active Ingredient","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","1","AP","ORIG",1959-03-12,"STANDARD","TYPE 2",NA,"Triamcinolone Diacetate (ARISTOCORT®)","NDA011685","Mycosis Fungoides","PI available and reviewed 12-16-18",NA,NA,"Missing",NA,NA,NA,"Not listed in PI",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Injectable"
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",1980-10-06,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","12","AP","SUPPL",1980-10-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",1989-10-12,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","16","AP","SUPPL",1989-10-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",1992-02-06,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","14","AP","SUPPL",1992-02-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",1992-02-06,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","19","AP","SUPPL",1992-02-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",1992-11-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","18","AP","SUPPL",1992-11-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",1993-09-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","20","AP","SUPPL",1993-09-07,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",1994-08-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","21","AP","SUPPL",1994-08-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",1995-11-09,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","22","AP","SUPPL",1995-11-09,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",1999-10-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","23","AP","SUPPL",1999-10-25,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",2001-08-29,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","24","AP","SUPPL",2001-08-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA011685",2014-07-03,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML","26","AP","SUPPL",2014-07-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1961-09-05,"Type 5 - New Formulation or New Manufacturer","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","1","AP","ORIG",1961-09-05,"STANDARD","TYPE 5",NA,"Triamcinolone Diacetate (ARISTOCORT®)","NDA012802","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet; label could not be found, thus, I'm assuming indication includes MF, as other formulations do so generically",NA,NA,"Missing",NA,NA,NA,"Not listed in PI",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","IM injection"
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1980-10-03,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","13","AP","SUPPL",1980-10-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1989-10-12,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","19","AP","SUPPL",1989-10-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1992-01-06,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","23","AP","SUPPL",1992-01-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1992-01-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","21","AP","SUPPL",1992-01-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1992-02-06,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","17","AP","SUPPL",1992-02-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1992-11-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","22","AP","SUPPL",1992-11-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1993-09-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","24","AP","SUPPL",1993-09-07,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1994-08-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","25","AP","SUPPL",1994-08-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1995-11-09,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","26","AP","SUPPL",1995-11-09,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",1999-10-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","27","AP","SUPPL",1999-10-25,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",2001-08-29,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","28","AP","SUPPL",2001-08-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",2003-01-17,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","14","AP","SUPPL",2003-01-17,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",2003-01-17,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","16","AP","SUPPL",2003-01-17,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",2010-01-14,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","31","AP","SUPPL",2010-01-14,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",2014-07-03,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","33","AP","SUPPL",2014-07-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE DIACETATE","ARISTOCORT","NDA012802",2014-09-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","32","AP","SUPPL",2014-09-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"AVELUMAB","BAVENCIO","BLA761049",2017-03-23,"Type 1 - New Molecular Entity","Yes","Metastatic Merkel Cell Carcinoma","MCC","88","AVELUMAB","AVELUMAB","EMD Serono, Inc.","Prescription","No","001","INJECTABLE","INJECTION","20MG/ML","1","AP","ORIG",2017-03-23,"PRIORITY","TYPE 1","88","Avelumab (BAVENCIO®)","BLA761049","BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC)","Null hypothesis of RR of 20% can be found on page 76 of the medical review","The efficacy and safety of BAVENCIO was demonstrated in the JAVELIN Merkel 200 trial (NCT02155647), an open-label, single-arm, multi-center study conducted in patients with histologically confirmed metastatic MCC whose disease had progressed on or after chemotherapy administered for distant metastatic disease","Overall Response Rate","ORR","Overall Response Rate",0,"RR diff","33% (29/88) vs. 20%","13","RR: 33%",NA,"RR: 33%","20","23.3","43.8","RECIST","RECIST","3","Yes",1,1,"1",0,0,"No","Yes","0","PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"AVELUMAB","BAVENCIO","BLA761049",2017-04-25,"Labeling",NA,NA,NA,NA,"AVELUMAB","AVELUMAB","EMD Serono, Inc.","Prescription","No","001","INJECTABLE","INJECTION","20MG/ML","1","AP","SUPPL",2017-04-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"AVELUMAB","BAVENCIO","BLA761049",2017-10-12,"Labeling",NA,"Replacement letter with the approved labeling",NA,NA,"AVELUMAB","AVELUMAB","EMD Serono, Inc.","Prescription","No","001","INJECTABLE","INJECTION","20MG/ML","2","AP","SUPPL",2017-10-12,"STANDARD","LABELING",NA,NA,NA,"Supplement approval letter which inadvertently did not include, as an attachment, the Content of Labeling enclosure. Therefore, we are issuing this replacement letter with the approved labeling attached.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"AVELUMAB","BAVENCIO","BLA761049",2018-10-19,"Efficacy",NA,"Dosing change from 10 mg/kg to 800 mg",NA,NA,"AVELUMAB","AVELUMAB","EMD Serono, Inc.","Prescription","No","001","INJECTABLE","INJECTION","20MG/ML","3","AP","SUPPL",2018-10-19,"STANDARD","EFFICACY",NA,NA,NA,"Convert from a weight-based dose regimen of 10 mg/kg every two weeks to a
flat dose regimen of 800 mg every two weeks.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"AVELUMAB","BAVENCIO","BLA761049",2019-05-14,"Efficacy",NA,"A new indication for RCC with Inlyta","RCC",NA,"AVELUMAB","AVELUMAB","EMD Serono, Inc.","Prescription","No","001","INJECTABLE","INJECTION","20MG/ML","6","AP","SUPPL",2019-05-14,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for Bavencio® (avelumab) in combination with Inlyta® (axitinib) for first-line treatment of patients with advanced renal cell carcinoma (RCC).",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"AVELUMAB","BAVENCIO","BLA761049",2020-06-30,"Efficacy",NA,"A new indication for Urothelial carcinoma","UC",NA,"AVELUMAB","AVELUMAB","EMD Serono, Inc.","Prescription","No","001","INJECTABLE","INJECTION","20MG/ML","9","AP","SUPPL",2020-06-30,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"AVELUMAB","BAVENCIO","BLA761049",2020-11-10,"Labeling",NA,NA,NA,NA,"AVELUMAB","AVELUMAB","EMD Serono, Inc.","Prescription","No","001","INJECTABLE","INJECTION","20MG/ML","5","AP","SUPPL",2020-11-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"AVELUMAB","BAVENCIO","BLA761049",2022-07-15,"Efficacy",NA,NA,NA,NA,"AVELUMAB","AVELUMAB","EMD Serono, Inc.","Prescription","No","001","INJECTABLE","INJECTION","20MG/ML","13","AP","SUPPL",2022-07-15,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ENCORAFENIB","BRAFTOVI","NDA210496",2018-06-27,"Type 1 - New Molecular Entity and Type 4 - New Combination","Yes","Regular Approval for use in combination with binimetinib for advanced BRAF mutant melanoma","Melanoma","577","ENCORAFENIB","ENCORAFENIB","Array BioPharma Inc.","Discontinued","Yes","001","CAPSULE","ORAL","50MG, 75MG","1","AP","ORIG",2018-06-27,"STANDARD","TYPE 1/4","577|
(Bin/Enc=192|
Enc=192|
Vem=191)","Encorafenib (BRAFTOVI™) in combination with Binimetinib","NDA210496","BRAFTOVI is a kinase inhibitor indicated, in combination with
binimetinib, for the treatment of patients with unresectable or metastatic
melanoma with a BRAF V600E or V600K mutation, as detected by an
FDA-approved test.",NA,"BRAFTOVI in combination with binimetinib was evaluated in a randomized, active-controlled, open-label, multicenter trial (COLUMBUS; NCT01909453).","Progression-Free Survival (Prim)
ORR/OS/DOR(Sec)","PFS","Progression-Free Survival",2,"HR","14.9 vs. 7.3 mo","0.54","HR: 0.54","HR: 0.54",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",1,0,"0",0,1,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"ENCORAFENIB","BRAFTOVI","NDA210496",2019-01-23,"Efficacy",NA,"Update label to include OS data","Melanoma","383","ENCORAFENIB","ENCORAFENIB","Array BioPharma Inc.","Discontinued","Yes","001","CAPSULE","ORAL","50MG, 75MG","1","AP","SUPPL",2019-01-23,"STANDARD","EFFICACY","383|
(T=192|
C=191)","Encorafenib (BRAFTOVI™) in combination with Binimetinib","NDA210496","To update U.S. prescribing information to include updated overall survival (OS) data from Part 1 of COLUMBUS trial (Study CMEK162B2301)","Label update with OS data - Label has N = 192 and N = 191 for Enco/Bini and Vem, respectively","Columbus Trial","Overall Survival","OS","Overall Survival",3,"HR",NA,"0.61","HR: 0.61","HR: 0.61",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"0",0,1,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"ENCORAFENIB","BRAFTOVI","NDA210496",2019-05-24,"Efficacy",NA,"Dose reduction recommendation for co-use with CYP3A4",NA,NA,"ENCORAFENIB","ENCORAFENIB","Array BioPharma Inc.","Discontinued","Yes","001","CAPSULE","ORAL","50MG, 75MG","3","AP","SUPPL",2019-05-24,"STANDARD","EFFICACY",NA,NA,NA,"Provides for modifications to
Table 1 entitled Recommended Dose Reductions with BRAFTOVI in the DOSAGE AND ADMINISTRATION, Dose Modifications for Adverse Reactions (2.3) subsection and to
the Dose Modifications for Coadministration with Strong or Moderate CYP3A4 Inhibitors",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"ENCORAFENIB","BRAFTOVI","NDA210496",2020-04-08,"Efficacy",NA,"New Indication in BRAF mutant colon cancer","Colon Cancer",NA,"ENCORAFENIB","ENCORAFENIB","Array BioPharma Inc.","Discontinued","Yes","001","CAPSULE","ORAL","50MG, 75MG","6","AP","SUPPL",2020-04-08,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for Braftovi, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"ENCORAFENIB","BRAFTOVI","NDA210496",2022-02-11,"Labeling",NA,NA,NA,NA,"ENCORAFENIB","ENCORAFENIB","Array BioPharma Inc.","Discontinued","Yes","001","CAPSULE","ORAL","50MG, 75MG","13","AP","SUPPL",2022-02-11,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"FLUOROURACIL","CARAC","NDA020985",2000-10-27,"Type 3 - New Dosage Form","Yes","Multiple Actinic Keratoses of the Face and Anterior Scalp","AK","384","FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","001","CREAM","TOPICAL","0.5%","1","AP","ORIG",2000-10-27,"STANDARD","TYPE 3","384|
(T=257|
C=127)","5-Fluorouracil 0.5% Cream (CARAC™)","NDA020985","Carac is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.",NA,"Two Phase 3 identically designed, multi-center, vehicle-controlled, double-blind studies with three treatment courses were conducted to evaluate the clinical safety and efficacy of Carac.","Complete Clearance Rate 4 weeks after treatment termination","CCR","Complete Clearance Rate",5,"RR diff","CRR 48% (41/85) with 4-weeek Tx vs. 2% (2/127)","46","CCR: 58% (Study 1) |
CCR: 38% (Study 2)",NA,"CCR: 58% (Study 1) |
CCR: 38% (Study 2)",NA,NA,NA,"Investigator Assessment","Clinical","1","Yes",0,0,"1",1,1,"Yes","No","1","Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,"I included all the patients from the three time points, not just the 4 week treatment course, thus, there 384 patients in total"
"FLUOROURACIL","CARAC","NDA020985",2001-01-29,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","001","CREAM","TOPICAL","0.5%","1","AP","SUPPL",2001-01-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","CARAC","NDA020985",2001-07-02,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","001","CREAM","TOPICAL","0.5%","2","AP","SUPPL",2001-07-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","CARAC","NDA020985",2002-11-15,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","001","CREAM","TOPICAL","0.5%","3","AP","SUPPL",2002-11-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","CARAC","NDA020985",2003-12-16,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","001","CREAM","TOPICAL","0.5%","4","AP","SUPPL",2003-12-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","CARAC","NDA020985",2014-11-20,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","001","CREAM","TOPICAL","0.5%","16","AP","SUPPL",2014-11-20,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","CARAC","NDA020985",2015-04-29,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","001","CREAM","TOPICAL","0.5%","17","AP","SUPPL",2015-04-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","CARAC","NDA020985",2022-05-26,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","001","CREAM","TOPICAL","0.5%","19","AP","SUPPL",2022-05-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1961-04-17,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","1","AP","ORIG",1961-04-17,"STANDARD","TYPE 1",NA,"Betamethasone (CELESTONE)","NDA012657","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,NA,"Missing",NA,NA,NA,"PI unavailable",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Tablet"
"BETAMETHASONE","CELESTONE","NDA012657",1978-11-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","5","AP","SUPPL",1978-11-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1979-07-23,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","7","AP","SUPPL",1979-07-23,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1979-10-03,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","6","AP","SUPPL",1979-10-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1981-04-11,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","10","AP","SUPPL",1981-04-11,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1982-06-30,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","12","AP","SUPPL",1982-06-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1982-11-23,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","14","AP","SUPPL",1982-11-23,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1983-04-26,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","13","AP","SUPPL",1983-04-26,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1986-10-20,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","15","AP","SUPPL",1986-10-20,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1987-04-02,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","16","AP","SUPPL",1987-04-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1992-12-17,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","17","AP","SUPPL",1992-12-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1993-09-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","18","AP","SUPPL",1993-09-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1994-04-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","20","AP","SUPPL",1994-04-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1994-08-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","19","AP","SUPPL",1994-08-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1996-09-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","21","AP","SUPPL",1996-09-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1997-05-07,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","23","AP","SUPPL",1997-05-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1998-03-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","24","AP","SUPPL",1998-03-16,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE","CELESTONE","NDA012657",1998-11-19,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","TABLET","ORAL","0.6MG","25","AP","SUPPL",1998-11-19,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1965-03-03,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","1","AP","ORIG",1965-03-03,"STANDARD","TYPE 1",NA,"Betamethasone Acetate; Betamethasone Sodium Phosphate (CELESTONE® SOLUSPAN®)","NDA014602","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,NA,"Missing",NA,NA,NA,"Not listed in PI",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Injection"
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1979-08-08,"Labeling",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","6","AP","SUPPL",1979-08-08,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1982-06-30,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","9","AP","SUPPL",1982-06-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1982-11-04,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","8","AP","SUPPL",1982-11-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1986-06-10,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","10","AP","SUPPL",1986-06-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1987-07-01,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","12","AP","SUPPL",1987-07-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1990-05-01,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","11","AP","SUPPL",1990-05-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1992-02-06,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","13","AP","SUPPL",1992-02-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1992-12-17,"Labeling",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","14","AP","SUPPL",1992-12-17,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1993-09-07,"Labeling",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","15","AP","SUPPL",1993-09-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1994-03-14,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","16","AP","SUPPL",1994-03-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1994-04-13,"Labeling",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","17","AP","SUPPL",1994-04-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1995-05-03,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","18","AP","SUPPL",1995-05-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1996-11-13,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","20","AP","SUPPL",1996-11-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1997-07-21,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","21","AP","SUPPL",1997-07-21,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1999-07-15,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","22","AP","SUPPL",1999-07-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",1999-10-08,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","23","AP","SUPPL",1999-10-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2000-04-10,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","24","AP","SUPPL",2000-04-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2001-07-24,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","25","AP","SUPPL",2001-07-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2006-07-12,"Labeling",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","19","AP","SUPPL",2006-07-12,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2008-06-24,"Labeling",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","47","AP","SUPPL",2008-06-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2013-01-09,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","55","AP","SUPPL",2013-01-09,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2013-03-13,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","56","AP","SUPPL",2013-03-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2014-05-21,"Manufacturing (CMC)",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","57","AP","SUPPL",2014-05-21,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2014-07-03,"Labeling",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","58","AP","SUPPL",2014-07-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2015-02-04,"Labeling",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","59","AP","SUPPL",2015-02-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2018-02-09,"Labeling",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","61","AP","SUPPL",2018-02-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"BETAMETHASONE ACETATE","CELESTONE SOLUSPAN","NDA014602",2018-04-10,"Labeling",NA,NA,NA,NA,"c(""BETAMETHASONE ACETATE"", ""BETAMETHASONE SODIUM PHOSPHATE"")","c(""BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE"", ""BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE"")","c(""Organon LLC"", ""Exela Pharma Sciences, LLC"")","Prescription","Yes","001","INJECTABLE","INJECTION","3MG/ML","62","AP","SUPPL",2018-04-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE","CORTEF","NDA008697",1952-12-15,"Type 5 - New Formulation or New Manufacturer","Yes","Mycosis Fungoides","CTCL",NA,"HYDROCORTISONE","HYDROCORTISONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Prescription","Yes","002","TABLET","ORAL","5MG, 10MG, 20MG","1","AP","ORIG",1952-12-15,"STANDARD","TYPE 5",NA,"Hydrocortisone (CORTEF)","NDA008697","Mycosis Fungoides","DESI Drug",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Tablet"
"HYDROCORTISONE","CORTEF","NDA008697",1978-02-08,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE","HYDROCORTISONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Prescription","Yes","002","TABLET","ORAL","5MG, 10MG, 20MG","14","AP","SUPPL",1978-02-08,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE","CORTEF","NDA008697",1983-03-09,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE","HYDROCORTISONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Prescription","Yes","002","TABLET","ORAL","5MG, 10MG, 20MG","16","AP","SUPPL",1983-03-09,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE","CORTEF","NDA008697",1993-12-08,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE","HYDROCORTISONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Prescription","Yes","002","TABLET","ORAL","5MG, 10MG, 20MG","20","AP","SUPPL",1993-12-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE","CORTEF","NDA008697",1993-12-28,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE","HYDROCORTISONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Prescription","Yes","002","TABLET","ORAL","5MG, 10MG, 20MG","21","AP","SUPPL",1993-12-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE","CORTEF","NDA008697",2001-03-16,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE","HYDROCORTISONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Prescription","Yes","002","TABLET","ORAL","5MG, 10MG, 20MG","25","AP","SUPPL",2001-03-16,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE","CORTEF","NDA008697",2016-09-08,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE","HYDROCORTISONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Prescription","Yes","002","TABLET","ORAL","5MG, 10MG, 20MG","32","AP","SUPPL",2016-09-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE","CORTEF","NDA008697",2016-09-08,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE","HYDROCORTISONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Prescription","Yes","002","TABLET","ORAL","5MG, 10MG, 20MG","33","AP","SUPPL",2016-09-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE","CORTEF","NDA008697",2019-11-21,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE","HYDROCORTISONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Prescription","Yes","002","TABLET","ORAL","5MG, 10MG, 20MG","36","AP","SUPPL",2019-11-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007750",1950-12-04,"Type 3 - New Dosage Form","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","003","TABLET","ORAL","25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","1","AP","ORIG",1950-12-04,"STANDARD","TYPE 3",NA,"Cortisone Acetate (CORTONE)","NDA007750","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,NA,"Missing",NA,NA,NA,"PI not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",1,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Tablet"
"CORTISONE ACETATE","CORTONE","NDA007750",1979-08-01,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","003","TABLET","ORAL","25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","11","AP","SUPPL",1979-08-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007750",1979-09-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","003","TABLET","ORAL","25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","12","AP","SUPPL",1979-09-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007750",1980-02-01,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","003","TABLET","ORAL","25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","13","AP","SUPPL",1980-02-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007750",1982-03-02,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","003","TABLET","ORAL","25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","17","AP","SUPPL",1982-03-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007750",1989-05-16,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","003","TABLET","ORAL","25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","18","AP","SUPPL",1989-05-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007750",1989-11-30,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","003","TABLET","ORAL","25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","24","AP","SUPPL",1989-11-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007750",1993-08-27,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","003","TABLET","ORAL","25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","25","AP","SUPPL",1993-08-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007750",1994-08-18,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","003","TABLET","ORAL","25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","27","AP","SUPPL",1994-08-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007750",1996-03-01,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","003","TABLET","ORAL","25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","29","AP","SUPPL",1996-03-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007110",1950-06-13,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML; 50MG/ML","1","AP","ORIG",1950-06-13,"PRIORITY","TYPE 1",NA,"Cortisone Acetate (CORTONE)","NDA007110","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,NA,"Missing",NA,NA,NA,"PI not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",1,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Injectable solutino"
"CORTISONE ACETATE","CORTONE","NDA007110",1979-08-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML; 50MG/ML","9","AP","SUPPL",1979-08-15,"PRIORITY","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007110",1982-03-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML; 50MG/ML","12","AP","SUPPL",1982-03-04,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007110",1982-12-09,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML; 50MG/ML","14","AP","SUPPL",1982-12-09,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007110",1989-05-16,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML; 50MG/ML","15","AP","SUPPL",1989-05-16,"PRIORITY","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007110",1993-08-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML; 50MG/ML","21","AP","SUPPL",1993-08-26,"PRIORITY","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007110",1994-04-20,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML; 50MG/ML","20","AP","SUPPL",1994-04-20,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"CORTISONE ACETATE","CORTONE","NDA007110",1996-03-01,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","003","INJECTABLE","INJECTION","25MG/ML; 50MG/ML","23","AP","SUPPL",1996-03-01,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"COBIMETINIB FUMARATE","COTELLIC","NDA206192",2015-11-10,"Type 1 - New Molecular Entity","Yes","Unresectable or Metastatic Melanoma with a BRAF-Mutated Melanoma In Combination with Vemurafenib","Melanoma","495","COBIMETINIB FUMARATE","COBIMETINIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","EQ 20MG BASE","1","AP","ORIG",2015-11-10,"PRIORITY","TYPE 1","495|
(T=247|
C=248)","Cobimetinib (COTELLIC®) In Combination with Vemurafenib (ZELBORAF®)","NDA206192","COTELLIC is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib","There is a small discrepancy b/t the PFS data in the medical review and the first label d/t updated info. I went with the data from the label","A multicenter, randomized (1:1), double-blinded, placebo-controlled trial conducted in 495 patients with previously untreated, BRAF V600 mutation-positive, unresectable or metastatic, melanoma","Progression-Free Survival","PFS","Progression-Free Survival",2,"HR","12.3 vs. 7.2 mo","0.56000000000000005","HR: 0.56","HR: 0.56",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",1,0,"0",1,1,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"COBIMETINIB FUMARATE","COTELLIC","NDA206192",2016-05-31,"Labeling",NA,NA,NA,NA,"COBIMETINIB FUMARATE","COBIMETINIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","EQ 20MG BASE","1","AP","SUPPL",2016-05-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"COBIMETINIB FUMARATE","COTELLIC","NDA206192",2018-01-26,"Efficacy","Yes","Updates label to include OS data","Melanoma",NA,"COBIMETINIB FUMARATE","COBIMETINIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","EQ 20MG BASE","2","AP","SUPPL",2018-01-26,"STANDARD","EFFICACY",NA,NA,NA,"Provides for updates to the Clinical Studies section of the package insert to include final overall survival data from Trial GO28141.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"COBIMETINIB FUMARATE","COTELLIC","NDA206192",2022-07-28,"Efficacy",NA,NA,NA,NA,"COBIMETINIB FUMARATE","COBIMETINIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","EQ 20MG BASE","4","AP","SUPPL",2022-07-28,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1959-11-16,"Type 2 - New Active Ingredient","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","1","AP","ORIG",1959-11-16,"PRIORITY","TYPE 2",NA,"Cyclophosphamide (Cytoxan)","NDA012142","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Alkylating Agent","Alkylating Agent","Cytotoxic Agent","Y","Solution"
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1976-01-13,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","25","AP","SUPPL",1976-01-13,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1976-06-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","29","AP","SUPPL",1976-06-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1976-11-01,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","30","AP","SUPPL",1976-11-01,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1977-04-20,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","35","AP","SUPPL",1977-04-20,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1977-04-26,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","33","AP","SUPPL",1977-04-26,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1977-04-26,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","34","AP","SUPPL",1977-04-26,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1978-08-29,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","38","AP","SUPPL",1978-08-29,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1978-12-13,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","40","AP","SUPPL",1978-12-13,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1979-02-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","41","AP","SUPPL",1979-02-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1979-06-19,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","43","AP","SUPPL",1979-06-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1979-08-03,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","44","AP","SUPPL",1979-08-03,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1979-12-03,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","39","AP","SUPPL",1979-12-03,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1980-09-27,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","45","AP","SUPPL",1980-09-27,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1981-03-21,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","46","AP","SUPPL",1981-03-21,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1981-10-13,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","50","AP","SUPPL",1981-10-13,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1981-11-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","48","AP","SUPPL",1981-11-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1981-12-11,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","47","AP","SUPPL",1981-12-11,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1982-07-28,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","52","AP","SUPPL",1982-07-28,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1982-08-30,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","54","AP","SUPPL",1982-08-30,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1983-03-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","56","AP","SUPPL",1983-03-15,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1984-01-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","58","AP","SUPPL",1984-01-04,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1984-04-05,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","59","AP","SUPPL",1984-04-05,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1984-05-24,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","64","AP","SUPPL",1984-05-24,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1984-06-14,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","55","AP","SUPPL",1984-06-14,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1984-06-14,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","63","AP","SUPPL",1984-06-14,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1984-06-15,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","66","AP","SUPPL",1984-06-15,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1984-07-18,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","67","AP","SUPPL",1984-07-18,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1984-08-20,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","65","AP","SUPPL",1984-08-20,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1984-10-17,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","61","AP","SUPPL",1984-10-17,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1984-12-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","71","AP","SUPPL",1984-12-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1985-05-02,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","74","AP","SUPPL",1985-05-02,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1985-05-06,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","72","AP","SUPPL",1985-05-06,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1985-06-18,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","73","AP","SUPPL",1985-06-18,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1985-08-06,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","57","AP","SUPPL",1985-08-06,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1985-08-30,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","75","AP","SUPPL",1985-08-30,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1985-08-30,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","76","AP","SUPPL",1985-08-30,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1985-09-24,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","69","AP","SUPPL",1985-09-24,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1985-12-05,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","68","AP","SUPPL",1985-12-05,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1985-12-10,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","70","AP","SUPPL",1985-12-10,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1986-02-14,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","77","AP","SUPPL",1986-02-14,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1986-05-30,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","80","AP","SUPPL",1986-05-30,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1986-05-30,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","84","AP","SUPPL",1986-05-30,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1986-05-30,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","85","AP","SUPPL",1986-05-30,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1986-07-11,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","81","AP","SUPPL",1986-07-11,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1986-07-11,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","82","AP","SUPPL",1986-07-11,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1986-07-11,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","83","AP","SUPPL",1986-07-11,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1986-12-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","86","AP","SUPPL",1986-12-08,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1986-12-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","87","AP","SUPPL",1986-12-08,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1987-04-29,"Efficacy",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","28","AP","SUPPL",1987-04-29,NA,"EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1987-04-29,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","53","AP","SUPPL",1987-04-29,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1987-04-29,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","88","AP","SUPPL",1987-04-29,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1987-11-20,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","89","AP","SUPPL",1987-11-20,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1988-01-11,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","90","AP","SUPPL",1988-01-11,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1988-01-12,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","91","AP","SUPPL",1988-01-12,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1988-04-28,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","79","AP","SUPPL",1988-04-28,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1989-03-01,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","92","AP","SUPPL",1989-03-01,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1990-10-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","93","AP","SUPPL",1990-10-22,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1995-12-20,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","98","AP","SUPPL",1995-12-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",1999-05-28,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","102","AP","SUPPL",1999-05-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",2000-06-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","101","AP","SUPPL",2000-06-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",2000-11-02,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","104","AP","SUPPL",2000-11-02,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",2001-01-30,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","103","AP","SUPPL",2001-01-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",2003-11-07,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","107","AP","SUPPL",2003-11-07,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",2012-03-31,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","109","AP","SUPPL",2012-03-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",2013-05-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","112","AP","SUPPL",2013-05-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",2014-07-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","114","AP","SUPPL",2014-07-22,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN (LYOPHILIZED)","NDA012142",2016-10-31,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","008","INJECTABLE","INJECTION","1GM/VIAL; 2GM/VIAL; 100MG/VIAL; 200MG/VIAL; 500MG/VIAL;","115","AP","SUPPL",2016-10-31,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1959-11-16,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","1","AP","ORIG",1959-11-16,"PRIORITY","TYPE 1",NA,"Cyclophosphamide (Cytoxan)","NDA012141","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Alkylating Agent","Alkylating Agent","Cytotoxic Agent","Y","Tablet"
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1976-06-09,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","40","AP","SUPPL",1976-06-09,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1976-06-09,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","41","AP","SUPPL",1976-06-09,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1976-10-18,"REMS",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","35","AP","SUPPL",1976-10-18,"PRIORITY","REMS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1976-10-18,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","44","AP","SUPPL",1976-10-18,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1976-11-01,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","42","AP","SUPPL",1976-11-01,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1977-03-17,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","39","AP","SUPPL",1977-03-17,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1977-03-17,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","45","AP","SUPPL",1977-03-17,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1977-04-25,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","48","AP","SUPPL",1977-04-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1977-05-16,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","46","AP","SUPPL",1977-05-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1977-11-16,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","49","AP","SUPPL",1977-11-16,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1977-11-16,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","50","AP","SUPPL",1977-11-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1978-05-23,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","51","AP","SUPPL",1978-05-23,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1978-07-19,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","52","AP","SUPPL",1978-07-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1978-08-08,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","47","AP","SUPPL",1978-08-08,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1978-08-16,"Supplement",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","54","AP","SUPPL",1978-08-16,"PRIORITY","S",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1978-08-28,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","55","AP","SUPPL",1978-08-28,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1978-11-27,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","53","AP","SUPPL",1978-11-27,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1979-04-30,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","56","AP","SUPPL",1979-04-30,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1979-05-24,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","58","AP","SUPPL",1979-05-24,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1979-08-03,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","59","AP","SUPPL",1979-08-03,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1980-01-25,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","57","AP","SUPPL",1980-01-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1980-09-27,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","61","AP","SUPPL",1980-09-27,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1981-02-27,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","60","AP","SUPPL",1981-02-27,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1982-03-04,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","64","AP","SUPPL",1982-03-04,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1982-07-28,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","62","AP","SUPPL",1982-07-28,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1983-03-15,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","65","AP","SUPPL",1983-03-15,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1984-08-10,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","66","AP","SUPPL",1984-08-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1985-08-30,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","69","AP","SUPPL",1985-08-30,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1985-12-04,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","70","AP","SUPPL",1985-12-04,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1985-12-05,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","67","AP","SUPPL",1985-12-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1986-01-15,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","71","AP","SUPPL",1986-01-15,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1986-07-11,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","72","AP","SUPPL",1986-07-11,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1986-07-11,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","73","AP","SUPPL",1986-07-11,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1986-07-11,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","74","AP","SUPPL",1986-07-11,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1986-07-11,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","75","AP","SUPPL",1986-07-11,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1987-04-29,"Efficacy",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","37","AP","SUPPL",1987-04-29,NA,"EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1987-04-29,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","63","AP","SUPPL",1987-04-29,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1987-04-29,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","77","AP","SUPPL",1987-04-29,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1995-12-20,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","81","AP","SUPPL",1995-12-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1999-05-28,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","84","AP","SUPPL",1999-05-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",1999-08-20,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","85","AP","SUPPL",1999-08-20,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",2000-06-15,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","83","AP","SUPPL",2000-06-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",2001-01-30,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","86","AP","SUPPL",2001-01-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",2003-02-27,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","87","AP","SUPPL",2003-02-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",2012-03-31,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","89","AP","SUPPL",2012-03-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",2013-05-07,"Labeling",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","90","AP","SUPPL",2013-05-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"CYCLOPHOSPHAMIDE","CYTOXAN","NDA012141",2020-08-07,"Manufacturing (CMC)",NA,NA,NA,NA,"CYCLOPHOSPHAMIDE","CYCLOPHOSPHAMIDE","Baxter Healthcare Corporation","Prescription","Yes","002","TABLET","ORAL","25MG; 50MG","91","AP","SUPPL",2020-08-07,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",1996-04-08,"Type 3 - New Dosage Form","Yes","HIV-associated Kaposi's Sarcoma - First Line","KS","227","NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","1","AP","ORIG",1996-04-08,"PRIORITY","TYPE 3","227|
(T=116|
C=111)","Daunorubicin citrate liposome (DAUNOXOME®)","NDA050704","DaunoXome is indicated as a first line cytotoxic therapy for advanced HIV-associated Kaposiʼs sarcoma","Primary endpoint likely ORR as per PI and primary paper; though neither says so specifically; RR data is not in FDA.gov","Open-label, randomized, controlled clinical study of Daunoxome vs. ABV","Response Rate","ORR","Response Rate",0,NA,"ORR: 23% (27/116) vs. 30% (33/111) (Diff 7%, -5%,18%)
OS HR=1.29 (0.92,1.79)",NA,"RR: 23%",NA,"RR: 23%",NA,NA,NA,"ACTG","ACTG","10","Yes",0,0,"1",0,1,"Yes","No","1","Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",1996-08-27,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","1","AP","SUPPL",1996-08-27,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",1996-10-11,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","2","AP","SUPPL",1996-10-11,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",1997-02-24,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","4","AP","SUPPL",1997-02-24,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",1997-03-11,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","3","AP","SUPPL",1997-03-11,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",1998-02-26,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","5","AP","SUPPL",1998-02-26,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",1998-02-26,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","6","AP","SUPPL",1998-02-26,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",1999-03-23,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","7","AP","SUPPL",1999-03-23,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",1999-10-28,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","10","AP","SUPPL",1999-10-28,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",2000-03-28,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","9","AP","SUPPL",2000-03-28,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",2000-05-23,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","11","AP","SUPPL",2000-05-23,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",2002-02-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","12","AP","SUPPL",2002-02-10,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DAUNORUBICIN CITRATE","DAUNOXOME","NDA050704",2002-02-21,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","INJECTABLE, LIPOSOMAL","INJECTION","EQ 2MG BASE/ML","8","AP","SUPPL",2002-02-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1958-10-30,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","1","AP","ORIG",1958-10-30,"PRIORITY","TYPE 1",NA,"Dexamethasone (DECADRON®)","NDA011664","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,NA,"Missing",NA,NA,NA,"Not listed in PI",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",1,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Tablet"
"DEXAMETHASONE","DECADRON","NDA011664",1978-10-11,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","25","AP","SUPPL",1978-10-11,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1979-07-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","24","AP","SUPPL",1979-07-26,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1979-07-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","27","AP","SUPPL",1979-07-26,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1979-07-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","28","AP","SUPPL",1979-07-26,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1979-07-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","29","AP","SUPPL",1979-07-26,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1979-08-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","31","AP","SUPPL",1979-08-15,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1979-09-24,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","30","AP","SUPPL",1979-09-24,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1979-10-26,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","26","AP","SUPPL",1979-10-26,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1980-02-04,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","33","AP","SUPPL",1980-02-04,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1980-02-04,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","34","AP","SUPPL",1980-02-04,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1980-02-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","32","AP","SUPPL",1980-02-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1980-04-23,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","35","AP","SUPPL",1980-04-23,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1981-04-01,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","38","AP","SUPPL",1981-04-01,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1982-02-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","37","AP","SUPPL",1982-02-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1982-07-30,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","21","AP","SUPPL",1982-07-30,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1982-07-30,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","36","AP","SUPPL",1982-07-30,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1983-03-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","42","AP","SUPPL",1983-03-22,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1983-05-11,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","43","AP","SUPPL",1983-05-11,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1984-05-03,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","41","AP","SUPPL",1984-05-03,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1985-11-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","45","AP","SUPPL",1985-11-26,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1988-05-03,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","47","AP","SUPPL",1988-05-03,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1989-05-16,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","44","AP","SUPPL",1989-05-16,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1993-08-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","50","AP","SUPPL",1993-08-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1996-03-01,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","53","AP","SUPPL",1996-03-01,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1998-02-26,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","57","AP","SUPPL",1998-02-26,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1998-05-14,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","55","AP","SUPPL",1998-05-14,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",1999-02-19,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","58","AP","SUPPL",1999-02-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",2002-06-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","60","AP","SUPPL",2002-06-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",2004-05-17,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","62","AP","SUPPL",2004-05-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",2016-07-29,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","63","AP","SUPPL",2016-07-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",2018-04-23,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","65","AP","SUPPL",2018-04-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA011664",2019-05-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","006","TABLET","ORAL","0.25MG, 0.5MG, 0.75MG, 1.5MG, 4MG, 6MG","64","AP","SUPPL",2019-05-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA012376",1960-07-07,"Type 3 - New Dosage Form","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","No","002","ELIXIR","ORAL","0.5MG/5ML","1","AP","ORIG",1960-07-07,"STANDARD","TYPE 3",NA,"Dexamethasone (DECADRON®)","NDA012376","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet; generic labelfor the elixir had MF as an indication, though Decadron in the elixir form was not found",NA,NA,"Missing",NA,NA,NA,"Not listed in PI",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",1,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Elixir Form"
"DEXAMETHASONE","DECADRON","NDA012376",1979-03-01,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","ELIXIR","ORAL","0.5MG/5ML","16","AP","SUPPL",1979-03-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA012376",1979-08-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","ELIXIR","ORAL","0.5MG/5ML","17","AP","SUPPL",1979-08-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA012376",1982-02-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","ELIXIR","ORAL","0.5MG/5ML","19","AP","SUPPL",1982-02-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA012376",1982-05-21,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","ELIXIR","ORAL","0.5MG/5ML","18","AP","SUPPL",1982-05-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA012376",1989-01-12,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","ELIXIR","ORAL","0.5MG/5ML","25","AP","SUPPL",1989-01-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA012376",1989-05-16,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","ELIXIR","ORAL","0.5MG/5ML","22","AP","SUPPL",1989-05-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE","DECADRON","NDA012376",1993-08-27,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","ELIXIR","ORAL","0.5MG/5ML","28","AP","SUPPL",1993-08-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1959-10-06,"Type 3 - New Dosage Form","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","1","AP","ORIG",1959-10-06,"STANDARD","TYPE 3",NA,"Dexamethasone Sodium Phosphate (DECADRON®)","NDA012071","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet; generic label had MF as an indication, though Decadron in the injectable form was not found",NA,NA,"Missing",NA,NA,NA,"Not listed in PI",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",1,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Injectable"
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1978-10-18,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","25","AP","SUPPL",1978-10-18,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1979-08-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","26","AP","SUPPL",1979-08-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1981-02-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","23","AP","SUPPL",1981-02-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1984-06-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","30","AP","SUPPL",1984-06-25,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1985-03-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","31","AP","SUPPL",1985-03-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1989-12-11,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","38","AP","SUPPL",1989-12-11,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1993-08-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","39","AP","SUPPL",1993-08-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1996-03-01,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","43","AP","SUPPL",1996-03-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1997-09-09,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","47","AP","SUPPL",1997-09-09,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1997-10-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","49","AP","SUPPL",1997-10-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",1999-02-17,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","46","AP","SUPPL",1999-02-17,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DEXAMETHASONE SODIUM PHOSPHATE","DECADRON","NDA012071",2000-02-18,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","004","INJECTABLE","INJECTION","EQ 4MG PHOSPHATE/ML, EQ 24MG PHOSPHATE/ML ","53","AP","SUPPL",2000-02-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE","DELTA-CORTEF","NDA009987",1955-06-21,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","No","004","TABLET","ORAL","5MG","1","AP","ORIG",1955-06-21,"STANDARD","TYPE 1",NA,"Prednisolone (DELTA-CORTEF™)","NDA009987","Mycosis Fungoides","DESI Drug",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Tablet"
"PREDNISOLONE","DELTA-CORTEF","NDA009987",1978-09-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","TABLET","ORAL","5MG","19","AP","SUPPL",1978-09-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1959-05-27,"Type 2 - New Active Ingredient","Yes","Mycosis Fungoides","CTCL",NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","1","AP","ORIG",1959-05-27,"STANDARD","TYPE 2",NA,"Methylprednisolone Acetate (DEPO-MEDROL®)","NDA011757","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Depo preparation"
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1978-07-12,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","52","AP","SUPPL",1978-07-12,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1980-07-29,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","54","AP","SUPPL",1980-07-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1981-02-17,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","50","AP","SUPPL",1981-02-17,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1983-03-09,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","57","AP","SUPPL",1983-03-09,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1983-03-09,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","58","AP","SUPPL",1983-03-09,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1986-05-12,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","53","AP","SUPPL",1986-05-12,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1986-05-12,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","55","AP","SUPPL",1986-05-12,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1986-05-12,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","60","AP","SUPPL",1986-05-12,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1989-01-05,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","59","AP","SUPPL",1989-01-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1989-12-14,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","63","AP","SUPPL",1989-12-14,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1990-11-15,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","64","AP","SUPPL",1990-11-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1993-12-28,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","70","AP","SUPPL",1993-12-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1994-01-07,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","72","AP","SUPPL",1994-01-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",1995-01-24,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","75","AP","SUPPL",1995-01-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2000-04-04,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","78","AP","SUPPL",2000-04-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2002-05-22,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","79","AP","SUPPL",2002-05-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2009-04-07,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","85","AP","SUPPL",2009-04-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2009-04-07,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","86","AP","SUPPL",2009-04-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2013-10-07,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","97","AP","SUPPL",2013-10-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2013-10-11,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","98","AP","SUPPL",2013-10-11,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2014-06-09,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","102","AP","SUPPL",2014-06-09,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2014-07-03,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","103","AP","SUPPL",2014-07-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2016-09-08,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","104","AP","SUPPL",2016-09-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2017-03-15,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","111","AP","SUPPL",2017-03-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2018-07-24,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","114","AP","SUPPL",2018-07-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2021-02-11,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","119","AP","SUPPL",2021-02-11,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","DEPO-MEDROL","NDA011757",2021-05-27,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE ACETATE","c(""METHYLPREDNISOLONE ACETATE"", ""DEPO-MEDROL, LIDOCAINE HCI, ISOPROPYL ALCOHOL"")","c(""Pharmacia & Upjohn Company LLC"", ""NuCare Pharmaceuticals,Inc."")","Prescription","Yes","001","INJECTABLE","INJECTION","40MG/ML, 20MG/ML, 80MG/ML","120","AP","SUPPL",2021-05-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1974-08-07,"Type 1 - New Molecular Entity",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","1","AP","ORIG",1974-08-07,"PRIORITY","TYPE 1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1974-11-13,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","1","AP","SUPPL",1974-11-13,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1975-05-05,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","4","AP","SUPPL",1975-05-05,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1975-05-12,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","5","AP","SUPPL",1975-05-12,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1975-08-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","6","AP","SUPPL",1975-08-25,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1975-10-16,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","7","AP","SUPPL",1975-10-16,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1975-11-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","8","AP","SUPPL",1975-11-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1976-03-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","9","AP","SUPPL",1976-03-25,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1976-09-14,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","10","AP","SUPPL",1976-09-14,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1976-12-21,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","11","AP","SUPPL",1976-12-21,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1977-01-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","12","AP","SUPPL",1977-01-13,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1977-03-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","13","AP","SUPPL",1977-03-22,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1977-03-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","14","AP","SUPPL",1977-03-22,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1977-03-29,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","15","AP","SUPPL",1977-03-29,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1977-07-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","16","AP","SUPPL",1977-07-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1977-07-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","17","AP","SUPPL",1977-07-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1977-07-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","18","AP","SUPPL",1977-07-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1977-08-10,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","19","AP","SUPPL",1977-08-10,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1977-08-18,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","20","AP","SUPPL",1977-08-18,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1978-01-09,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","21","AP","SUPPL",1978-01-09,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1978-07-03,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","23","AP","SUPPL",1978-07-03,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1978-09-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","22","AP","SUPPL",1978-09-13,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1978-11-28,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","24","AP","SUPPL",1978-11-28,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1978-12-07,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","25","AP","SUPPL",1978-12-07,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1979-03-14,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","26","AP","SUPPL",1979-03-14,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1979-10-30,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","27","AP","SUPPL",1979-10-30,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1979-10-30,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","28","AP","SUPPL",1979-10-30,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1979-10-31,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","29","AP","SUPPL",1979-10-31,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1980-03-31,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","30","AP","SUPPL",1980-03-31,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1981-07-28,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","32","AP","SUPPL",1981-07-28,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1982-03-15,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","33","AP","SUPPL",1982-03-15,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1982-03-15,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","34","AP","SUPPL",1982-03-15,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1983-02-24,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","35","AP","SUPPL",1983-02-24,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1983-08-10,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","36","AP","SUPPL",1983-08-10,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1983-08-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","37","AP","SUPPL",1983-08-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1985-01-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","39","AP","SUPPL",1985-01-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1985-03-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","40","AP","SUPPL",1985-03-04,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1985-05-20,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","41","AP","SUPPL",1985-05-20,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1985-06-07,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","42","AP","SUPPL",1985-06-07,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1986-02-11,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","44","AP","SUPPL",1986-02-11,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1986-03-21,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","45","AP","SUPPL",1986-03-21,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1986-05-21,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","46","AP","SUPPL",1986-05-21,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1986-11-06,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","47","AP","SUPPL",1986-11-06,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1987-02-19,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","52","AP","SUPPL",1987-02-19,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1987-03-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","48","AP","SUPPL",1987-03-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1987-03-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","49","AP","SUPPL",1987-03-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1987-03-27,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","50","AP","SUPPL",1987-03-27,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1987-04-28,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","53","AP","SUPPL",1987-04-28,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1987-07-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","54","AP","SUPPL",1987-07-22,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1987-07-22,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","55","AP","SUPPL",1987-07-22,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1987-12-30,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","56","AP","SUPPL",1987-12-30,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1988-03-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","57","AP","SUPPL",1988-03-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1994-11-29,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","2","AP","SUPPL",1994-11-29,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1995-04-26,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","59","AP","SUPPL",1995-04-26,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1996-05-03,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","60","AP","SUPPL",1996-05-03,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1997-10-14,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","61","AP","SUPPL",1997-10-14,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1998-02-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","62","AP","SUPPL",1998-02-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",1999-03-04,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","63","AP","SUPPL",1999-03-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2002-01-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","65","AP","SUPPL",2002-01-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2002-04-02,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","66","AP","SUPPL",2002-04-02,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2002-09-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","64","AP","SUPPL",2002-09-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2002-09-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","67","AP","SUPPL",2002-09-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2003-05-08,"Efficacy",NA,"Adjuvant therapy in Breast Cancer","Breast Cancer",NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","68","AP","SUPPL",2003-05-08,"STANDARD","EFFICACY",NA,NA,NA,"The use of Doxorubicin Hydrochloride for Injection and Doxorubicin Hydrochloride Injection for use in combination with cyclophosphamide as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2003-05-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","69","AP","SUPPL",2003-05-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2010-07-30,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","70","AP","SUPPL",2010-07-30,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2011-09-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","71","AP","SUPPL",2011-09-26,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2013-10-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","74","AP","SUPPL",2013-10-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2013-10-31,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","73","AP","SUPPL",2013-10-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2015-09-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","75","AP","SUPPL",2015-09-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2019-08-09,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","77","AP","SUPPL",2019-08-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2019-12-20,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","76","AP","SUPPL",2019-12-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXORUBICIN HYDROCHLORIDE","NDA050467",2020-08-28,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","004","INJECTABLE","INJECTION","10MG/VIAL, 50MG/VIAL, 200MG/VIAL, 150MG/VIAL","78","AP","SUPPL",2020-08-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",1995-11-17,"Type 3 - New Dosage Form","Yes","Accelerated Approval for Refractory AIDS-Related Kaposi's Sarcoma","KS","77","DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","1","AP","ORIG",1995-11-17,"STANDARD","TYPE 3","77","Doxorubicin HCL Liposome (DOXIL®)","NDA050718","The treatment of AIDS-related Kaposi’s sarcoma in patients after failure or prior systemic chemotherapy or intolerance to such therapy.
has progressed on prior combination chemotherapy or in patients who are
intolerant to such therapy","77 patients in the trial, 42 patients had lesions evaluable as Indication lesion assessment; 38 as independent assessment","Open label, single-arm, multicenter study","Response Rate","ORR","Response Rate",0,NA,"27% (9/34) Invest Assess
48% (20/42) Indicator lesion assessment",NA,"RR: 27% (Investigator Assessment) | 
RR: 48% (Indicator Lesion Assessment)",NA,"RR: 27% (Investigator Assessment) | 
RR: 48% (Indicator Lesion Assessment)",NA,"12.9 | 32.0","44.4 | 63.6","Modified ACTG","ACTG","10","Yes",0,1,"1",0,0,"No","Yes","0","Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",1996-03-08,"Labeling",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","1","AP","SUPPL",1996-03-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",1996-07-10,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","2","AP","SUPPL",1996-07-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",1997-07-31,"Labeling",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","4","AP","SUPPL",1997-07-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",1998-03-31,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","5","AP","SUPPL",1998-03-31,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",1999-06-28,"Efficacy",NA,"Accelerated Approval for Refractory Ovarian Cancer","Ovarian Cancer",NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","6","AP","SUPPL",1999-06-28,"PRIORITY","EFFICACY",NA,NA,NA,"The use of Doxil (doxorubicin HCl liposome injection) for the treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinum-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2000-03-30,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","7","AP","SUPPL",2000-03-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2000-06-13,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","8","AP","SUPPL",2000-06-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2002-01-10,"Labeling",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","10","AP","SUPPL",2002-01-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2002-04-18,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","12","AP","SUPPL",2002-04-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2002-08-09,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","14","AP","SUPPL",2002-08-09,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2002-12-17,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","16","AP","SUPPL",2002-12-17,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2004-10-27,"Efficacy",NA,"Label Changes",NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","19","AP","SUPPL",2004-10-27,"UNKNOWN","EFFICACY",NA,NA,NA,"Provides significant changes to the following sections of the product labeling – BOX WARNING, WARNINGS, PRECAUTIONS (Information for the Patient), DOSAGE AND ADMINISTRATION (AIDS-KS Patients, Dose Modifications and Preparation for Intravenous Administration). ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2005-01-28,"Efficacy",NA,"Regular Approval for Refractory Ovarian Cancer","Ovarian Cancer",NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","20","AP","SUPPL",2005-01-28,"UNKNOWN","EFFICACY",NA,NA,NA,"The use of Doxil® for the treatment of patients
with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2007-05-17,"Labeling",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","28","AP","SUPPL",2007-05-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2007-05-17,"Efficacy",NA,"New Use in Multiple Myeloma","Multiple Myeloma",NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","29","AP","SUPPL",2007-05-17,"PRIORITY","EFFICACY",NA,NA,NA,"The use of DOXIL® (doxorubicin HCl liposome injection) in combination with bortezomib for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2008-06-10,"Efficacy","Yes","Regular Aprroval for Refractory AIDS-Related Kaposi's Sarcoma","KS","28","DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","33","AP","SUPPL",2008-06-10,"UNKNOWN","EFFICACY","28","Doxorubicin HCL Liposome (DOXIL®)","NDA050718","DOXIL is an anthracycline topoisomerase inhibitor indicated for AIDS-related Kaposi’s Sarcoma after failure of prior systemic chemotherapy or intolerance to such therapy","This recommendation is based on totality of data, though Steven thought best to go with RR. This includes durable responses (40%) observed in Studies 30-38 and ECOG E1D96 in KS patients in whom the results were not confounded by changes in highly-active antiretroviral treatment (HAART). Although the sample size of the non-confounded 
patients is small (n=11 in study 30-38B and n=17 in E1D 96), it is consistent across both studies. 
These results are supported by published literature. Confounding by changes in HAART and decreased incidence in  the HAART era has made adequate enrollment in to clinical trials difficult in a disease that remains as the most common malignancy in AIDS patients",NA,"Response Rate","ORR","Overall Response Rate",0,NA,"Dur RR: Study 1: 41% (7/17); study 2 36.4% (4/11) (of note, the label says 40% for both, so they must have been rounding)",NA,"RR: 41% (Study 1) |
RR: 36% (Study 2)",NA,"RR: 41% (Study 1) |
RR: 36% (Study 2)",NA,"18.4 | 10.9","67.1 | 69.2",NA,NA,NA,"Yes",0,1,"1",0,0,"Yes","No","1","Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2012-09-19,"Labeling",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","43","AP","SUPPL",2012-09-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2013-08-30,"Labeling",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","45","AP","SUPPL",2013-08-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2013-12-12,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","31","AP","SUPPL",2013-12-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2014-04-14,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","47","AP","SUPPL",2014-04-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2015-01-22,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","46","AP","SUPPL",2015-01-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2015-04-16,"Efficacy",NA,"Updates Label for Multiple Myeloma","Multiple Myeloma",NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","48","AP","SUPPL",2015-04-16,"STANDARD","EFFICACY",NA,NA,NA,"Updates to the CLINICAL STUDIES section of the United States Prescribing Information based on the final study report for DOXIL Study MMY-3001 entitled “A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2015-10-09,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","49","AP","SUPPL",2015-10-09,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2015-12-28,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","50","AP","SUPPL",2015-12-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2016-03-29,"Manufacturing (CMC)",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","51","AP","SUPPL",2016-03-29,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2019-08-12,"Labeling",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","55","AP","SUPPL",2019-08-12,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"DOXORUBICIN HYDROCHLORIDE","DOXIL (LIPOSOMAL)","NDA050718",2022-05-06,"Labeling",NA,NA,NA,NA,"DOXORUBICIN HYDROCHLORIDE","c(""DOXORUBICIN HYDROCHLORIDE LIPOSOME"", ""DOXORUBICIN HYDROCHLORIDE"")","Baxter Healthcare Corporation","Prescription","Yes","001","INJECTABLE, LIPOSOMAL","INJECTION","20MG/10ML, 50MG/25ML","60","AP","SUPPL",2022-05-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Topoisomerase Inhibitor","Topoisomerase Inhibitor","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1967-12-07,"Type 1 - New Molecular Entity","Yes","Melanoma","Melanoma",NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","1","AP","ORIG",1967-12-07,"PRIORITY","TYPE 1",NA,"Hydroxyurea (DROXIA)","NDA016295","Significant tumor response to HYDREA (hydroxyurea capsules, USP) has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma
of the ovary.","Very little corroborated; ORR was likely secondhand",NA,"ORR","ORR","Overall Response Rate",0,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",1,NA,"1",NA,NA,"Yes","No","1","Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1977-05-03,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","8","AP","SUPPL",1977-05-03,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1980-02-19,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","9","AP","SUPPL",1980-02-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1985-07-16,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","14","AP","SUPPL",1985-07-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1987-03-19,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","13","AP","SUPPL",1987-03-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1987-03-19,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","15","AP","SUPPL",1987-03-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1988-05-10,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","17","AP","SUPPL",1988-05-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1988-08-25,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","18","AP","SUPPL",1988-08-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1992-07-31,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","20","AP","SUPPL",1992-07-31,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1993-03-09,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","22","AP","SUPPL",1993-03-09,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1995-09-05,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","19","AP","SUPPL",1995-09-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1996-09-24,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","11","AP","SUPPL",1996-09-24,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1996-09-24,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","23","AP","SUPPL",1996-09-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1996-10-15,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","24","AP","SUPPL",1996-10-15,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1996-11-25,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","25","AP","SUPPL",1996-11-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1997-04-07,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","27","AP","SUPPL",1997-04-07,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1997-05-23,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","28","AP","SUPPL",1997-05-23,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1998-02-25,"Efficacy",NA,"New Indication For Sickle Cell Anemia","Sickle Cell Anemia",NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","29","AP","SUPPL",1998-02-25,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1998-02-25,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","30","AP","SUPPL",1998-02-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1998-11-10,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","31","AP","SUPPL",1998-11-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",1999-08-11,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","26","AP","SUPPL",1999-08-11,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2000-01-12,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","33","AP","SUPPL",2000-01-12,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2001-02-20,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","35","AP","SUPPL",2001-02-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2001-04-04,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","34","AP","SUPPL",2001-04-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2003-06-26,"Efficacy",NA,"Updated Data","Sickle Cell Anemia",NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","36","AP","SUPPL",2003-06-26,"STANDARD","EFFICACY",NA,NA,NA,"Revisions to the labeling based on data obtained from a Phase 4 commitment study to determine the influence of renal impairment on the
pharmacokinetics of hydroxyurea in adults with sickle cell disease",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2004-02-19,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","37","AP","SUPPL",2004-02-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2006-09-19,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","39","AP","SUPPL",2006-09-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2010-05-07,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","40","AP","SUPPL",2010-05-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2012-01-26,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","41","AP","SUPPL",2012-01-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2012-01-26,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","42","AP","SUPPL",2012-01-26,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2015-07-16,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","45","AP","SUPPL",2015-07-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2015-07-16,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","46","AP","SUPPL",2015-07-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2016-03-23,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","47","AP","SUPPL",2016-03-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2016-03-23,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","48","AP","SUPPL",2016-03-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2017-12-18,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","49","AP","SUPPL",2017-12-18,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2017-12-18,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","50","AP","SUPPL",2017-12-18,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2019-07-22,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","51","AP","SUPPL",2019-07-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2019-12-18,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","52","AP","SUPPL",2019-12-18,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2021-02-09,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","54","AP","SUPPL",2021-02-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2021-08-05,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","55","AP","SUPPL",2021-08-05,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"HYDROXYUREA","DROXIA","NDA016295",2022-01-13,"Labeling",NA,NA,NA,NA,"HYDROXYUREA","HYDROXYUREA","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","003","CAPSULE","ORAL","200MG, 300MG, 400MG, 500MG","56","AP","SUPPL",2022-01-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1975-05-27,"Type 1 - New Molecular Entity","Yes","Metastatic Malignant Melanoma","Melanoma",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","1","AP","ORIG",1975-05-27,"STANDARD","TYPE 1",NA,"Dacarbazine (DTIC-DOME®)","NDA017575",NA,NA,NA,"ORR","ORR","Overall Response Rate",0,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",1,1,"1",0,0,"Yes","No","1","Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1975-11-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","1","AP","SUPPL",1975-11-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1979-05-24,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","2","AP","SUPPL",1979-05-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1980-10-27,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","4","AP","SUPPL",1980-10-27,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1981-04-29,"Efficacy",NA,"Cannot verify efficacy supplement",NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","3","AP","SUPPL",1981-04-29,NA,"EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1983-04-05,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","7","AP","SUPPL",1983-04-05,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1985-07-15,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","6","AP","SUPPL",1985-07-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1986-05-22,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","9","AP","SUPPL",1986-05-22,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1988-12-02,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","12","AP","SUPPL",1988-12-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1989-04-19,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","13","AP","SUPPL",1989-04-19,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1991-07-29,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","16","AP","SUPPL",1991-07-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1996-05-24,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","19","AP","SUPPL",1996-05-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1996-11-07,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","15","AP","SUPPL",1996-11-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"DACARBAZINE","DTIC-DOME","NDA017575",1998-09-24,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","100MG/VIAL; 200MG/VIAL","20","AP","SUPPL",1998-09-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1970-07-29,"Type 3 - New Dosage Form","Yes","Multiple Actinic Keratoses","AK",NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","1","AP","ORIG",1970-07-29,"STANDARD","TYPE 3",NA,"5-Fluorouracil Solutions and Cream (EFUDEX®)","NDA016831","Efudex is recommended for the topical treatment of multiple actinic or solar keratoses",NA,NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",0,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1974-09-19,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","9","AP","SUPPL",1974-09-19,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1975-05-07,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","10","AP","SUPPL",1975-05-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1975-05-07,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","11","AP","SUPPL",1975-05-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1975-06-30,"Efficacy","Yes","Superficial Basal Cell Carcinoma","BCC","54","FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","8","AP","SUPPL",1975-06-30,"STANDARD","EFFICACY","54","5-Fluorouracil 5% cream/solution  (EFUDEX®)","NDA016831","In the 5% strength, Efudex is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites.","The label reports a 93% success rate based on 113 lesiosn in 54 patients",NA,"Complete Clearance Rate","CCR","Complete Clearance Rate",5,NA,"CRR 93% (105/113)",NA,"CCR: 93%",NA,"CCR: 93%",NA,NA,NA,NA,NA,NA,"Yes",0,NA,NA,NA,NA,"Yes","No","1","Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1977-12-14,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","12","AP","SUPPL",1977-12-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1977-12-14,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","13","AP","SUPPL",1977-12-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1978-11-21,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","14","AP","SUPPL",1978-11-21,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1979-10-23,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","15","AP","SUPPL",1979-10-23,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1979-12-18,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","16","AP","SUPPL",1979-12-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1982-03-10,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","18","AP","SUPPL",1982-03-10,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1982-05-14,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","19","AP","SUPPL",1982-05-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1983-03-14,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","20","AP","SUPPL",1983-03-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1983-08-12,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","21","AP","SUPPL",1983-08-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1983-08-12,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","22","AP","SUPPL",1983-08-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1984-05-04,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","23","AP","SUPPL",1984-05-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1984-08-13,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","24","AP","SUPPL",1984-08-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1985-03-14,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","25","AP","SUPPL",1985-03-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1985-06-10,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","26","AP","SUPPL",1985-06-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1986-11-14,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","27","AP","SUPPL",1986-11-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1987-03-26,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","17","AP","SUPPL",1987-03-26,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1988-11-30,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","28","AP","SUPPL",1988-11-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1993-03-04,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","30","AP","SUPPL",1993-03-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1993-08-05,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","31","AP","SUPPL",1993-08-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1995-03-21,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","29","AP","SUPPL",1995-03-21,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1997-02-18,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","32","AP","SUPPL",1997-02-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",1998-11-02,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","33","AP","SUPPL",1998-11-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2000-04-05,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","35","AP","SUPPL",2000-04-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2000-06-20,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","38","AP","SUPPL",2000-06-20,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2000-07-07,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","36","AP","SUPPL",2000-07-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2000-07-07,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","37","AP","SUPPL",2000-07-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2001-02-12,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","39","AP","SUPPL",2001-02-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2001-07-03,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","40","AP","SUPPL",2001-07-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2001-07-03,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","41","AP","SUPPL",2001-07-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2001-08-30,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","42","AP","SUPPL",2001-08-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2002-11-27,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","43","AP","SUPPL",2002-11-27,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2004-04-27,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","46","AP","SUPPL",2004-04-27,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2004-06-24,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","47","AP","SUPPL",2004-06-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2005-10-13,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","49","AP","SUPPL",2005-10-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2006-05-10,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","51","AP","SUPPL",2006-05-10,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2013-07-02,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","56","AP","SUPPL",2013-07-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2013-12-12,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","55","AP","SUPPL",2013-12-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2015-05-06,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","57","AP","SUPPL",2015-05-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2015-08-18,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","58","AP","SUPPL",2015-08-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2015-11-04,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","59","AP","SUPPL",2015-11-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","EFUDEX","NDA016831",2021-10-14,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","c(""Mylan Pharmaceuticals Inc."", ""Bausch Health US, LLC"")","Prescription","Yes","003","CREAM; SOLUTION; SOLUTION","TOPICAL","5%, 5%, 2%","63","AP","SUPPL",2021-10-14,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2012-01-30,"Type 1 - New Molecular Entity","Yes","Locally Advanced or Metastatic Basal Cell Carcinoma","BCC","96","VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","1","AP","ORIG",2012-01-30,"PRIORITY","TYPE 1","96|
(mBCC=33|
laBCC=63)","Vismodegib (ERIVEDGE™)","NDA203388","ERIVEDGE™ (vismodegib) capsule is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation","On 1/25/2011 the applicant requested Orphan Status, but this was denied","A single, international, single-arm, multi-center, open-label, 2-cohort trial was conducted in 104 patients with either metastatic basal cell carcinoma (mBCC) (n = 33) or locally advanced BCC (laBCC) (n = 71)","Objective Response Rate by IRF (10)ORR by Inv/DOR(20)","ORR","Objective Response Rate",0,"RR diff","30.3 vs. 10% (mBCC) | 42.9 vs. 20% (laBCC)","20.3 | 22.9","RR: 30.3% (mBCC) |
RR: 42.9% (laBCC)",NA,"RR: 30.3% (mBCC) |
RR: 42.9% (laBCC)","10 
20","15.6 |30.5","48.2| 56","RECIST mBCCModified RECIST laBCC","mRECIST","7","Yes",1,1,"1",0,0,"Yes","No","1","Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2013-05-08,"Manufacturing (CMC)",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","1","AP","SUPPL",2013-05-08,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2013-06-03,"Manufacturing (CMC)",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","2","AP","SUPPL",2013-06-03,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2013-12-19,"Manufacturing (CMC)",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","3","AP","SUPPL",2013-12-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2014-10-15,"Manufacturing (CMC)",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","4","AP","SUPPL",2014-10-15,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2015-05-21,"Labeling",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","5","AP","SUPPL",2015-05-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2015-05-21,"Labeling",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","6","AP","SUPPL",2015-05-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2015-05-21,"Labeling",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","7","AP","SUPPL",2015-05-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2015-05-21,"Labeling",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","8","AP","SUPPL",2015-05-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2016-11-02,"Labeling",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","10","AP","SUPPL",2016-11-02,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2017-08-01,"Labeling",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","11","AP","SUPPL",2017-08-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2019-01-18,"Efficacy","Yes","To allow for treatment interruptions of up to 8 weeks for intolerable AEs","BCC",NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","12","AP","SUPPL",2019-01-18,"STANDARD","EFFICACY",NA,"Vismodegib (ERIVEDGE™)","NDA203388","To allow for treatment interruptions of up to 8 weeks for intolerable adverse reactions.","Very little data available re: this decision",NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",0,NA,NA,NA,NA,"Yes","No","1","Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2019-03-26,"Labeling",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","14","AP","SUPPL",2019-03-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"VISMODEGIB","ERIVEDGE","NDA203388",2020-07-31,"Labeling",NA,NA,NA,NA,"VISMODEGIB","VISMODEGIB","Genentech, Inc.","Prescription","Yes","001","CAPSULE","ORAL","150MG","16","AP","SUPPL",2020-07-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"PREDNISOLONE ACETATE","FLO-PRED","NDA022067",2008-01-17,"Type 3 - New Dosage Form","Yes","Mycosis Fungoides","CTCL","72","PREDNISOLONE ACETATE","PREDNISOLONE ACETATE","Taro Pharmaceuticals U.S.A., Inc.","Discontinued","No","001","SUSPENSION","ORAL","EQ 5MG BASE/5ML, EQ 15MG BASE/5ML","1","AP","ORIG",2008-01-17,"STANDARD","TYPE 3","72","Prednisolone acetate (FLO-PRED™)","NDA022067","Mycosis Fungoides","efficacy not part of application; bioequivelance only","Three clinical studies in healthy volunteers","Bioequivalence","PK","Bioequivalence",6,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,"12","Yes",0,0,"0",0,1,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Yes","Novel delivery system to minimzie spillage"
"PREDNISOLONE ACETATE","FLO-PRED","NDA022067",2008-06-27,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE ACETATE","PREDNISOLONE ACETATE","Taro Pharmaceuticals U.S.A., Inc.","Discontinued","No","001","SUSPENSION","ORAL","EQ 5MG BASE/5ML, EQ 15MG BASE/5ML","1","AP","SUPPL",2008-06-27,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE ACETATE","FLO-PRED","NDA022067",2008-10-03,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE ACETATE","PREDNISOLONE ACETATE","Taro Pharmaceuticals U.S.A., Inc.","Discontinued","No","001","SUSPENSION","ORAL","EQ 5MG BASE/5ML, EQ 15MG BASE/5ML","2","AP","SUPPL",2008-10-03,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE ACETATE","FLO-PRED","NDA022067",2010-05-06,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE ACETATE","PREDNISOLONE ACETATE","Taro Pharmaceuticals U.S.A., Inc.","Discontinued","No","001","SUSPENSION","ORAL","EQ 5MG BASE/5ML, EQ 15MG BASE/5ML","4","AP","SUPPL",2010-05-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE ACETATE","FLO-PRED","NDA022067",2011-06-14,"Labeling",NA,NA,NA,NA,"PREDNISOLONE ACETATE","PREDNISOLONE ACETATE","Taro Pharmaceuticals U.S.A., Inc.","Discontinued","No","001","SUSPENSION","ORAL","EQ 5MG BASE/5ML, EQ 15MG BASE/5ML","7","AP","SUPPL",2011-06-14,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE ACETATE","FLO-PRED","NDA022067",2014-02-28,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE ACETATE","PREDNISOLONE ACETATE","Taro Pharmaceuticals U.S.A., Inc.","Discontinued","No","001","SUSPENSION","ORAL","EQ 5MG BASE/5ML, EQ 15MG BASE/5ML","10","AP","SUPPL",2014-02-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE ACETATE","FLO-PRED","NDA022067",2014-09-29,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE ACETATE","PREDNISOLONE ACETATE","Taro Pharmaceuticals U.S.A., Inc.","Discontinued","No","001","SUSPENSION","ORAL","EQ 5MG BASE/5ML, EQ 15MG BASE/5ML","11","AP","SUPPL",2014-09-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE ACETATE","FLO-PRED","NDA022067",2014-10-03,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE ACETATE","PREDNISOLONE ACETATE","Taro Pharmaceuticals U.S.A., Inc.","Discontinued","No","001","SUSPENSION","ORAL","EQ 5MG BASE/5ML, EQ 15MG BASE/5ML","12","AP","SUPPL",2014-10-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE ACETATE","FLO-PRED","NDA022067",2021-07-15,"Labeling",NA,NA,NA,NA,"PREDNISOLONE ACETATE","PREDNISOLONE ACETATE","Taro Pharmaceuticals U.S.A., Inc.","Discontinued","No","001","SUSPENSION","ORAL","EQ 5MG BASE/5ML, EQ 15MG BASE/5ML","14","AP","SUPPL",2021-07-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1971-08-06,"Type 5 - New Formulation or New Manufacturer","Yes","Actinic Keratoses","AK",NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","1","AP","ORIG",1971-08-06,"STANDARD","TYPE 5",NA,"5-Fluorouracil 1% Cream (FLUOROPLEX®)","NDA016988",NA,NA,NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",0,NA,NA,NA,NA,"Yes","No","1","Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1974-12-17,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","7","AP","SUPPL",1974-12-17,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1975-12-24,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","8","AP","SUPPL",1975-12-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1976-07-09,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","10","AP","SUPPL",1976-07-09,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1976-08-06,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","11","AP","SUPPL",1976-08-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1977-03-02,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","12","AP","SUPPL",1977-03-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1977-09-01,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","14","AP","SUPPL",1977-09-01,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1978-04-17,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","15","AP","SUPPL",1978-04-17,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1980-07-07,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","17","AP","SUPPL",1980-07-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1980-09-18,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","16","AP","SUPPL",1980-09-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1981-01-12,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","18","AP","SUPPL",1981-01-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1987-01-28,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","20","AP","SUPPL",1987-01-28,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1992-12-08,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","22","AP","SUPPL",1992-12-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1997-06-30,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","23","AP","SUPPL",1997-06-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1998-11-30,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","24","AP","SUPPL",1998-11-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",1998-12-01,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","25","AP","SUPPL",1998-12-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",2002-06-18,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","26","AP","SUPPL",2002-06-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",2016-01-29,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","29","AP","SUPPL",2016-01-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",2016-03-01,"Manufacturing (CMC)",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","28","AP","SUPPL",2016-03-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",2016-07-25,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","30","AP","SUPPL",2016-07-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"FLUOROURACIL","FLUOROPLEX","NDA016988",2022-02-28,"Labeling",NA,NA,NA,NA,"FLUOROURACIL","FLUOROURACIL","Almirall, LLC","Discontinued","Yes","001","CREAM","TOPICAL","1%","33","AP","SUPPL",2022-02-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2003-04-18,"Type 3 - New Dosage Form",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","1","AP","ORIG",2003-04-18,"PRIORITY","TYPE 3",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2003-05-20,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","1","AP","SUPPL",2003-05-20,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2003-12-08,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","2","AP","SUPPL",2003-12-08,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2004-06-23,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","3","AP","SUPPL",2004-06-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2005-03-14,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","5","AP","SUPPL",2005-03-14,"UNKNOWN","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2005-05-18,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","7","AP","SUPPL",2005-05-18,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2005-05-19,"Manufacturing (CMC)",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","6","AP","SUPPL",2005-05-19,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2005-10-20,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","8","AP","SUPPL",2005-10-20,"UNKNOWN","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2006-05-31,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","10","AP","SUPPL",2006-05-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2006-09-27,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","16","AP","SUPPL",2006-09-27,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2006-10-19,"Efficacy","Yes","Unresectable, Recurrent and/or Metastatic Dermatofibrosarcoma Protuberans","DFSP","18","IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","11","AP","SUPPL",2006-10-19,"STANDARD","EFFICACY","18","Imatinib (GLEEVEC™)","NDA021588","GLEEVEC is indicated for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)","Assessment tool not reported in PI or medical review",NA,"Objective Response Rate","ORR","Overall Response Rate",0,NA,NA,NA,"RR: 83.3%",NA,"RR: 83.3%",NA,"58.6","96.4",NA,NA,NA,"Yes",0,1,"1",0,0,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2006-10-19,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","12","AP","SUPPL",2006-10-19,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2006-10-19,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","13","AP","SUPPL",2006-10-19,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2006-10-19,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","14","AP","SUPPL",2006-10-19,"UNKNOWN","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2006-10-19,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","17","AP","SUPPL",2006-10-19,"UNKNOWN","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2006-10-30,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","9","AP","SUPPL",2006-10-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2007-09-13,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","20","AP","SUPPL",2007-09-13,"UNKNOWN","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2008-04-30,"Manufacturing (CMC)",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","23","AP","SUPPL",2008-04-30,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2008-09-26,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","21","AP","SUPPL",2008-09-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2008-09-26,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","22","AP","SUPPL",2008-09-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2008-09-26,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","24","AP","SUPPL",2008-09-26,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2008-12-19,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","25","AP","SUPPL",2008-12-19,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2009-02-10,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","27","AP","SUPPL",2009-02-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2009-05-27,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","26","AP","SUPPL",2009-05-27,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2009-05-27,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","28","AP","SUPPL",2009-05-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2011-04-01,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","30","AP","SUPPL",2011-04-01,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2011-04-01,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","31","AP","SUPPL",2011-04-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2012-01-31,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","35","AP","SUPPL",2012-01-31,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2013-01-25,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","37","AP","SUPPL",2013-01-25,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2013-02-21,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","38","AP","SUPPL",2013-02-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2013-10-30,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","39","AP","SUPPL",2013-10-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2014-05-22,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","40","AP","SUPPL",2014-05-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2015-01-30,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","42","AP","SUPPL",2015-01-30,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2016-08-25,"Efficacy",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","45","AP","SUPPL",2016-08-25,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2016-08-25,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","46","AP","SUPPL",2016-08-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2016-09-27,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","47","AP","SUPPL",2016-09-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2017-04-24,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","49","AP","SUPPL",2017-04-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2017-09-06,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","51","AP","SUPPL",2017-09-06,"901 REQUIRED","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2017-09-29,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","52","AP","SUPPL",2017-09-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2018-08-21,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","53","AP","SUPPL",2018-08-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2020-08-10,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","56","AP","SUPPL",2020-08-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2020-08-10,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","57","AP","SUPPL",2020-08-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"IMATINIB MESYLATE","GLEEVEC","NDA021588",2022-03-24,"Labeling",NA,NA,NA,NA,"IMATINIB MESYLATE","IMATINIB MESYLATE","Novartis Pharmaceuticals Corporation","Prescription","Yes","001","TABLET","ORAL","EQ 100MG BASE, EQ 400MG BASE","60","AP","SUPPL",2022-03-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TALIMOGENE LAHERPAREPVEC","IMLYGIC","BLA125518",2015-10-27,"Type 1 - New Molecular Entity","Yes","Unresectable Cutaneous, Subcutaneous, and Nodal Recurrent Melanoma","Melanoma","436","TALIMOGENE LAHERPAREPVEC","TALIMOGENE LAHERPAREPVEC","Amgen Inc.",NA,NA,NA,NA,NA,NA,"1",NA,"ORIG",NA,NA,"TYPE 1","436|
(T=295|
C=141)","Talimogene laherparepvec (IMLYGIC™)","BLA125518","IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.",NA,"The safety and efficacy of intralesional injections of IMLYGIC compared with subcutaneously administered GM-CSF was evaluated in a multicenter, open-label, randomized clinical study in patients with stage IIIB, IIIC, and IV melanoma that was considered to be not surgically resectable","Durable Response Rate (CR or PR rate ≥6 mo)","DRR","Durable Response Rate",8,"DRR6 Diff","16.3% vs. 2.1%","14.2","RR: 16.3%",NA,"RR: 16.3%",NA,NA,NA,"Modified WHO","WHO","5","Yes",1,0,"1",0,1,"Yes","No","1","Oncolytic Virus","Oncolytic Virus","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",1986-06-04,"Type 1 - New Molecular Entity",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","1","AP","ORIG",1986-06-04,"UNKNOWN","TYPE 1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",1988-11-21,"Efficacy","Yes","AIDS-Related Kaposi's Sarcoma","KS","144","INTERFERON ALFA-2B","INTERFERON ALFA-2B",NA,NA,NA,NA,NA,NA,NA,"1002",NA,"SUPPL",1988-11-21,NA,"EFFICACY","144","Interferon alfa-2b (INTRON® A)","BLA103132","INTRON A is indicated for the treatment of selected patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma","PI notes 144 patients in total. It reports 2 studies, and data from one study with Ns; 
however, one study in which 44% of asx patients had a response and 7% of sx patients, the numbers are notdisclosed. Thus, I am not going to conclude that there are only two studies.",NA,"Response Rate","ORR","Response Rate",0,NA,"30 million IU study, RR: 29% (21/72) of 
35 million IU study, RR: 30% (7/23)",NA,"RR: 29% (30 million IU study) |
RR: 30% (35 million IU study)",NA,"RR: 29% (30 million IU study) |
RR: 30% (35 million IU study)",NA,"19.0 | 13.2","41.1 | 52.9",NA,NA,NA,"Yes",0,1,"1",0,0,"Yes","No","1","Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",1992-07-13,"Efficacy",NA,"Not available",NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","1030","AP","SUPPL",1992-07-13,"UNKNOWN","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",1993-05-14,"Efficacy",NA,"Not available",NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","1040","AP","SUPPL",1993-05-14,"UNKNOWN","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",1995-12-05,"Efficacy","Yes","Adjuvant Melanoma","Melanoma","280","INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","1096","AP","SUPPL",1995-12-05,"UNKNOWN","EFFICACY","280|
(T=143|
C=137)","Interferon alfa-2b (INTRON® A)","BLA103132","INTRON A is indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence, within 56 days of surgery","I have not been able to validate that RFS was the prim endpoint for approval, as not stated in the PI; Supplment number also not validated externally","Randomized, controlled trial in 280 patients, IFN vs. observation","RFS","RFS","Relapse-Free Survival",1,NA,"RFS: 1.72 vs. 0.98 years; OS benefit also est 3.82 ys vs. 2.78 years",NA,"RFS: 1.72 vs. 0.98 years |
OS: 3.82 vs. 2.78 years",NA,"RFS: 1.72 vs. 0.98 years |
OS: 3.82 vs. 2.78 years",NA,NA,NA,"Investigator Assessment","Clinical","1","Yes",0,0,"0",0,1,"Yes","No","1","Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",1997-03-26,"Efficacy",NA,"Not available",NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","1107","AP","SUPPL",1997-03-26,"UNKNOWN","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",1997-04-29,"Supplement",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","1120","AP","SUPPL",1997-04-29,NA,"S",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",1997-11-06,"Efficacy",NA,"Follicular Lymphoma",NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","1116","AP","SUPPL",1997-11-06,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",1998-08-18,"Efficacy",NA,"Not available",NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","1127","AP","SUPPL",1998-08-18,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2001-06-21,"Efficacy",NA,"Not available",NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","1144","AP","SUPPL",2001-06-21,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2001-11-29,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5009","AP","SUPPL",2001-11-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2001-11-29,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5016","AP","SUPPL",2001-11-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2002-02-01,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5006","AP","SUPPL",2002-02-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2002-06-21,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5022","AP","SUPPL",2002-06-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2003-11-26,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5018","AP","SUPPL",2003-11-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2004-10-27,"Supplement",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5064","AP","SUPPL",2004-10-27,NA,"S",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2006-07-28,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5086","AP","SUPPL",2006-07-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2007-05-22,"Supplement",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5059","AP","SUPPL",2007-05-22,NA,"S",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2007-05-22,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5095","AP","SUPPL",2007-05-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2007-07-13,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5096","AP","SUPPL",2007-07-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2008-05-02,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5108","AP","SUPPL",2008-05-02,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2009-08-07,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5122","AP","SUPPL",2009-08-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2010-02-16,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5118","AP","SUPPL",2010-02-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2010-07-21,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5140","AP","SUPPL",2010-07-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2011-02-01,"Supplement",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5143","AP","SUPPL",2011-02-01,NA,"S",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2011-05-13,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5153","AP","SUPPL",2011-05-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2011-06-06,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5148","AP","SUPPL",2011-06-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2011-12-20,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5161","AP","SUPPL",2011-12-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2012-06-04,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5163","AP","SUPPL",2012-06-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2013-11-15,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5178","AP","SUPPL",2013-11-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2014-04-02,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5183","AP","SUPPL",2014-04-02,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2014-08-11,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5190","AP","SUPPL",2014-08-11,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2015-05-21,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5191","AP","SUPPL",2015-05-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2017-06-12,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5195","AP","SUPPL",2017-06-12,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2017-10-02,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5196","AP","SUPPL",2017-10-02,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2018-05-04,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5199","AP","SUPPL",2018-05-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2B","INTRON A","BLA103132",2021-11-26,"Labeling",NA,NA,NA,NA,"INTERFERON ALFA-2B","INTERFERON ALFA-2B","Merck Sharp & Dohme LLC","Prescription","No","003","VIAL",NA,"10MIU/VIAL, 18MIU/VIAL, 25MIU/VIAL","5202","AP","SUPPL",2021-11-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2009-11-05,"Type 1 - New Molecular Entity","Yes","Refractory Cutaneous T-Cell Lymphoma","CTCL","167","NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","1","AP","ORIG",2009-11-05,"STANDARD","TYPE 1","167","Romidepsin (ISTODAX®)","NDA022393","ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for: Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy","do we want to include non pivotal trials? Altho supportive voting for approval was based on both and both made it on the label?","ISTODAX was evaluated in 2 multicenter, single-arm clinical studies in patients with CTCL","Objective Response Rate (10)DOR/TTR (20)","ORR","Objective Response Rate",0,"RR diff","Pivotal Study: ORR 34% (32/96) (25, 45) vs. 15%
Supportive Study: ORR 35% (25/71) (25, 49)","19","RR: 34% (Pivotal Study) | 
RR: 35% (Supportive Study)",NA,"RR: 34% (Pivotal Study) | 
RR: 35% (Supportive Study)","15","25 |25","45|49","OPDREC","Composite","6","Yes",1,1,"1",0,0,"Yes","No","1","HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2011-04-12,"Labeling",NA,NA,NA,NA,"NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","1","AP","SUPPL",2011-04-12,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2011-06-16,"Efficacy",NA,"Fulfillment of PMR for safety","CTCL",NA,"NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","4","AP","SUPPL",2011-06-16,"PRIORITY","EFFICACY",NA,NA,NA,"Fulfillment of PMR for safety",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2011-09-30,"Labeling",NA,NA,NA,NA,"NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","6","AP","SUPPL",2011-09-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2013-06-13,"Labeling",NA,NA,NA,NA,"NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","11","AP","SUPPL",2013-06-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2013-09-13,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","12","AP","SUPPL",2013-09-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2014-10-15,"Efficacy",NA,"Updates several sections","CTCL",NA,"NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","13","AP","SUPPL",2014-10-15,"STANDARD","EFFICACY",NA,NA,NA,"This Prior Approval supplemental new drug application proposes changes to the following sections of the United States Prescribing Information (USPI): Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies, and Patient Counseling Information. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2016-07-27,"Labeling",NA,NA,NA,NA,"NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","14","AP","SUPPL",2016-07-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2018-11-27,"Labeling",NA,NA,NA,NA,"NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","15","AP","SUPPL",2018-11-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2021-03-24,"Labeling",NA,NA,NA,NA,"NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","16","AP","SUPPL",2021-03-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"ROMIDEPSIN","ISTODAX","NDA022393",2021-07-30,"Efficacy",NA,NA,NA,NA,"NULL","ROMIDEPSIN","Celgene Corporation","Prescription","Yes","001","POWDER","INTRAVENOUS","10MG/VIAL","17","AP","SUPPL",2021-07-30,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","HDAC Inhibitor",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1965-02-01,"Type 5 - New Formulation or New Manufacturer","Yes","Mycosis Fungoides","CTCL",NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","1","AP","ORIG",1965-02-01,"STANDARD","TYPE 5",NA,"Triamcinolone Acetonide (KENALOG-40®)","NDA014901","Mycosis Fungoides","Efficacy not confirmed; original indication not confirmed",NA,NA,"Missing",NA,NA,NA,"Not listed in PI",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,"Injection"
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1978-04-07,"Labeling",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","10","AP","SUPPL",1978-04-07,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1978-04-07,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","16","AP","SUPPL",1978-04-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1979-07-17,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","17","AP","SUPPL",1979-07-17,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1979-07-27,"Labeling",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","9","AP","SUPPL",1979-07-27,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1979-08-21,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","19","AP","SUPPL",1979-08-21,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1980-05-20,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","18","AP","SUPPL",1980-05-20,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1982-06-30,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","21","AP","SUPPL",1982-06-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1984-04-13,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","24","AP","SUPPL",1984-04-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1985-06-14,"Labeling",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","25","AP","SUPPL",1985-06-14,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1985-12-04,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","22","AP","SUPPL",1985-12-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1986-11-19,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","27","AP","SUPPL",1986-11-19,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1987-11-30,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","26","AP","SUPPL",1987-11-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1991-07-19,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","29","AP","SUPPL",1991-07-19,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1992-02-14,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","28","AP","SUPPL",1992-02-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1994-03-28,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","30","AP","SUPPL",1994-03-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1995-01-10,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","31","AP","SUPPL",1995-01-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",1996-05-22,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","33","AP","SUPPL",1996-05-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",2001-01-05,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","35","AP","SUPPL",2001-01-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",2006-11-20,"Labeling",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","34","AP","SUPPL",2006-11-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",2010-01-28,"Labeling",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","37","AP","SUPPL",2010-01-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",2011-06-16,"Labeling",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","38","AP","SUPPL",2011-06-16,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",2011-07-15,"Labeling",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","39","AP","SUPPL",2011-07-15,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",2014-07-03,"Labeling",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","42","AP","SUPPL",2014-07-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",2015-10-26,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","43","AP","SUPPL",2015-10-26,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",2018-03-29,"Labeling",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","44","AP","SUPPL",2018-03-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",2018-06-22,"Labeling",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","45","AP","SUPPL",2018-06-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRIAMCINOLONE ACETONIDE","KENALOG-40","NDA014901",2019-04-12,"Manufacturing (CMC)",NA,NA,NA,NA,"TRIAMCINOLONE ACETONIDE","TRIAMCINOLONE ACETONIDE","E.R. Squibb & Sons, L.L.C.","Prescription","Yes","001","INJECTABLE","INJECTION","2MG, 4MG, 1MG, 16MG, 8MG","47","AP","SUPPL",2019-04-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TEBENTAFUSP-TEBN","KIMMTRAK","BLA761228",2022-01-25,"Type 1 - New Molecular Entity","Yes","HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma","Melanoma","378","TEBENTAFUSP","TEBENTAFUSP","Immunocore Commercial LLC","Prescription","No","001","INJECTABLE","INJECTION","100MCG/0.5ML","1","AP","ORIG",2022-01-25,"PRIORITY","TYPE 1","378","Tebentafusp-tebn (KIMMTRAK®)","BLA761228","KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma",NA,NA,NA,"OS",NA,3,"HR",NA,"0.51","HR: 0.51","HR: 0.51",NA,NA,NA,NA,NA,NA,NA,"Yes",1,NA,NA,NA,NA,"Yes","No",NA,"Bispecific Antibody","Bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor CD3 T cell engager","Immunotherapy",NA,NA
"TIRBANIBULIN","KLISYRI","NDA213189",2020-12-14,"Type 1 - New Molecular Entity","Yes","Actinic keratosis of the face or scalp","AK","702","TIRBANIBULIN","TIRBANIBULIN","Almirall, LLC","Prescription","Yes","001","OINTMENT","TOPICAL","1%","1","AP","ORIG",2020-12-14,"STANDARD","TYPE 1","702|
(T=353|
C=349)","Tirbanibulin (KLISYRI)","NDA213189","Actinic keratosis of the face or scalp",NA,"Two double-blind, vehicle-controlled clinical trials (NCT03285477 and NCT03285490) were conducted with 702 adult subjects with actinic keratosis on the face or scalp","Complete Clearance Rate","CCR","Complete Clearance Rate",5,NA,"Study 1 - 77/175 (44%) |
Study 2 - 97/178 (54%)",NA,"CCR: 44% (Study 1) |
CCR: 54% (Study 2)",NA,"CCR: 44% (Study 1) |
CCR: 54% (Study 2)",NA,NA,NA,"Investigator Assessment","Clinical","1","yes",1,0,"1",1,1,"Yes","No","1","Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",1999-12-03,"Type 1 - New Molecular Entity","Yes","Non-Hyperkeratotic Actinic Keratoses of the Face or Scalp","AK","241","NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","1","AP","ORIG",1999-12-03,"STANDARD","TYPE 1","241|
(T=180|
C=61)","Aminolevulinic HCL 20% Solution (LEVULAN® KERASTICK™)","NDA020965","The LEVULAN KERASTICK for Topical Solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp","Of note the language in the PI says 232 patients, but the numbers in the table add up to 241 patients, so that's what I'm going with","LEVULAN KERASTICK for Topical Solution, 20%, plus blue light at 6-10.9 J/cm2, has been used to treat actinic keratoses in 232 patients in two phase 3 studies","Complete Response Rate at Week 8 on per-protocol population","CCR","Complete Response Rate",5,"RR diff","CRR 66% (119/180) vs. 13% (8/61) @ wk 8 (This is the compilation of Trial 1 and 2)","53","CCR: 69% (Trial 1) |
CCR: 63% (Trial 2)",NA,"CCR: 69% (Trial 1) |
CCR: 63% (Trial 2)",NA,NA,NA,"Investigator Assessment","Clinical","1","Yes",1,0,"1",1,1,"Yes","No","1","Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2001-07-27,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","1","AP","SUPPL",2001-07-27,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2003-03-26,"Labeling",NA,NA,NA,NA,"NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","2","AP","SUPPL",2003-03-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2003-06-27,"Labeling",NA,NA,NA,NA,"NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","3","AP","SUPPL",2003-06-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2003-07-11,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","4","AP","SUPPL",2003-07-11,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2009-07-17,"Labeling",NA,NA,NA,NA,"NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","6","AP","SUPPL",2009-07-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2010-03-12,"Efficacy","Yes","Allow user to mix contents for 30 seconds prior to use & to use 'Kerastick Krusher'","AK",NA,"NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","7","AP","SUPPL",2010-03-12,"STANDARD","EFFICACY",NA,"Aminolevulinic HCL 20% Solution (LEVULAN® KERASTICK™)","NDA020965","This “Prior Approval” supplemental new drug application provides for revisions to the Clinical Studies section of the labeling",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2013-11-14,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","13","AP","SUPPL",2013-11-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2016-01-07,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","14","AP","SUPPL",2016-01-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2018-03-06,"Efficacy","Yes","Minimally to moderately thick Actinic Keratosis of the upper extremities","AK","269","NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","15","AP","SUPPL",2018-03-06,"STANDARD","EFFICACY","269|
(T=135|
C=134)","Aminolevulinic HCL 20% Solution (LEVULAN® KERASTICK™)","NDA020965","This Prior Approval supplemental new drug application proposed an expanded indication for the treatment of minimally to moderately thick actinic keratosis of the upper extremities in conjunction with the BLU-U ® Blue Light Photodynamic Therapy Illuminator.",NA,"multicenter randomized, parallel-group, evaluator-blinded, vehicle-controlled trial of 269 subjects","Complete clearance of all actinic keratosis lesions in the treatment area 12 weeks after initial treatment.","CCR","Complete Response Rate",5,NA,"CCR: 31% (42/135)",NA,"CCR: 31%",NA,"CCR: 31%",NA,NA,NA,NA,NA,"1","Yes",0,0,"1",1,1,"Yes","No","1","Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2018-04-19,"Labeling",NA,NA,NA,NA,"NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","16","AP","SUPPL",2018-04-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"AMINOLEVULINIC ACID HYDROCHLORIDE","LEVULAN","NDA020965",2022-05-09,"Labeling",NA,NA,NA,NA,"NULL","AMINOLEVULINIC ACID HYDROCHLORIDE","DUSA Pharmaceuticals, Inc.","Prescription","Yes","001","SOLUTION","TOPICAL","20%","17","AP","SUPPL",2022-05-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"CEMIPLIMAB-RWLC","LIBTAYO","BLA761097",2018-09-28,"Type 1 - New Molecular Entity","Yes","Locally Advanced or Metastatic Squamous Cell Carcinoma","SCC","108","CEMIPLIMAB","CEMIPLIMAB-RWLC","Regeneron Pharmaceuticals, Inc.","Prescription","No","001","INJECTABLE","INTRAVENOUS","350MG","1","AP","ORIG",2018-09-28,"PRIORITY","TYPE 1","108|
(mSCC=75|
laSCC=33)","Cemiplimab-rwlc (LIBTAYO®)","BLA761097","LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation",NA,"Two open-label, multi-center, non-randomized, multicohort studies (Study 1423 and Study 1540)","Objective Response Rate","ORR","Overall Response Rate",0,"RR diff","46.7% vs. 15% (mSCC) | 48.5% vs. 25% (laSCC)","31.7 | 23.5","RR: 46.7% (mCSCC) | 
RR: 48.5% (laCSCC)",NA,"RR: 46.7% (mCSCC) | 
RR: 48.5% (laCSCC)","15
25","35.1 |30.8","58.6 |66.5","mCSCC-RECIST;laCSCC-Composite(RECIST plus medical photography WHO criteria)","Composite","6","Yes",1,1,"1",0,0,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"CEMIPLIMAB-RWLC","LIBTAYO","BLA761097",2019-01-18,"Labeling",NA,NA,NA,NA,"CEMIPLIMAB","CEMIPLIMAB-RWLC","Regeneron Pharmaceuticals, Inc.","Prescription","No","001","INJECTABLE","INTRAVENOUS","350MG","2","AP","SUPPL",2019-01-18,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"CEMIPLIMAB-RWLC","LIBTAYO","BLA761097",2019-03-20,"Labeling",NA,NA,NA,NA,"CEMIPLIMAB","CEMIPLIMAB-RWLC","Regeneron Pharmaceuticals, Inc.","Prescription","No","001","INJECTABLE","INTRAVENOUS","350MG","1","AP","SUPPL",2019-03-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"CEMIPLIMAB-RWLC","LIBTAYO","BLA761097",2020-06-25,"Efficacy",NA,"Updates for response data",NA,NA,"CEMIPLIMAB","CEMIPLIMAB-RWLC","Regeneron Pharmaceuticals, Inc.","Prescription","No","001","INJECTABLE","INTRAVENOUS","350MG","5","AP","SUPPL",2020-06-25,"STANDARD","EFFICACY",NA,NA,NA,"Revises the Clinical Studies section of the prescribing information to include additional response data from Trials R2810-ONC-1540 and R2810-ONC-1423.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"CEMIPLIMAB-RWLC","LIBTAYO","BLA761097",2020-11-10,"Labeling",NA,NA,NA,NA,"CEMIPLIMAB","CEMIPLIMAB-RWLC","Regeneron Pharmaceuticals, Inc.","Prescription","No","001","INJECTABLE","INTRAVENOUS","350MG","3","AP","SUPPL",2020-11-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"CEMIPLIMAB-RWLC","LIBTAYO","BLA761097",2021-02-09,"Efficacy","Yes","Locally Advanced Basal Cell Carcinoma","BCC","112","CEMIPLIMAB","CEMIPLIMAB-RWLC","Regeneron Pharmaceuticals, Inc.","Prescription","No","001","INJECTABLE","INTRAVENOUS","350MG","8","AP","SUPPL",2021-02-09,"PRIORITY","EFFICACY","112|
(laBCC=84)","Cemiplimab-rwlc (LIBTAYO®)","BLA761097","For the treatment of patients with locally advanced BCC (laBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate",NA,"An open-label, multi-center, non-randomized study","Objective Response Rate","ORR","Objective Response Rate",0,NA,"24/84 (29%)",NA,"RR: 29%",NA,"RR: 29%","20","19","40","mCSCC-RECIST;laCSCC-Composite(RECIST plus medical photography WHO criteria)","Composite","6","Yes",1,1,"1",0,0,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,"the 20% lb_95CI comes from the Lancet Oncology Article, not from the PI or the review, as it was not available"
"CEMIPLIMAB-RWLC","LIBTAYO","BLA761097",2021-02-09,"Efficacy","Yes","Metastatic Basal Cell Carcinoma","BCC","112","CEMIPLIMAB","CEMIPLIMAB-RWLC","Regeneron Pharmaceuticals, Inc.","Prescription","No","001","INJECTABLE","INTRAVENOUS","350MG","9","AP","SUPPL",2021-02-09,"PRIORITY","EFFICACY","112|
(mBCC=28)","Cemiplimab-rwlc (LIBTAYO®)","BLA761097","For the treatment of patients with metastatic BCC (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate",NA,"An open-label, multi-center, non-randomized study","Objective Response Rate","ORR","Objective Response Rate",0,NA,"6/28 (21%)",NA,"RR: 21%",NA,"RR: 21%",NA,"8","41","Composite(RECIST plus medical photography WHO criteria)","Composite","6","Yes",1,1,"1",0,0,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"CEMIPLIMAB-RWLC","LIBTAYO","BLA761097",2021-02-22,"Efficacy",NA,NA,NA,NA,"CEMIPLIMAB","CEMIPLIMAB-RWLC","Regeneron Pharmaceuticals, Inc.","Prescription","No","001","INJECTABLE","INTRAVENOUS","350MG","7","AP","SUPPL",2021-02-22,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1957-10-24,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","1","AP","ORIG",1957-10-24,"STANDARD","TYPE 1",NA,"Methylprednisolone (MEDROL)","NDA011153","Mycosis Fungoides","DESI Drug; efficacy not confirmed",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Tablet"
"METHYLPREDNISOLONE","MEDROL","NDA011153",1976-09-10,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","37","AP","SUPPL",1976-09-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1978-04-11,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","41","AP","SUPPL",1978-04-11,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1979-04-05,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","39","AP","SUPPL",1979-04-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1979-04-05,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","42","AP","SUPPL",1979-04-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1979-05-30,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","40","AP","SUPPL",1979-05-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1980-04-14,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","43","AP","SUPPL",1980-04-14,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1980-10-08,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","44","AP","SUPPL",1980-10-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1983-03-09,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","46","AP","SUPPL",1983-03-09,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1987-02-24,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","47","AP","SUPPL",1987-02-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1989-01-05,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","49","AP","SUPPL",1989-01-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1993-01-28,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","52","AP","SUPPL",1993-01-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1993-12-28,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","51","AP","SUPPL",1993-12-28,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",1999-12-01,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","58","AP","SUPPL",1999-12-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",2002-10-25,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","59","AP","SUPPL",2002-10-25,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",2013-07-18,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","71","AP","SUPPL",2013-07-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",2018-07-24,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","75","AP","SUPPL",2018-07-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE","MEDROL","NDA011153",2019-08-26,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE","METHYLPREDNISOLONE","c(""Pharmacia and Upjohn Company LLC"", ""Greenstone LLC"")","Discontinued","No","005","TABLET","ORAL","4MG, 2MG, 16MG, 8MG, 24MG, 32MG","77","AP","SUPPL",2019-08-26,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","MEDROL ACETATE","NDA012421",1960-06-21,"Type 3 - New Dosage Form","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","No","002","OINTMENT","TOPICAL","0.25%, 1%","1","AP","ORIG",1960-06-21,"STANDARD","TYPE 3",NA,"Methylprednisolone Acetate (MEDROL ACETATE)","NDA012421","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet; label could not be found, thus, I'm assuming indication includes MF, as other formulations do so generically",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Topical formulation"
"METHYLPREDNISOLONE ACETATE","MEDROL ACETATE","NDA012421",1976-02-27,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","OINTMENT","TOPICAL","0.25%, 1%","17","AP","SUPPL",1976-02-27,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","MEDROL ACETATE","NDA012421",1977-11-11,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","OINTMENT","TOPICAL","0.25%, 1%","18","AP","SUPPL",1977-11-11,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","MEDROL ACETATE","NDA012421",1980-02-29,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","OINTMENT","TOPICAL","0.25%, 1%","19","AP","SUPPL",1980-02-29,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","MEDROL ACETATE","NDA012421",1981-12-28,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","OINTMENT","TOPICAL","0.25%, 1%","21","AP","SUPPL",1981-12-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE ACETATE","MEDROL ACETATE","NDA012421",1982-04-02,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","002","OINTMENT","TOPICAL","0.25%, 1%","22","AP","SUPPL",1982-04-02,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2013-05-29,"Type 1 - New Molecular Entity","Yes","Unresectable or Metastatic BRAF-Mutated Melanoma","Melanoma","322","TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","1","AP","ORIG",2013-05-29,"STANDARD","TYPE 1","322|
(T=214|
C=108)","Trametinib (MEKINIST®)","NDA204114","MEKINIST is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",NA,"The safety and efficacy of MEKINIST were evaluated in an international, multi-center, randomized (2:1), open label, active-controlled trial (Trial 1) in 322 patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma","Progression-Free Survival","PFS","Progression-Free Survival",2,"HR","4.8 vs. 1.5 mo","0.47","HR: 0.47","HR: 0.47",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",1,0,"0",0,1,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2014-01-08,"Efficacy","Yes","Unresectable or Metastatic BRAF-Mutated Melanoma","Melanoma","162","TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","1","AP","SUPPL",2014-01-08,"PRIORITY","EFFICACY","162|
(DT2=55|
DT1=54
D=53)","Trametinib (MEKINIST®) In Combination With Dabrafenib (TAFINLAR®)","NDA204114","MEKINIST is indicated, in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.","You need to look into the Approval package for Dabrafenib to find that a co-primary endpoint was used, as the label makes it look like ORR was the primary endpoint. 
Look at page 289 or 290 of the 505 page review","Trial 2 was a multicenter, open-label, randomized (1:1:1) dose-ranging trial designed to evaluate the clinical activity and safety of TAFINLAR in combination with trametinib (at two different doses) and to compare the safety with TAFINLAR as a single agent in patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma","Objective Response Rate (ORR)
PFS","Coprimary","Objective Response Rate & Progression-Free Survival",4,"RR diff","76% (41/54) vs. 54% (29/54) : 9.4 vs 5.8 mo","22","ORR: 76%",NA,"ORR: 76%",NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"1",0,1,"No","Yes","0","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,"AA aproval, later converted to RA"
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2014-08-13,"Manufacturing (CMC)",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","2","AP","SUPPL",2014-08-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2014-09-26,"Manufacturing (CMC)",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","3","AP","SUPPL",2014-09-26,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2015-11-20,"Efficacy","Yes","Unresectable or Metastatic Melanoma with a BRAF-Mutated Melanoma In Combination with Dabrafenib","Melanoma","423","TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","4","AP","SUPPL",2015-11-20,"PRIORITY","EFFICACY","423|
(DT=211|
DP=212)","Trametinib (MEKINIST®) In Combination With Dabrafenib (TAFINLAR®)","NDA204114","MEKINIST is indicated, in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.","Unable to validate ODAC, Fast Track 

Trial 3 (combi-v) is not on the PI for Mekinist on the 2015 approval, it is for the TAFINLAR. Since we are being strict about using the label as the reference, we will use only trial 2, which the major efficacy outcomes was PFS","The safety and efficacy of MEKINIST administered with dabrafenib were evaluated in an international, randomized, double-blind, active-controlled trial (the COMBI-d study; NCT01584648).","PFS","PFS","Progression-Free Survival",2,"HR","9.3 mon vs 8.8mon","0.75
","HR: 0.75","HR: 0.75",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"0",1,1,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy","No",NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2017-02-24,"Labeling",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","6","AP","SUPPL",2017-02-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2017-06-22,"Efficacy",NA,"A new indication in BRAF mutant NSCLC","NSCLC",NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","5","AP","SUPPL",2017-06-22,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for Mekinist, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2018-03-09,"Labeling",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","8","AP","SUPPL",2018-03-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2018-04-30,"Efficacy","Yes","Adjuvant BRAF Mutant Melanoma In Combination with Dabrafenib","Melanoma","870","TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","7","AP","SUPPL",2018-04-30,"PRIORITY","EFFICACY","870|
(T=438|
C=432)","Trametinib (MEKINIST®) In Combination With Dabrafenib (TAFINLAR®)","NDA204114","MEKINIST is indicated, in combination with dabrafenib for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",NA,"COMBI-AD (NCT 01682083) was an international, multi-center, randomized, double-blind, placebo-controlled trial that enrolled patients with Stage III melanoma with BRAF V600E or V600K mutations","Relapse-Free Survival","RFS","Relapse-Free Survival",1,"HR","NE vs. 16.6 mo","0.47","HR: 0.47","HR: 0.47",NA,NA,NA,NA,"Investigator assessment","Clinical","1","Yes",0,0,"0",1,1,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2018-05-04,"Efficacy",NA,"A new indication in BRAF mutant ATC","ATC",NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","9","AP","SUPPL",2018-05-04,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for MEKINIST in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2019-07-16,"Labeling",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","13","AP","SUPPL",2019-07-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2019-10-06,"Efficacy","Yes","Updating results  in subjects with brain metastases","Melanoma","121","TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","12","AP","SUPPL",2019-10-06,"STANDARD","EFFICACY","121","Trametinib (MEKINIST®) In Combination With Dabrafenib (TAFINLAR®)","NDA204114","Updating results  in subjects with BRAF mutation-positive melanoma that has metastasized to the brain",NA,"The COMBI-MB study -  non-randomized, open-label, multi-center, multi-cohort trial","Overall Response Rate","ORR","Overall Response Rate",0,NA,NA,NA,"RR: 50%",NA,"RR: 50%",NA,"40","60","Modified RECIST","mRECIST","7","Yes",0,1,"1",0,0,NA,"No",NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2020-04-09,"Labeling",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","14","AP","SUPPL",2020-04-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2020-06-23,"Labeling",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","16","AP","SUPPL",2020-06-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2021-05-07,"Labeling",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","18","AP","SUPPL",2021-05-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2021-12-03,"Labeling",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","20","AP","SUPPL",2021-12-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2022-01-28,"Efficacy",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","19","AP","SUPPL",2022-01-28,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2022-01-28,"Labeling",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","21","AP","SUPPL",2022-01-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2022-05-27,"Efficacy",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","23","AP","SUPPL",2022-05-27,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"TRAMETINIB DIMETHYL SULFOXIDE","MEKINIST","NDA204114",2022-06-22,"Efficacy",NA,NA,NA,NA,"TRAMETINIB DIMETHYL SULFOXIDE","TRAMETINIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","003","TABLET","ORAL","EQ 0.5MG, EQ 1MG, EQ 2MG","24","AP","SUPPL",2022-06-22,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"BINIMETINIB","MEKTOVI","NDA210498",2018-06-27,"Type 1 - New Molecular Entity and Type 4 - New Combination","Yes","Unresectable or Metastatic BRAF-Mutated Melanoma In Combination with Encorafenib","Melanoma","577","BINIMETINIB","BINIMETINIB","Array BioPharma Inc.","Prescription","Yes","001","TABLET","ORAL","15MG","1","AP","ORIG",2018-06-27,"STANDARD","TYPE 1/4","577|
(Bin/Enc=192|
Enc=192|
Vem=191)","Binimetinib (MEKTOVI®) in combination with Encorafenib","NDA210498","MEKTOVI is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic
melanoma with a BRAF V600E or V600K mutation, as detected by an
FDA-approved test.",NA,"MEKTOVI in combination with encorafenib was evaluated in a randomized, active-controlled, open-label, multicenter trial (COLUMBUS; NCT01909453).","Progression-Free Survival (Prim)
ORR/OS/DOR(Sec)","PFS","Progression-Free Survival",2,"HR","14.9 vs. 7.3 mo","0.54","HR: 0.54","HR: 0.54",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",1,0,"0",0,1,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"BINIMETINIB","MEKTOVI","NDA210498",2019-01-23,"Efficacy",NA,"Update label with OS data from COLUMBUS Trial",NA,NA,"BINIMETINIB","BINIMETINIB","Array BioPharma Inc.","Prescription","Yes","001","TABLET","ORAL","15MG","1","AP","SUPPL",2019-01-23,"STANDARD","EFFICACY",NA,NA,NA,"This Prior Approval supplemental new drug application provides for an update to the Clinical Studies section (14) of the U.S. prescribing information to include updated overall survival (OS) data from Part 1 of COLUMBUS trial (Study CMEK162B2301)",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1959-08-10,"Type 2 - New Active Ingredient","Yes","Mycosis Fungoides","CTCL",NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","1","AP","ORIG",1959-08-10,"STANDARD","TYPE 2",NA,"Methotrexate Sodium Solution","NDA011719","Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas.","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,"Response Rate","ORR","Response Rate",0,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,"1",NA,NA,"Yes","No","1","Antimetabolite","Antimetabolite","Cytotoxic Agent","Y","Solution"
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1975-07-22,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","21","AP","SUPPL",1975-07-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1975-11-03,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","22","AP","SUPPL",1975-11-03,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1975-11-03,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","23","AP","SUPPL",1975-11-03,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1975-12-05,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","24","AP","SUPPL",1975-12-05,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1976-06-29,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","25","AP","SUPPL",1976-06-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1976-06-29,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","26","AP","SUPPL",1976-06-29,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1976-06-29,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","28","AP","SUPPL",1976-06-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1976-08-03,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","27","AP","SUPPL",1976-08-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1976-09-07,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","29","AP","SUPPL",1976-09-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1976-09-07,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","30","AP","SUPPL",1976-09-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1976-09-07,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","31","AP","SUPPL",1976-09-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1976-09-14,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","32","AP","SUPPL",1976-09-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1976-09-14,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","33","AP","SUPPL",1976-09-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1977-03-18,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","37","AP","SUPPL",1977-03-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1977-03-28,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","36","AP","SUPPL",1977-03-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1977-07-14,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","38","AP","SUPPL",1977-07-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1977-08-02,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","35","AP","SUPPL",1977-08-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1978-08-08,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","46","AP","SUPPL",1978-08-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1978-08-22,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","39","AP","SUPPL",1978-08-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1978-12-14,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","47","AP","SUPPL",1978-12-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1979-01-02,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","43","AP","SUPPL",1979-01-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1979-02-15,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","49","AP","SUPPL",1979-02-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1979-10-15,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","51","AP","SUPPL",1979-10-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1980-02-29,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","52","AP","SUPPL",1980-02-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1980-06-11,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","50","AP","SUPPL",1980-06-11,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1980-12-03,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","53","AP","SUPPL",1980-12-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1981-05-11,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","54","AP","SUPPL",1981-05-11,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1981-12-07,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","56","AP","SUPPL",1981-12-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1982-03-31,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","57","AP","SUPPL",1982-03-31,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1982-03-31,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","58","AP","SUPPL",1982-03-31,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1982-08-24,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","62","AP","SUPPL",1982-08-24,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1983-04-08,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","59","AP","SUPPL",1983-04-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1983-04-08,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","63","AP","SUPPL",1983-04-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1986-09-16,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","71","AP","SUPPL",1986-09-16,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1986-09-16,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","73","AP","SUPPL",1986-09-16,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1986-12-08,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","75","AP","SUPPL",1986-12-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1987-03-19,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","70","AP","SUPPL",1987-03-19,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1987-08-18,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","74","AP","SUPPL",1987-08-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1988-04-07,"Efficacy",NA,"Osteogenic Sarcoma",NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","77","AP","SUPPL",1988-04-07,NA,"EFFICACY",NA,NA,NA,"For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1988-04-07,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","78","AP","SUPPL",1988-04-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1988-04-21,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","79","AP","SUPPL",1988-04-21,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1989-03-01,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","81","AP","SUPPL",1989-03-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1990-01-18,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","76","AP","SUPPL",1990-01-18,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1990-10-24,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","85","AP","SUPPL",1990-10-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1991-02-20,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","83","AP","SUPPL",1991-02-20,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1991-11-05,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","86","AP","SUPPL",1991-11-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1992-01-23,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","89","AP","SUPPL",1992-01-23,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1995-04-25,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","94","AP","SUPPL",1995-04-25,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1997-05-20,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","95","AP","SUPPL",1997-05-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1998-06-22,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","97","AP","SUPPL",1998-06-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1999-02-12,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","98","AP","SUPPL",1999-02-12,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",1999-10-29,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","99","AP","SUPPL",1999-10-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2000-11-08,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","96","AP","SUPPL",2000-11-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2001-05-08,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","100","AP","SUPPL",2001-05-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2002-02-20,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","102","AP","SUPPL",2002-02-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2002-02-20,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","103","AP","SUPPL",2002-02-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2003-01-03,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","104","AP","SUPPL",2003-01-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2003-07-29,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","105","AP","SUPPL",2003-07-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2004-01-27,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","106","AP","SUPPL",2004-01-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2004-12-15,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","107","AP","SUPPL",2004-12-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2005-04-13,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","108","AP","SUPPL",2005-04-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2011-11-01,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","117","AP","SUPPL",2011-11-01,"901 REQUIRED","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2015-08-14,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","121","AP","SUPPL",2015-08-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2015-11-20,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","122","AP","SUPPL",2015-11-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2016-02-03,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","124","AP","SUPPL",2016-02-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2018-03-15,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","126","AP","SUPPL",2018-03-15,"901 REQUIRED","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2018-05-07,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","125","AP","SUPPL",2018-05-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2021-03-29,"Efficacy",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","131","AP","SUPPL",2021-03-29,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE PRESERVATIVE FREE","NDA011719",2022-05-02,"Labeling",NA,NA,NA,NA,"METHOTREXATE SODIUM","METHOTREXATE","Hospira, Inc.","Discontinued","Yes","014","INJECTABLE","INJECTION","EQ 25MG BASE/ML, EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), EQ 500MG BASE/20ML (EQ 25MG BASE/ML), EQ 20MG BASE/2ML (EQ 10MG BASE/ML), EQ 20MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 2.5MG BASE/ML, EQ 25MG BASE/ML, EQ 100MG BASE/VIAL, EQ 50MG BASE/2ML (EQ 25MG BASE/ML), EQ 1GM BASE/VIAL, EQ 1GM BASE/40ML (EQ 25MG BASE/ML)","135","AP","SUPPL",2022-05-02,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1953-12-07,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","1","AP","ORIG",1953-12-07,"PRIORITY","TYPE 1",NA,"Methotrexate Sodium Tablet","NDA008085","Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas.","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,"Response Rate","ORR","Response Rate",0,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,"1",NA,NA,"Yes","No","1","Antimetabolite","Antimetabolite","Cytotoxic Agent","Y","Tablet"
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1976-01-26,"Supplement",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","11","AP","SUPPL",1976-01-26,"PRIORITY","S",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1977-04-29,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","13","AP","SUPPL",1977-04-29,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1977-04-29,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","14","AP","SUPPL",1977-04-29,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1978-07-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","16","AP","SUPPL",1978-07-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1979-05-01,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","15","AP","SUPPL",1979-05-01,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1979-09-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","17","AP","SUPPL",1979-09-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1983-02-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","19","AP","SUPPL",1983-02-04,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1983-08-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","21","AP","SUPPL",1983-08-04,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1984-04-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","23","AP","SUPPL",1984-04-04,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1984-07-19,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","24","AP","SUPPL",1984-07-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1986-09-16,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","30","AP","SUPPL",1986-09-16,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1986-12-08,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","31","AP","SUPPL",1986-12-08,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1988-10-31,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","27","AP","SUPPL",1988-10-31,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1988-10-31,"Efficacy",NA,"Rheumatoid Arthritis",NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","28","AP","SUPPL",1988-10-31,NA,"EFFICACY",NA,NA,NA,"Rheumatoid Arthritis",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1989-04-24,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","35","AP","SUPPL",1989-04-24,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1989-05-18,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","36","AP","SUPPL",1989-05-18,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1989-11-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","34","AP","SUPPL",1989-11-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1990-01-18,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","32","AP","SUPPL",1990-01-18,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1990-10-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","40","AP","SUPPL",1990-10-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1990-10-24,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","38","AP","SUPPL",1990-10-24,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1991-07-24,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","39","AP","SUPPL",1991-07-24,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1997-05-20,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","45","AP","SUPPL",1997-05-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1998-06-18,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","47","AP","SUPPL",1998-06-18,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",1999-10-29,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","48","AP","SUPPL",1999-10-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2000-02-09,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","50","AP","SUPPL",2000-02-09,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2000-11-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","46","AP","SUPPL",2000-11-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2001-05-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","51","AP","SUPPL",2001-05-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2002-02-20,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","53","AP","SUPPL",2002-02-20,"PRIORITY","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2002-02-20,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","54","AP","SUPPL",2002-02-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2003-10-24,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","52","AP","SUPPL",2003-10-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2003-10-24,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","55","AP","SUPPL",2003-10-24,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2006-05-31,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","58","AP","SUPPL",2006-05-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2015-12-02,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","65","AP","SUPPL",2015-12-02,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2016-01-29,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","66","AP","SUPPL",2016-01-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2018-03-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","68","AP","SUPPL",2018-03-15,"901 REQUIRED","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2019-08-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","63","AP","SUPPL",2019-08-16,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"METHOTREXATE SODIUM","METHOTREXATE SODIUM","NDA008085",2020-05-04,"Efficacy",NA,"Revise Indication and Usage for several indications",NA,NA,"NULL","NULL","NULL","Discontinued","Yes","002","TABLET","ORAL","EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","71","AP","SUPPL",2020-05-04,"STANDARD","EFFICACY",NA,NA,NA,"Revise Indication and Usage for several indications",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Antimetabolite","Antimetabolite","Cytotoxic Agent",NA,NA
"PREDNISONE","METICORTEN","NDA009766",1955-02-21,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","1","AP","ORIG",1955-02-21,"PRIORITY","TYPE 1",NA,"Prednisone (METICORTEN)","NDA009766","Mycosis Fungoides","DESI Drug; label for Orasone (which came out in Aug 1955 has MF on it; no label exists for meticorten); but pred is definitely indicated for MF",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y",NA
"PREDNISONE","METICORTEN","NDA009766",1978-01-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","5","AP","SUPPL",1978-01-25,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",1979-02-26,"Supplement",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","6","AP","SUPPL",1979-02-26,"PRIORITY","S",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",1980-08-27,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","7","AP","SUPPL",1980-08-27,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",1987-04-02,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","10","AP","SUPPL",1987-04-02,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",1992-07-06,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","11","AP","SUPPL",1992-07-06,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",1992-12-17,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","12","AP","SUPPL",1992-12-17,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",1993-09-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","13","AP","SUPPL",1993-09-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",1994-04-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","14","AP","SUPPL",1994-04-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",1997-08-26,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","16","AP","SUPPL",1997-08-26,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",2002-11-12,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","15","AP","SUPPL",2002-11-12,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",2002-11-12,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","8","AP","SUPPL",2002-11-12,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISONE","METICORTEN","NDA009766",2002-11-12,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","TABLET","ORAL","5MG, 1MG","9","AP","SUPPL",2002-11-12,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYL AMINOLEVULINATE HYDROCHLORIDE","METVIXIA","NDA021415",2004-07-27,"Type 3 - New Dosage Form","Yes","Non-Keratotic Actinic Keratoses of the Face and Scalp","AK","191","NULL","NULL","NULL","Discontinued","No","001","CREAM","TOPICAL","EQ 16.8% BASE","1","AP","ORIG",2004-07-27,"STANDARD","TYPE 3","191|
(T=130|
C=61)","Methyl aminolevulinate HCL 16.8% Cream (METVIXIA®)","NDA021415","METVIXIA is indicated for use in combination with 570 to 670 nm wavelength red light illumination using the CureLight BoradBand Model CureLight 01 lamp for treatment of non-keratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal currette) in the physician's office when other therapyies are unacceptable or considered medically less appropriate.",NA,"Two randomized, double-blind, vehicle controlled studies.","Complete Response Rate","CCR","Complete Response Rate",5,"RR diff","CRR 80% (104/130) vs. 28% (11/61)","52","CRR: 81% (Australian Study) |
CCR: 79% (U.S. Study)",NA,"CRR: 81% (Australian Study) |
CCR: 79% (U.S. Study)",NA,NA,NA,"Investigator Assessment","Clinical","1","Yes",0,0,"1",1,1,"Yes","No","1","Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHYL AMINOLEVULINATE HYDROCHLORIDE","METVIXIA","NDA021415",2005-05-31,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","001","CREAM","TOPICAL","EQ 16.8% BASE","1","AP","SUPPL",2005-05-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHYL AMINOLEVULINATE HYDROCHLORIDE","METVIXIA","NDA021415",2008-06-26,"Efficacy","Yes","Use of Metvixia with a new Lamp (Aktilite) in AKs","AK","211","NULL","NULL","NULL","Discontinued","No","001","CREAM","TOPICAL","EQ 16.8% BASE","3","AP","SUPPL",2008-06-26,"STANDARD","EFFICACY","211|(T=106|C=105)",NA,NA,"Provides for the use of Metvixia (methyl aminolevulinate hydrochloride) Cream, 16.8%, in combination with the new Aktilite® CL128 lamp for the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratoses of the face and scalp in immunocompetent patients.",NA,"Two multicenter, randomized, double-blind vehiclecontrolled clinical trials","Complete Response Rate","CCR","Complete Response Rate",NA,NA,NA,NA,"CCR: 59.2% (Study 1) | CCR: 68.4% (Study 2)",NA,"CCR: 59.2% (Study 1) | CCR: 68.4% (Study 2)",NA,NA,NA,"Investigator Assessment","Clinical","1","Yes",NA,0,"1",1,1,"Yes","No","1","Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHYL AMINOLEVULINATE HYDROCHLORIDE","METVIXIA","NDA021415",2012-11-20,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","No","001","CREAM","TOPICAL","EQ 16.8% BASE","4","AP","SUPPL",2012-11-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1949-03-15,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","1","AP","ORIG",1949-03-15,"PRIORITY","TYPE 1",NA,"Mechlorethamine HCL (MUSTARGEN®)","NDA006695","MUSTARGEN, administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma.","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Alkylating Agent","Alkylating Agent","Cytotoxic Agent","Y",NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1978-06-12,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","13","AP","SUPPL",1978-06-12,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1980-02-19,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","14","AP","SUPPL",1980-02-19,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1982-03-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","15","AP","SUPPL",1982-03-04,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1983-02-21,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","16","AP","SUPPL",1983-02-21,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1986-03-29,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","17","AP","SUPPL",1986-03-29,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1987-01-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","19","AP","SUPPL",1987-01-15,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1987-09-18,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","20","AP","SUPPL",1987-09-18,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1994-10-20,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","22","AP","SUPPL",1994-10-20,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1995-01-12,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","21","AP","SUPPL",1995-01-12,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1995-03-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","23","AP","SUPPL",1995-03-22,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1995-04-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","24","AP","SUPPL",1995-04-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1995-12-13,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","25","AP","SUPPL",1995-12-13,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1998-10-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","26","AP","SUPPL",1998-10-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",1998-10-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","27","AP","SUPPL",1998-10-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",2000-03-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","28","AP","SUPPL",2000-03-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",2000-11-17,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","29","AP","SUPPL",2000-11-17,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",2003-03-19,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","30","AP","SUPPL",2003-03-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","MUSTARGEN","NDA006695",2004-02-09,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL","31","AP","SUPPL",2004-02-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"SONIDEGIB PHOSPHATE","ODOMZO","NDA205266",2015-07-24,"Type 1 - New Molecular Entity","Yes","Locally Advanced Basal Cell Carcinoma","BCC","194","SONIDEGIB PHOSPHATE","SONIDEGIB","Sun Pharmaceutical Industries, Inc.","Prescription","Yes","001","CAPSULE","ORAL","EQ 200MG BASE","1","AP","ORIG",2015-07-24,"STANDARD","TYPE 1","194","Sonidegib (ODOMZO®)","NDA205266","ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.",NA,"The safety and effectiveness of ODOMZO were evaluated in a single, multicenter, double-blind, multiple cohort clinical trial conducted in patients with locally advanced basal cell carcinoma (laBCC) (n=194) or metastatic basal cell carcinoma (mBCC) (n=36) (Study 1)","Objective Response Rate (Prim End)
DOR (Sec End)","ORR","Objective Response Rate",0,"RR diff","58% (200mg) 44%(800mg)  vs. 20% included failed but labeled arm","38","RR: 57.5%",NA,"RR: 57.5%","20","44.7","69.7","Modified RECIST","mRECIST","7","Yes",1,0,"1",0,0,"Yes","No","1","Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,"This was a double-blind non-comparator trial, thus it's not single arm, but it's non-comparator
The application had a total of 230 patient (laBCC N=194 and mBCC n=36); thus since the indicatin is only for laBCC, I'm using N-194"
"SONIDEGIB PHOSPHATE","ODOMZO","NDA205266",2016-02-17,"Labeling",NA,NA,NA,NA,"SONIDEGIB PHOSPHATE","SONIDEGIB","Sun Pharmaceutical Industries, Inc.","Prescription","Yes","001","CAPSULE","ORAL","EQ 200MG BASE","3","AP","SUPPL",2016-02-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"SONIDEGIB PHOSPHATE","ODOMZO","NDA205266",2016-05-12,"Labeling",NA,NA,NA,NA,"SONIDEGIB PHOSPHATE","SONIDEGIB","Sun Pharmaceutical Industries, Inc.","Prescription","Yes","001","CAPSULE","ORAL","EQ 200MG BASE","2","AP","SUPPL",2016-05-12,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"SONIDEGIB PHOSPHATE","ODOMZO","NDA205266",2017-09-18,"Efficacy",NA,"Updates Clinical Studies Information","BCC",NA,"SONIDEGIB PHOSPHATE","SONIDEGIB","Sun Pharmaceutical Industries, Inc.","Prescription","Yes","001","CAPSULE","ORAL","EQ 200MG BASE","4","AP","SUPPL",2017-09-18,"STANDARD","EFFICACY",NA,NA,NA,"This Prior Approval supplemental new drug application provides for updates to the Clinical Studies (14) section of the full prescribing information to include updated Overall Response Rate (ORR) data from 12 to 30 months of patient follow up.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"SONIDEGIB PHOSPHATE","ODOMZO","NDA205266",2019-05-13,"Labeling",NA,NA,NA,NA,"SONIDEGIB PHOSPHATE","SONIDEGIB","Sun Pharmaceutical Industries, Inc.","Prescription","Yes","001","CAPSULE","ORAL","EQ 200MG BASE","6","AP","SUPPL",2019-05-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Smoothened Inhibitor","Smoothened Inhibitor","Targeted Therapy",NA,NA
"DENILEUKIN DIFTITOX","ONTAK","BLA103767",1999-02-05,"Type 1 - New Molecular Entity","Yes","Accelerated Approval for Persistent or Recurrent CD25+ Cutaneous T-Cell Lymphoma","CTCL","71","NULL","NULL","NULL","Prescription","No","001","VIAL",NA,"150UG/ML","1","AP","ORIG",1999-02-05,"PRIORITY","TYPE 1","71|
(18mcg=36|
9mcg=35)","Denileukin diftitox (ONTAK®)","BLA103767","Ontak is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express CD25 comonent of the IL-2 receptor","Note truly a single-arm study, as there were two dose levels (but not placebo controlled)","A randomized, double-blind study of two dose levels","Response Rate","ORR","Response Rate",0,"RR diff","23% (8/35) (9 mcg/kg/day) vs. 36% (13/36) (18 mcg/kg/day)","13","RR: 36% (18 mcg) |RR: 23% (9 mcg)",NA,"RR: 36% (18 mcg) |RR: 23% (9 mcg)",NA,NA,NA,"SWAT","SWAT","8","Yes",1,0,"1",0,1,"No","Yes","0","Cytokine-Cytotoxin","Cytokine-Cytotoxin","Cytotoxic Agent",NA,"Unclear if it went to ODAC"
"DENILEUKIN DIFTITOX","ONTAK","BLA103767",2008-10-15,"Efficacy","Yes","Regular Approval for Persistent or Recurrent CD25+ Cutaneous T-Cell Lymphoma","CTCL","144","NULL","NULL","NULL","Prescription","No","001","VIAL",NA,"150UG/ML","5094","AP","SUPPL",2008-10-15,"PRIORITY","EFFICACY","144|
(18mcg=55|
9mcg=45
C=44)","Denileukin diftitox (ONTAK®)","BLA103767","Ontak is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express CD25 comonent of the IL-2 receptor",NA,"Radominzed, double-blind controlled trial, placebo-controlled, 3-arm trial in patients with Stage Ia to III CD25+ CTCL","Response Rate","ORR","Response Rate",0,"RR diff","46% (25/55) vs. 15% (5/45) (18mcg) | 37% (17/45) vs. 15% (5/45) (9mcg) TYPO placebo should have n=44 ; confirm since total 3 arm 144","31 | 22","RR: 46% (18 mcg) | RR: 37% (9 mcg)",NA,"RR: 46% (18 mcg) | RR: 37% (9 mcg)",NA,NA,NA,"Weighted Skin Severity Index","WSSI","11","Yes",0,0,"1",1,1,"Yes","No","1","Cytokine-Cytotoxin","Cytokine-Cytotoxin","Cytotoxic Agent",NA,NA
"DENILEUKIN DIFTITOX","ONTAK","BLA103767",2010-03-05,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","001","VIAL",NA,"150UG/ML","5118","AP","SUPPL",2010-03-05,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine-Cytotoxin","Cytokine-Cytotoxin","Cytotoxic Agent",NA,NA
"DENILEUKIN DIFTITOX","ONTAK","BLA103767",2011-08-30,"Supplement",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","001","VIAL",NA,"150UG/ML","5119","AP","SUPPL",2011-08-30,NA,"S",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine-Cytotoxin","Cytokine-Cytotoxin","Cytotoxic Agent",NA,NA
"DENILEUKIN DIFTITOX","ONTAK","BLA103767",2019-02-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","001","VIAL",NA,"150UG/ML","5143","AP","SUPPL",2019-02-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine-Cytotoxin","Cytokine-Cytotoxin","Cytotoxic Agent",NA,NA
"DENILEUKIN DIFTITOX","ONTAK","BLA103767",2020-02-10,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","001","VIAL",NA,"150UG/ML","5144","AP","SUPPL",2020-02-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine-Cytotoxin","Cytokine-Cytotoxin","Cytotoxic Agent",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2014-12-22,"Type 1 - New Molecular Entity","Yes","Accelerated Approval for Unresectable or Metastatic Melanoma in the Second-Line Setting","Melanoma","120","NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","1","AP","ORIG",2014-12-22,"PRIORITY","TYPE 1","120","Nivolumab (OPDIVO®)","BLA125554","OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.","H0 can be found in the summary review 
Data based on CHECKMATE-037","BLA relied on the results of an interim, non-comparative analysis of an ongoing, randomized (2:1), open-label study (Protocol CA209037) conducted in patients with metastatic or locally advanced, unresectable melanoma that has progressed following ipilimumab and, if BRAF V600-mutation positive has also progressed following treatment with a BRAF inhibitor. The interim analysis was conducted in the first 120 patients randomized to receive nivolumab.
Trial 1 was a multicenter, open-label trial that randomized (2:1) patients with unresectable or metastatic melanoma to receive either OPDIVO administered intravenously at 3 mg/kg every 2 weeks or investigator’s choice of chemotherapy, either single-agent dacarbazine 1000 mg/m2 every 3 weeks or the combination of carboplatin AUC 6 every 3 weeks plus paclitaxel 175 mg/m2 every 3 weeks","Overall Response Rate (10 AA) OS (10 RA)
Of note, there was a co-primary endpoint with alpha splitting for the BLA that was granted AA. However, the OS data was immature, thus ORR was used for clinical benefit assessment.","ORR","Overall Response Rate",0,"RR diff","32% vs. 15%","17","RR: 32%",NA,"RR: 32%","15","23","41","RECIST","RECIST","3","Yes",1,1,"1",0,0,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,"On January 23, 2013, Breakthrough Therapy Designation was denied based on the following: (1) limited data regarding the details of the prior therapy administered for unresectable or metastatic melanoma, (2) no information was provided regarding the BRAF mutation status, (3) and response rates with nivolumab 31.1% (95% CI: 22.5%, 40.9%) not substantially superior to the response rates observed with available BRAF inhibitor therapy and not of sufficient magnitude to be likely to predict an effect on overall survival that is substantially superior to the survival effect with ipilimumab"
"NIVOLUMAB","OPDIVO","BLA125554",2015-04-14,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","3","AP","SUPPL",2015-04-14,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2015-04-14,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","4","AP","SUPPL",2015-04-14,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2015-09-30,"Efficacy","Yes","Accelerated Approval of OPDIVO with YERVOY in BRAF Wild Type Unresectable or Metastatic Melanoma","Melanoma","109","NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","2","AP","SUPPL",2015-09-30,"PRIORITY","EFFICACY","109|
(T=72|
C=37)","Nivolumab (OPDIVO®) In Combination With Ipilimumab (YERVOY®)","BLA125554","OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of unresectable or metastatic melanoma in combination with ipilimumab in patients with BRAF V600 wild-type melanoma","There is no label available from this supplement; http://www.ascopost.com/issues/october-25-2015/nivolumab-in-combination-with-ipilimumab-in-braf-v600-wild-type-unresectable-or-metastatic-melanoma/","Trial 4 was a multicenter, double-blind trial that randomized (2:1) patients with previously untreated, unresectable or metastatic melanoma to receive either OPDIVO in combination with ipilimumab or single-agent ipilimumab (CheckMate-069)","Objective Response Rate (Prim End for AA) 
PFS (Prim End for RA)","ORR","Objective Response Rate",0,"RR diff","60% vs. 11%","49","RR: 60%",NA,"RR: 60%",NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"1",0,1,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,"Approval was based on demonstration of improved objective response rate, prolonged response duration, and improved progression-free survival in an international, multicenter, double-blind phase II trial in 142 previously untreated patients.3 Patients were randomly assigned 2:1 to receive intravenous nivolumab at 1 mg/kg and ipilimumab at 3 mg/kg every 3 weeks for four doses and then nivolumab at 3 mg/kg every 2 weeks (n = 95, including 72 with wild-type BRAF V600) or intravenous ipilimumab at 3 mg/kg and placebo every 3 weeks for four doses followed by intravenous placebo every 2 weeks (n = 47, including 37 with wild-type BRAF V600) until disease progression or unacceptable toxicity.

Among the 109 patients with BRAF V600 wild-type disease, median age was 66 years, Eastern Cooperative Oncology Group performance score was 0 in 84% and 1 in 15%, 46% had M1c disease, and 20% had elevated lactate dehydrogenase. Baseline differences between the combination and ipilimumab groups consisted of history of brain metastasis (6% vs 0%), acral/mucosal melanoma (10% vs 24%), and cutaneous melanoma (82% vs 57%)."
"NIVOLUMAB","OPDIVO","BLA125554",2015-10-09,"Efficacy",NA,"A new indication for use in NSCLC in 2nd-line setting","NSCLC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","5","AP","SUPPL",2015-10-09,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2015-11-23,"Efficacy","Yes","Regular Approval for Unresectable or Metastatic BRAF-Wild Type Melanoma","Melanoma","418","NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","1","AP","SUPPL",2015-11-23,"PRIORITY","EFFICACY","418|
(T=210|
C=208)","Nivolumab (OPDIVO®)","BLA125554","OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment as a single agent, of patients with BRAF V600 wild-type unresectable or metastatic melanoma",NA,"Trial 5 (CheckMate-066; confirmed 066, not 067) was a multicenter, double-blind, randomized (1:1) trial conducted in patients with BRAF V600 wild-type unresectable or metastatic melanoma","Overall Survival","OS","Overall Survival",3,"HR","NR vs. 10.8 mo","0.42","HR: 0.42","HR: 0.42",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"0",0,1,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,"PMC fulfilled on 3/7/19"
"NIVOLUMAB","OPDIVO","BLA125554",2015-11-23,"Efficacy",NA,"A new indication for use in RCC in 2nd-line setting","RCC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","12","AP","SUPPL",2015-11-23,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for nivolumab in advanced renal cell carcinoma patients who have received prior antiangiogenic therapy.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2016-01-23,"Efficacy","Yes","Accelerated Approved for BRAF Mutant Unresectable or Metastatic Melanoma in the First Line Setting","Melanoma","198","NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","7","AP","SUPPL",2016-01-23,"PRIORITY","EFFICACY","198|
(T=98|
C=100)","Nivolumab (OPDIVO®)","BLA125554","The expansion of the indication for OPDIVO (nivolumab) as a single agent for the treatment of patients with BRAF V600 mutation positive, unresectable or metastatic melanoma to remove the restriction that such patients should have disease progression following ipilimumab and a BRAF inhibitor","N=198 b/c that's how many BRAF mut patients received either opdivo monotherapy or ipi (98 and 100 resp). This can be found in S2 of the 2015 Larkin paper)","A single, multicenter, three-arm, placebo- and active-controlled trial, Protocol CA209067 (aka Trial 7)","PFS and OS","Coprimary","Progression-Free Survival & Overall Survival",4,"HR","PFS: 6.9 vs. 2.9 mo (all BRAF)
BRAF Mut: 5.6 vs. 4.0 mo
(OS not significant and not used)","0.57 (for all BRAF; look at Table 15 in PI, results from Trial 7) 
0.77 (BRAF mut, look at Figure S2 of Checkmate 067 Supplemental for this HR)","HR: 0.57 (BRAF wt & mutant) |
HR: 0.77 (BRAF mutant only)","HR: 0.57 (BRAF wt & mutant) |
HR: 0.77 (BRAF mutant only)",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"0",0,1,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,"1"
"NIVOLUMAB","OPDIVO","BLA125554",2016-05-17,"Efficacy",NA,"A new indication for use in HL in 3rd-line setting","HL",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","19","AP","SUPPL",2016-05-17,"PRIORITY","EFFICACY",NA,NA,NA,"Provides for OPDIVO® (nivolumab) injection for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2016-09-13,"Efficacy","Yes","Flat Dosing for Melanoma, NSCLC and RCC","Melanoma",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","17","AP","SUPPL",2016-09-13,"STANDARD","EFFICACY",NA,NA,NA,"Provide updates to remove or modify the currently approved recommended dosage regimen and include a new recommended dosage regimen for nivolumab to 240 mg intravenously every two weeks for the currently approved indications for treatment of renal cell carcinoma (RCC), metastatic melanoma, and non-small cell lung cancer (NSCLC).",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2016-09-13,"Efficacy","Yes","Flat Dosing for Melanoma, NSCLC and RCC","Melanoma",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","18","AP","SUPPL",2016-09-13,"STANDARD","EFFICACY",NA,NA,NA,"Provide updates to remove or modify the currently approved recommended dosage regimen and include a new recommended dosage regimen for nivolumab to 240 mg intravenously every two weeks for the currently approved indications for treatment of renal cell carcinoma (RCC), metastatic melanoma, and non-small cell lung cancer (NSCLC).",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2016-10-04,"Efficacy",NA,"Updates for use in NSCLC","NSCLC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","16","AP","SUPPL",2016-10-04,"STANDARD","EFFICACY",NA,NA,NA,"Provides for updates to the Clinical Studies section 14.2 of the package insert, titled Metastatic Non-Small Cell Lung Cancer (NSCLC), to incorporate demographic data and supportive efficacy results for progression-free survival, overall response rate, and response duration from Study CA209017",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2016-11-10,"Efficacy",NA,"New Indication for SCCHN","SCCHN",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","22","AP","SUPPL",2016-11-10,"PRIORITY","EFFICACY",NA,NA,NA,"A  new indication for nivolumab, as a single agent, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinumbased therapy",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2017-02-02,"Efficacy",NA,"New indication for Urothelial Carcinoma","Urothelial Carcinoma",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","24","AP","SUPPL",2017-02-02,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication in locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or following platinum-containing chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2017-04-25,"Efficacy",NA,"Revised indication for HL","HL",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","31","AP","SUPPL",2017-04-25,"PRIORITY","EFFICACY",NA,NA,NA," A revised indication of OPDIVO® (nivolumab) injection for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or 3 or more lines of systemic therapy that includes autologous HSCT.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2017-07-31,"Efficacy",NA,"New indication for MSI-H CRC","Colon Cancer",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","34","AP","SUPPL",2017-07-31,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for OPDIVO, as a single agent, for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2017-09-06,"Labeling",NA,"Updates regarding irAEs",NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","40","AP","SUPPL",2017-09-06,"STANDARD","LABELING",NA,NA,NA,"Dose Modifications subsection within the DOSAGE AND ADMINISTRATION section and the Other Immune-Mediated Adverse Reactions subsection within the WARNINGS AND PRECAUTIONS ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2017-09-22,"Efficacy",NA,"New indication for HCC","HCC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","41","AP","SUPPL",2017-09-22,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for OPDIVO, as a single agent, for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2017-12-20,"Efficacy","Yes","Regular Approval for Adjuvant Melanoma","Melanoma","906","NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","55","AP","SUPPL",2017-12-20,"PRIORITY","EFFICACY","906|
(T=453|
C=453)","Nivolumab (OPDIVO®)","BLA125554","OPDIVO is indicated for patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting","Did not confirm ODAC, assumption was made; fast track not confirmed","One randomized, double-blind trial of OPDIVO vs. Ipilimumab that enrolled patients with completely resected Stage IIIB/C or Stage IV melanoma","Relapse-Free Survival (Prim End)
OS (Sec End)","RFS","Relapse-Free Survival",1,"HR","NR vs. NR","0.65","HR: 0.65","HR: 0.65",NA,NA,NA,NA,"Investigator assessment","Clinical","1","Yes",0,0,"0",0,1,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-01-09,"Efficacy","Yes","Updates infusion from 60 to 30 minutes","Melanoma",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","35","AP","SUPPL",2018-01-09,"STANDARD","EFFICACY",NA,NA,NA,"Updates to modify the recommended dosage regimens for the indications for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin Lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma to reduce the infusion duration from 60 minutes to 30 minutes.","Supplememts 35-39 were approved on the same day, I am not able to verfiy which of the five was dedicated to melanoma, but we are going with 35 since melanoma is the first letter",NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-01-09,"Efficacy",NA,"Updates infusion from 60 to 30 minutes","Multiple",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","36","AP","SUPPL",2018-01-09,"STANDARD","EFFICACY",NA,NA,NA,"Updates to modify the recommended dosage regimens for the indications for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin Lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma to reduce the infusion duration from 60 minutes to 30 minutes.","Supplememts 35-39 were approved on the same day, I am not able to verfiy which supplements correlate with which cancer",NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-01-09,"Efficacy",NA,"Updates infusion from 60 to 30 minutes","Multiple",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","37","AP","SUPPL",2018-01-09,"STANDARD","EFFICACY",NA,NA,NA,"Updates to modify the recommended dosage regimens for the indications for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin Lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma to reduce the infusion duration from 60 minutes to 30 minutes.","Supplememts 35-39 were approved on the same day, I am not able to verfiy which supplements correlate with which cancer",NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-01-09,"Efficacy",NA,"Updates infusion from 60 to 30 minutes","Multiple",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","38","AP","SUPPL",2018-01-09,"STANDARD","EFFICACY",NA,NA,NA,"Updates to modify the recommended dosage regimens for the indications for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin Lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma to reduce the infusion duration from 60 minutes to 30 minutes.","Supplememts 35-39 were approved on the same day, I am not able to verfiy which supplements correlate with which cancer",NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-01-09,"Efficacy",NA,"Updates infusion from 60 to 30 minutes","Multiple",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","39","AP","SUPPL",2018-01-09,"STANDARD","EFFICACY",NA,NA,NA,"Updates to modify the recommended dosage regimens for the indications for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin Lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma to reduce the infusion duration from 60 minutes to 30 minutes.","Supplememts 35-39 were approved on the same day, I am not able to verfiy which supplements correlate with which cancer",NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-02-13,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","56","AP","SUPPL",2018-02-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-02-15,"Efficacy",NA,"New dosing for HL","HL",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","44","AP","SUPPL",2018-02-15,"STANDARD","EFFICACY",NA,NA,NA,"Classical Hodgkin lymphoma indication and for the squamous cell carcinoma of the head and neck indication of nivolumab 3 mg/kg intravenously over 60 minutes every 2 weeks until disease progression or unacceptable toxicity with the recommended dosage regimen of nivolumab 240 mg intravenously over 60 minutes every 2 weeks until disease progression or unacceptable toxicity. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-02-15,"Efficacy",NA,"New dosing for SCCHN","SCCHN",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","45","AP","SUPPL",2018-02-15,"STANDARD","EFFICACY",NA,NA,NA,"Classical Hodgkin lymphoma indication and for the squamous cell carcinoma of the head and neck indication of nivolumab 3 mg/kg intravenously over 60 minutes every 2 weeks until disease progression or unacceptable toxicity with the recommended dosage regimen of nivolumab 240 mg intravenously over 60 minutes every 2 weeks until disease progression or unacceptable toxicity. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-03-05,"Efficacy","Yes","Every 4 Week Dosing for Advanced Melanoma","Melanoma","4166","NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","48","AP","SUPPL",2018-03-05,"STANDARD","EFFICACY","4166","Nivolumab (OPDIVO®)","BLA125554","OPDIVO 480 mg intravenously over 30 minutes every 4 weeks (Q4W) for adult and pediatric patients weighing 40 kg or more until disease progression or unacceptable toxicity","It's hard to say how many patients were evaluated. This indication is not considered tumor agnostic. It was for several indications, but not all and it is only approved for melanoma in the skin cancer cohort
Look to the paper by Bi et al for the number of 4166 (DOI:https://doi.org/10.1093/annonc/mdz037)","The proposed new dosage regimen was supported by pharmacokinetic modeling and simulation, dose/exposure–
response relationships for efficacy and safety in the indicated patient populations, and the clinical safety data with the 480 mg Q4W dosage regimen. Pharmacokinetic exposures achieved with 480 mg Q4W were predicted for 4166 patients in 21 clinical studies with various types of solid and hematological tumors. Exposure–response analyses were conducted to predict 480 mg Q4W safety and efficacy across all FDA-approved indications for nivolumab.","PK","PK","Pharmacokinetic Analysis",6,NA,NA,NA,"",NA,NA,NA,NA,NA,"PK","PK","12","Yes",0,0,"0",0,1,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-03-05,"Efficacy",NA,"Every 4 week dosing in RCC","RCC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","49","AP","SUPPL",2018-03-05,"STANDARD","EFFICACY",NA,NA,NA,"A new dosage regimen of Opdivo 480 mg as an intravenous infusion over 30 minutes every 4 weeks ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-03-05,"Efficacy",NA,"Every 4 week dosing in HL","HL",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","50","AP","SUPPL",2018-03-05,"STANDARD","EFFICACY",NA,NA,NA,"A new dosage regimen of Opdivo 480 mg as an intravenous infusion over 30 minutes every 4 weeks ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-03-05,"Efficacy",NA,"Every 4 week dosing in SCCHN","SCCHN",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","51","AP","SUPPL",2018-03-05,"STANDARD","EFFICACY",NA,NA,NA,"A new dosage regimen of Opdivo 480 mg as an intravenous infusion over 30 minutes every 4 weeks ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-03-05,"Efficacy",NA,"Every 4 week dosing in Urothelial Carcinoma","Urothelial Carcinoma",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","52","AP","SUPPL",2018-03-05,"STANDARD","EFFICACY",NA,NA,NA,"A new dosage regimen of Opdivo 480 mg as an intravenous infusion over 30 minutes every 4 weeks ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-03-05,"Efficacy","Yes","Every 4 week dosing in Adjuvant Melanoma","Melanoma",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","61","AP","SUPPL",2018-03-05,"STANDARD","EFFICACY",NA,NA,NA,"A new dosage regimen of Opdivo 480 mg as an intravenous infusion over 30 minutes every 4 weeks ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-03-05,"Efficacy",NA,"Every 4 week dosing in HCC","HCC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","62","AP","SUPPL",2018-03-05,"STANDARD","EFFICACY",NA,NA,NA,"A new dosage regimen of Opdivo 480 mg as an intravenous infusion over 30 minutes every 4 weeks ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-03-05,"Efficacy","Yes","Updates infusion from 60 to 30 minutes in adjuvant Melanoma","Melanoma",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","64","AP","SUPPL",2018-03-05,"STANDARD","EFFICACY",NA,NA,NA,"Modification of the approved dosage regimens of Opdivo 240 mg every two weeks, to reduce to the infusion time from 60 minutes to 30 minutes",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-03-05,"Efficacy",NA,"Updates infusion from 60 to 30 minutes","Colon Cancer",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","65","AP","SUPPL",2018-03-05,"STANDARD","EFFICACY",NA,NA,NA,"Modification of the approved dosage regimens of Opdivo 240 mg every two weeks, to reduce to the infusion time from 60 minutes to 30 minutes",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-03-05,"Efficacy",NA,"Updates infusion from 60 to 30 minutes","HCC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","66","AP","SUPPL",2018-03-05,"STANDARD","EFFICACY",NA,NA,NA,"Modification of the approved dosage regimens of Opdivo 240 mg every two weeks, to reduce to the infusion time from 60 minutes to 30 minutes",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-04-16,"Efficacy",NA,"New indication of ipi/nivo for RCC","RCC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","58","AP","SUPPL",2018-04-16,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the use of
nivolumab, in combination with ipilimumab, for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-07-10,"Efficacy",NA,"A new indication of ipi/nivo for MSI-H CRC","Colon Cancer",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","63","AP","SUPPL",2018-07-10,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for
OPDIVO, in combination with ipilimumab, is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-08-16,"Efficacy",NA,"New indication in SCLC","SCLC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","67","AP","SUPPL",2018-08-16,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for OPDIVO for the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2018-11-15,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","69","AP","SUPPL",2018-11-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2019-02-01,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","72","AP","SUPPL",2019-02-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2019-03-07,"Efficacy","Yes","Conversion to Regular Approval for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma","Melanoma","405","NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","42","AP","SUPPL",2019-03-07,"PRIORITY","EFFICACY","405|(T=272|C=133)","Nivolumab (OPDIVO®)","BLA125554","This supplement modifies the previous label for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, and of OPDIVO, in combination with ipilimumab, for the treatment of patients with unresectable or metastatic melanoma to remove the following statement: 'This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.'In addition, this Prior Approval supplemental biologics application provides for the simplification of the following approved indications: OPDIVO, as a single agent, for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma OPDIVO, as a single agent, for the treatment of patients with BRAF V600 mutation positive unresectable or metastatic melanoma OPDIVO, in combination with ipilimumab, for the treatment of patients with unresectable or metastatic melanoma into a single approved indication: OPDIVO, as a single agent or administered with ipilimumab, for the treatment of patients with unresectable or metastatic melanoma","Data is based on several trials, as this supplement provided modification of the label on two fronts: CHECKMATE-037 (n = 405 for the trial, n = 120 tx'd with opdivo) for previously treated (though the number of BRAF mutants in the application are not known) and CHECKMATE-067 (N=945) for Ipi/Nivo Combo","CHECKMATE-037 (NCT01721746) was a multicenter, open-label trial that randomized (2:1) patients with unresectable or metastatic melanoma to receive either 3 mg/kg of OPDIVO by intravenous infusion every 2 weeks or investigator’s choice of chemotherapy","Overall Survival","OS","Overall Survival",3,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,"3","Yes",0,0,"0",0,1,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2019-04-18,"Efficacy",NA,"Dosing change in CRC","Colon Cancer",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","70","AP","SUPPL",2019-04-18,"STANDARD","EFFICACY",NA,NA,NA,"New recommended dosage regimens for nivolumab for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2019-05-02,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","73","AP","SUPPL",2019-05-02,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2019-09-18,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","75","AP","SUPPL",2019-09-18,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-03-10,"Efficacy",NA,"New indication for ipi/nivo in HCC in the 2nd line","HCC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","78","AP","SUPPL",2020-03-10,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for Opdivo in combination with ipilimumab, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-05-15,"Efficacy",NA,"New indication for ipi/nivo in first line NSCLC if PD-L1 ≥1%","NSCLC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","80","AP","SUPPL",2020-05-15,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for Opdivo in combination with ipilimumab, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test with no EGFR or ALK genomic tumor aberrations. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-05-26,"Efficacy",NA,"Ipi/Nivo as first line with chemo in NSCLC","NSCLC",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","82","AP","SUPPL",2020-05-26,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the use of nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-06-10,"Efficacy",NA,"New indication of Opdivo in Esophageal SCC in the 2nd line","Esophageal Squamous Cell Cancer",NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","81","AP","SUPPL",2020-06-10,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-06-23,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","83","AP","SUPPL",2020-06-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-09-18,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","84","AP","SUPPL",2020-09-18,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-09-18,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","85","AP","SUPPL",2020-09-18,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-09-25,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","86","AP","SUPPL",2020-09-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-10-02,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","89","AP","SUPPL",2020-10-02,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-11-10,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","71","AP","SUPPL",2020-11-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2020-12-29,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","95","AP","SUPPL",2020-12-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2021-01-22,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","90","AP","SUPPL",2021-01-22,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2021-03-30,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","98","AP","SUPPL",2021-03-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2021-04-16,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","91","AP","SUPPL",2021-04-16,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2021-05-20,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","92","AP","SUPPL",2021-05-20,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2021-07-15,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","99","AP","SUPPL",2021-07-15,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2021-07-23,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","107","AP","SUPPL",2021-07-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2021-08-19,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","97","AP","SUPPL",2021-08-19,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2022-02-25,"Labeling",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","109","AP","SUPPL",2022-02-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2022-03-04,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","112","AP","SUPPL",2022-03-04,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2022-05-11,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","108","AP","SUPPL",2022-05-11,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2022-05-27,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","105","AP","SUPPL",2022-05-27,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2022-05-27,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","106","AP","SUPPL",2022-05-27,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2022-07-14,"Efficacy",NA,NA,NA,NA,"NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","114","AP","SUPPL",2022-07-14,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"NIVOLUMAB","OPDIVO","BLA125554",2016-01-23,"Efficacy","Yes","Accelerated approval of Ipi/Nivo Expansion for BRAF mutant as well as BRAF WT","Melanoma","202","NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","7_Part_2","AP","SUPPL",2016-01-23,"PRIORITY","EFFICACY","198|
(T=98|
C=100)","Nivolumab (OPDIVO®)","BLA125554","The expansion of the indication for OPDIVO (nivolumab), in combination with ipilimumab, for the treatment of patients with unresectable or metastatic melanoma to remove the restriction for the treatment of only patients with BRAF wild-type melanoma","N=202 b/c that's how many BRAF mut patients received either ipi/nivo or ipi (102 and 100 resp). This can be found in S2 of the 2015 Larkin paper)","A single, multicenter, three-arm, placebo- and active-controlled trial, Protocol CA209067 (aka Trial 7)","PFS and OS","Coprimary","Progression-Free Survival & Overall Survival",4,"HR","PFS: 6.9 vs. 2.9 mo (all BRAF)
BRAF Mut: 5.6 vs. 4.0 mo
(OS not significant and not used)","0.57 (for all BRAF; look at Table 15 in PI, results from Trial 7) 
0.77 (BRAF mut, look at Figure S2 of Checkmate 067 Supplemental for this HR)","HR: 0.42 (BRAF wt & mut) | HR: 0.47 (BRAF mut only)","HR: 0.42 (BRAF wt & mut) | HR: 0.47 (BRAF mut only)",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"0",0,1,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,"1"
"NIVOLUMAB","OPDIVO","BLA125554",2019-03-07,"Efficacy","Yes","Conversion to Regular Approval of OPDIVO, in combination with ipilimumab, for the treatment of patients with unresectable or metastatic melanoma","Melanoma","945","NIVOLUMAB","NIVOLUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","TBD","001","INJECTABLE","INJECTION","40MG/4ML","42","AP","SUPPL",2019-03-07,"PRIORITY","EFFICACY","945|(IN=314|N=316|I=315)","Nivolumab (OPDIVO®)","BLA125554","This supplement modifies the previous label for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, and of OPDIVO, in combination with ipilimumab, for the treatment of patients with unresectable or metastatic melanoma to remove the following statement: 'This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.'In addition, this Prior Approval supplemental biologics application provides for the simplification of the following approved indications: OPDIVO, as a single agent, for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma OPDIVO, as a single agent, for the treatment of patients with BRAF V600 mutation positive unresectable or metastatic melanoma OPDIVO, in combination with ipilimumab, for the treatment of patients with unresectable or metastatic melanoma into a single approved indication: OPDIVO, as a single agent or administered with ipilimumab, for the treatment of patients with unresectable or metastatic melanoma","Data is based on several trials, as this supplement provided modification of the label on two fronts: CHECKMATE-037 (n = 405 for the trial, n = 120 tx'd with opdivo) for previously treated (though the number of BRAF mutants in the application are not known) and CHECKMATE-067 (N=945) for Ipi/Nivo Combo","CHECKMATE-067 (NCT01844505) was a multicenter, double-blind trial that randomized (1:1:1) patients with previously untreated, unresectable or metastatic melanoma to one of the following arms: OPDIVO plus ipilimumab, OPDIVO, or ipilimumab.","Overall Survival","OS","Overall Survival",3,NA,NA,NA,"",NA,NA,NA,NA,NA,"Investigator Assessment","Clinical","3","Yes",0,0,"0",0,1,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"RELATLIMAB-RMBW","OPDUALAG","BLA761234",2022-03-18,"Type 1 - New Molecular Entity","Yes","Unresectable or Metastatic Melanoma","Melanoma","714","c(""NIVOLUMAB"", ""RELATLIMAB"")","NIVOLUMAB AND RELATLIMAB-RMBW","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","SOLUTION","INTRAVENOUS","240MG","1","AP","ORIG",2022-03-18,"PRIORITY","TYPE 1","714","Relatlimab-rmbw (OPDUALAG)","BLA761234","OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma",NA,"Randomized (1:1), double-blinded trial","Progression-Free Survival","PFS","Progression-Free Survival",2,"HR","10.1 vs. 4.6 months","0.75","HR: 0.75","HR: 0.75",NA,NA,NA,NA,"RECIST","RECIST","2","Yes",1,0,"0",0,1,"Yes","No","1","LAG-3 Ab","LAG-3 Targeted Antibody","Immunotherapy",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","ORAPRED ODT","NDA021959",2006-06-01,"Type 3 - New Dosage Form","Yes","Mycosis Fungoides","CTCL",NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Prasco Laboratories"", ""Concordia Pharmaceuticals Inc."")","Prescription","Yes","002","TABLET, ORALLY DISINTEGRATING","ORAL","EQ 10MG BASE, EQ 15MG BASE, EQ 30MG BASE","1","AP","ORIG",2006-06-01,"STANDARD","TYPE 3",NA,"Prednisolone sodium phosphate (ORAPRED ODT™)","NDA021959","Mycosis Fungoides","No efficacy estimates","Two bioavaiability studies","Bioequivalence","PK","Bioequivalence",6,NA,NA,NA,"",NA,NA,NA,NA,NA,"PK","PK","12","Yes",0,0,"0",0,1,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,"Study of ODT tablets; N = 35, but I'm pretty sure this wasn't in cancer patients, so probably best to remove"
"PREDNISOLONE SODIUM PHOSPHATE","ORAPRED ODT","NDA021959",2009-04-27,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Prasco Laboratories"", ""Concordia Pharmaceuticals Inc."")","Prescription","Yes","002","TABLET, ORALLY DISINTEGRATING","ORAL","EQ 10MG BASE, EQ 15MG BASE, EQ 30MG BASE","3","AP","SUPPL",2009-04-27,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","ORAPRED ODT","NDA021959",2010-07-28,"Labeling",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Prasco Laboratories"", ""Concordia Pharmaceuticals Inc."")","Prescription","Yes","002","TABLET, ORALLY DISINTEGRATING","ORAL","EQ 10MG BASE, EQ 15MG BASE, EQ 30MG BASE","4","AP","SUPPL",2010-07-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","ORAPRED ODT","NDA021959",2016-04-08,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Prasco Laboratories"", ""Concordia Pharmaceuticals Inc."")","Prescription","Yes","002","TABLET, ORALLY DISINTEGRATING","ORAL","EQ 10MG BASE, EQ 15MG BASE, EQ 30MG BASE","8","AP","SUPPL",2016-04-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","ORAPRED ODT","NDA021959",2016-07-28,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Prasco Laboratories"", ""Concordia Pharmaceuticals Inc."")","Prescription","Yes","002","TABLET, ORALLY DISINTEGRATING","ORAL","EQ 10MG BASE, EQ 15MG BASE, EQ 30MG BASE","9","AP","SUPPL",2016-07-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","ORAPRED ODT","NDA021959",2020-03-06,"Labeling",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Prasco Laboratories"", ""Concordia Pharmaceuticals Inc."")","Prescription","Yes","002","TABLET, ORALLY DISINTEGRATING","ORAL","EQ 10MG BASE, EQ 15MG BASE, EQ 30MG BASE","11","AP","SUPPL",2020-03-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1954-12-03,"Type 1 - New Molecular Entity",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","1","AP","ORIG",1954-12-03,"PRIORITY","TYPE 1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1974-11-13,"Supplement",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","5","AP","SUPPL",1974-11-13,"PRIORITY","S",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1975-04-04,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","6","AP","SUPPL",1975-04-04,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1982-05-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","20","AP","SUPPL",1982-05-07,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1982-05-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","21","AP","SUPPL",1982-05-07,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1983-04-21,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","22","AP","SUPPL",1983-04-21,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1984-04-16,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","25","AP","SUPPL",1984-04-16,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1988-03-23,"Efficacy","Yes","Refractory Cutaneous T-Cell Lymphoma","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","30","AP","SUPPL",1988-03-23,NA,"EFFICACY",NA,"Methoxsalen Caspsule (8-MOP®)","NDA009048","Photopheresis (methoxsalen with long wave ultraviolet radiation of white blood cells) is indicated for use with the UVAR* System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) in persons who have not been responsive to other forms of treatment","The PMA for the device was granted in April of 1987, but labeling was approved in March 1988 for 8-MOP with the UVAR Photopheresis system","Single-arm, multi-center, non-blinded trial","Response Rate","ORR","Response Rate",0,NA,"RR: 74% (29/39) (58, 87) 
RR: 53.9% (21/39) (37.2, 69.9) @6 mo
This data does not appear publically available, thus we will not include",NA,"",NA,NA,NA,NA,NA,NA,NA,"6","Yes",0,1,"1",0,0,"Yes","No","1","Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1996-01-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","31","AP","SUPPL",1996-01-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1997-09-23,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","33","AP","SUPPL",1997-09-23,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1997-09-23,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","34","AP","SUPPL",1997-09-23,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1998-03-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","35","AP","SUPPL",1998-03-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",1998-04-07,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","36","AP","SUPPL",1998-04-07,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",2000-04-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","38","AP","SUPPL",2000-04-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",2001-10-31,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","40","AP","SUPPL",2001-10-31,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",2003-03-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","37","AP","SUPPL",2003-03-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",2013-03-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","45","AP","SUPPL",2013-03-22,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",2013-09-20,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","46","AP","SUPPL",2013-09-20,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",2015-07-28,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","47","AP","SUPPL",2015-07-28,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","8-MOP","NDA009048",2015-07-30,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","CAPSULE","ORAL","1%, 10MG","48","AP","SUPPL",2015-07-30,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"ALITRETINOIN","PANRETIN","NDA020886",1999-02-02,"Type 1 - New Molecular Entity","Yes","AIDS-Related Kaposi's Sarcoma - Cutaneous Lesions Only","KS","350","ALITRETINOIN","ALITRETINOIN","Concordia Pharmaceuticals Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.1% BASE","1","AP","ORIG",1999-02-02,"PRIORITY","TYPE 1","350|
(T=170|
C=180)","Alitretinoin gel 0.1% (PANRETIN®)","NDA020886","Panretin gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. PanretinÒ gel is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement).",NA,"Two double-blind, randomized placebo-controlled studies","Response Rate","ORR","Response Rate",0,"RR diff","Combined: 46 vs. 15% | Study 1 (35% (47/134) vs. 18% (24/134)| Study 2 36% Per label (in the SAS the sponsor reports; 42% (15/36) vs. 7% (3/46) 15/36 is found on page 10 of Part 3 of the Stast Analysis Summary,which is different from the label. Originally there was a TYPO should be 46 for the vehicle arm -onfirmed on SAS and label, changed by DMM 12-20-21. )","31","RR: 35% (Study 1)| 
RR: 36% (Study 2)",NA,"RR: 35% (Study 1)| 
RR: 36% (Study 2)",NA,NA,NA,"Modified ACTG","ACTG","10","Yes",1,0,"1",1,1,"Yes","No","1","Retinoid","Retinoid","Retinoid",NA,NA
"ALITRETINOIN","PANRETIN","NDA020886",1999-07-12,"Manufacturing (CMC)",NA,NA,NA,NA,"ALITRETINOIN","ALITRETINOIN","Concordia Pharmaceuticals Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.1% BASE","1","AP","SUPPL",1999-07-12,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"ALITRETINOIN","PANRETIN","NDA020886",2000-11-21,"Manufacturing (CMC)",NA,NA,NA,NA,"ALITRETINOIN","ALITRETINOIN","Concordia Pharmaceuticals Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.1% BASE","2","AP","SUPPL",2000-11-21,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"ALITRETINOIN","PANRETIN","NDA020886",2013-11-22,"Manufacturing (CMC)",NA,NA,NA,NA,"ALITRETINOIN","ALITRETINOIN","Concordia Pharmaceuticals Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.1% BASE","6","AP","SUPPL",2013-11-22,NA,"MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1986-05-28,"Type 3 - New Dosage Form","Yes","Mycosis Fungoides","CTCL","12","PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","1","AP","ORIG",1986-05-28,"STANDARD","TYPE 3","12","Prednisolone sodium phosphate (PEDIAPRED®)","NDA019157","Mycosis Fungoides","No efficacy as DESI Drug","Bioequivalence study of 12 healthy adults in Open Label, single-dose, randomized, two-legged crossover study","Bioequivalence","PK","Bioequivalence",6,NA,"Efficacy not evaluted",NA,"",NA,NA,NA,NA,NA,"PK","PK","12","Yes",0,0,"0",0,1,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,"Novel oral solution; I had an N of 12, but I can't find where I got this, so I am going to remove it"
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1986-08-14,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","1","AP","SUPPL",1986-08-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1988-10-31,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","5","AP","SUPPL",1988-10-31,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1989-02-02,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","4","AP","SUPPL",1989-02-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1989-10-27,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","6","AP","SUPPL",1989-10-27,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1993-11-08,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","8","AP","SUPPL",1993-11-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1993-11-22,"Labeling",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","9","AP","SUPPL",1993-11-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1995-05-10,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","10","AP","SUPPL",1995-05-10,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1997-05-29,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","14","AP","SUPPL",1997-05-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1998-01-21,"Labeling",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","16","AP","SUPPL",1998-01-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1998-12-17,"Labeling",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","11","AP","SUPPL",1998-12-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1998-12-17,"Labeling",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","12","AP","SUPPL",1998-12-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1998-12-17,"Labeling",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","13","AP","SUPPL",1998-12-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",1998-12-17,"Efficacy","Yes","Expansion to include pediatric populations","CTCL",NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","15","AP","SUPPL",1998-12-17,"STANDARD","EFFICACY",NA,NA,NA,"Expansion to include pediatric populations",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",2002-01-03,"Manufacturing (CMC)",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","17","AP","SUPPL",2002-01-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",2004-12-03,"Labeling",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","18","AP","SUPPL",2004-12-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",2013-10-08,"Labeling",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","20","AP","SUPPL",2013-10-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PREDNISOLONE SODIUM PHOSPHATE","PEDIAPRED","NDA019157",2018-02-05,"Labeling",NA,NA,NA,NA,"PREDNISOLONE SODIUM PHOSPHATE","PREDNISOLONE SODIUM PHOSPHATE","c(""Seton Pharmaceuticals, LLC"", ""Royal Pharmaceuticals"")","Prescription","Yes","001","SOLUTION","ORAL","EQ 5MG BASE/5ML","21","AP","SUPPL",2018-02-05,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2014-09-04,"Type 1 - New Molecular Entity","Yes","Unresectable or Metastatic Melanoma - Second Line","Melanoma","173","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","1","AP","ORIG",2014-09-04,"PRIORITY","TYPE 1","173","Pembrolizumab (KEYTRUDA®)","BLA125514","KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.","89 patients were in the 2 mg/kg dosing group, which is what got approved, but 173 patients are listed in the label); H0 can be found in the summary review (page 3 of 22)","The efficacy of KEYTRUDA was investigated in a multicenter, open-label, randomized (1:1), dose-comparative, activity-estimating cohort of Trial 1","Objective Response Rate (ORR)","ORR","Overall Response Rate",0,"RR diff","23.6% (21/89) vs. 10% (HC)","13.6","RR: 23.6%",NA,"RR: 23.6%","10","15","34","Modified RECIST","mRECIST","7","Yes",1,1,"1",0,0,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,"Multiple dosing arms (2 mg/kg and 10 mg/kg)"
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2015-06-19,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","3","AP","SUPPL",2015-06-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2015-10-02,"Efficacy",NA,"Metastatic, PD-L1 positive, non-small cell lung cancer","NSCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","5","AP","SUPPL",2015-10-02,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2015-12-18,"Efficacy","Yes","Unresectable or Metastatic Melanoma","Melanoma","540","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","4","AP","SUPPL",2015-12-18,"PRIORITY","EFFICACY","540|
(P2=180|
P10=181
C=179)","Pembrolizumab (KEYTRUDA®)","BLA125514","KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma.",NA,"One randomized, double-blind, active-controlled study.  In trial 2, 540 ipilimumab-refractory patients were randomized to receive one of two doses of KEYTRUDA in a blinded fashion or investigator’s choice chemotherapy.","PFS and OS","Coprimary","Progression-Free Survival & Overall Survival",4,"HR","PFS: 2.9 vs. 2.7 mo 
(OS was not sign)","0.56999999999999995","HR: 0.57  (2 mg/kg) |
HR: 0.50 (10 mg/kg)","HR: 0.57  (2 mg/kg) |
HR: 0.50 (10 mg/kg)",NA,NA,NA,NA,"Modified RECIST","mRECIST","7","Yes",0,0,"0",0,1,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,"This trial was Pembro vs. Chemo in Ipi-refractory patients"
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2015-12-18,"Efficacy","Yes","Removing language limiting the indication to disease progression following ipilimumab","Melanoma","834","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","6","AP","SUPPL",2015-12-18,"PRIORITY","EFFICACY","834|
(T=556|
C=278)","Pembrolizumab (KEYTRUDA®)","BLA125514","KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma. Specifically, this supplement is intended to remove the following language (italicized) limiting the indication to patients with disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor and removing the statements that This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.","Approval of Supplements #4 and #6 fulfill the following postmarketing requirement listed in the September 4, 2014, approval letter for BLA 125514","One randomized, double-blind, active-controlled studiy (KEYNOTE-006). In trial 6, 834 ipiliumab-naïve patients were randomized to receive KEYTRUDA at a dose of 10 mg/kg every 2 weeks or 10mg/kg every 3 weeks as an intravenous infusion until disease progression or unacceptable toxicity or to ipilimumab 3 mg/kg every 3 weeks as an intravenous infusion for 4 doses
unless discontinued earlier for disease progression or unacceptable toxicity.","PFS and OS","Coprimary","Progression-Free Survival & Overall Survival",4,"HR","OS: 33% vs. 40%;         
PFS: 4.1 vs. 2.8 mo","0.69 (OS)| 0.58 (PFS)","HR: 0.69 (OS)| 
HR: 0.58 (PFS)","HR: 0.69 (OS)| 
HR: 0.58 (PFS)",NA,NA,NA,NA,"Modified RECIST","mRECIST","7","Yes",0,0,"0",0,1,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,"This trial is for ipi-niave patients"
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2016-08-05,"Efficacy",NA,"New indication for SCCHN in the 2nd line setting","SCCHN",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","9","AP","SUPPL",2016-08-05,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-containing chemotherapy",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2016-10-24,"Efficacy",NA,"Expansion to include first-line for TPS ≥ 50% in NSCLC","NSCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","12","AP","SUPPL",2016-10-24,"PRIORITY","EFFICACY",NA,NA,NA,"Provides for an expansion of the metastatic NSCLC indication to include first-line treatment of patients whose tumors have high PD-L1 expression (TPS ≥ 50%) as determined by an FDA approved test, with no EGFR or ALK genomic tumor aberrations. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2016-10-24,"Efficacy",NA,"Regular approval for use in NSCLC in 2nd line setting","NSCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","8","AP","SUPPL",2016-10-24,"STANDARD","EFFICACY",NA,NA,NA,"For modifications of the approved indication for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 [Tumor Proportion Score (TPS) ≥ 1%] as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy approved on October 2, 2015, under the provisions of 21 CFR 601.70, to remove the following language (italicized) that This indication is approved under accelerated approval based on tumor response rate and durability of response. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2017-03-14,"Efficacy",NA,"New indication for HL in the 4th line","HL",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","15","AP","SUPPL",2017-03-14,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2017-05-10,"Efficacy",NA,"Accelerated Approval for first line in NSCLC with Pem/Carbo","NSCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","16","AP","SUPPL",2017-05-10,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the use of pembrolizumab, in combination with pemetrexed and carboplatin, for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2017-05-17,"Efficacy","Yes","Flat Dosing of 200 mg q3 weeks in melanoma","Melanoma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","13","AP","SUPPL",2017-05-17,"STANDARD","EFFICACY",NA,NA,NA,"This Prior Approval supplemental biologics application updates the CLINICAL STUDIES, Melanoma (14.1) subsection with the final analyses of overall survival from studies P002 and P006 and revises the DOSAGE AND ADMINISTRATION, Recommended Dosing (2.2) subsection to replace the 2 mg/kg dose for melanoma patients with 200 mg.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2017-05-18,"Efficacy",NA,"New indication for patients with advanced urothelial carcinoma not eligible for chemo","Urothelial Carcioma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","17","AP","SUPPL",2017-05-18,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the use of pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2017-05-18,"Efficacy",NA,"New indication for advanced urothelial carcinoma after progression","Urothelial Carcinoma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","18","AP","SUPPL",2017-05-18,"PRIORITY","EFFICACY",NA,NA,NA,"A  new indication for the use of pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2017-05-23,"Efficacy","Yes","Unresectable or Metastatic, Microsatellite Instability-High or Mismatch Repair Deficient Solid Tumors","Agnostic","149","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","14","AP","SUPPL",2017-05-23,"PRIORITY","EFFICACY","149","Pembrolizumab (KEYTRUDA®)","BLA125514","U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co.) for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",NA,"The approval was based on data from 149 patients with MSI-H or dMMR cancers enrolled across five uncontrolled, multi-cohort, multi-center, single-arm clinical trials. Ninety patients had colorectal cancer and 59 patients were diagnosed with one of 14 other cancer types","Objective Response Rate (ORR)
Duration of Response (DOR)","Coprimary","Objective Response Rate & Duration of Response",4,NA,"39.6% (59/149)",NA,"RR: 39.6% |
DoR: Not Reached",NA,"RR: 39.6% |
DoR: Not Reached",NA,"31.7","47.9","Modified RECIST","mRECIST","7","Yes",0,1,"1",0,0,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2017-07-27,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","19","AP","SUPPL",2017-07-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2017-07-27,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","23","AP","SUPPL",2017-07-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2017-09-22,"Efficacy",NA,"New Indication for advanced esophageal","Esophageal Carcinoma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","24","AP","SUPPL",2017-09-22,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2017-11-29,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","31","AP","SUPPL",2017-11-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2018-06-12,"Efficacy",NA,"Cervical Cancer, 2nd line with CPS >1","Cervical Cancer",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","34","AP","SUPPL",2018-06-12,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >1) ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2018-06-13,"Efficacy",NA,"PMBCL in 3rd line","PMBCL",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","30","AP","SUPPL",2018-06-13,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2018-06-19,"Efficacy",NA,"Revised indication for UC","Urothelial Carcinoma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","43","AP","SUPPL",2018-06-19,"PRIORITY","EFFICACY",NA,NA,NA,"Revised approved indication is: KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) ≥10], or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2018-08-16,"Efficacy",NA,"Updates the Keytruda (pembrolizumab)
USPI to add language about PD-L1 testing","Urothelial Carcinoma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","46","AP","SUPPL",2018-08-16,"PRIORITY","EFFICACY",NA,NA,NA,"Updates the Keytruda (pembrolizumab)
USPI to add language about PD-L1 testing.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2018-08-20,"Efficacy",NA,"Fulfillment of PMR","NSCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","35","AP","SUPPL",2018-08-20,"PRIORITY","EFFICACY",NA,NA,NA,"<odifications to the product labeling for the approved indication of pembrolizumab, in combination with pemetrexed and carboplatin, for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2018-10-30,"Efficacy",NA,"First line in combination with Carbo/Taxol in NSCLC-SCC","NSCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","41","AP","SUPPL",2018-10-30,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the first-line treatment of patients with metastatic squamous non-small cell lung cancer, in combination with carboplatin and either paclitaxel or nab-paclitaxel.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2018-11-09,"Efficacy",NA,"Accelerated aproval in 2nd line HCC","HCC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","42","AP","SUPPL",2018-11-09,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2018-12-19,"Efficacy","Yes","Locally Advanced or Metastatic Merkel Cell Carcinoma","MCC","50","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","45","AP","SUPPL",2018-12-19,"PRIORITY","EFFICACY","50","Pembrolizumab (KEYTRUDA®)","BLA125514","For the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma",NA,"KEYNOTE-017: a multicenter, non-randomized, open-label trial that enrolled 50 patients with recurrent locally advanced or metastatic MCC who had not received prior systemic therapy for their advanced disease","ORR and Duration of Response","Coprimary","Overall Response Rate & Duration of Response",4,"ORR","ORR: 56% (41, 70), CR 24%; Duration: 5.9-34.5+",NA,"RR: 56% |
DoR: 5.9-34.5+ (months)",NA,"RR: 56% |
DoR: 5.9-34.5+ (months)",NA,"41","70","RECIST","RECIST","3","Yes",0,1,"1",0,0,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,"Label has both ORR and duration of response as major efficacy outcome measures"
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2018-12-28,"Efficacy",NA,"Fulfillment of PMC","NSCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","37","AP","SUPPL",2018-12-28,"STANDARD","EFFICACY",NA,NA,NA,"Fulfillment of PMC",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2019-02-15,"Efficacy","Yes","Adjuvant Melanoma","Melanoma","1019","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","40","AP","SUPPL",2019-02-15,"STANDARD","EFFICACY","1019|
(T=509|
C=502)","Pembrolizumab (KEYTRUDA®)","BLA125514","For the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection",NA,"Approval was based on EORTC1325/KEYNOTE-054 (NCT02362594), a randomized, double-blind, placebo-controlled, trial in 1019 patients with completely resected, stage IIIA (>1 mm lymph node metastasis), IIIB or IIIC melanoma (AJCC 7th ed","Relapse-Free Survival","RFS","Relapse-Free Survival",1,"HR","NR vs. 20.4 mo","0.56999999999999995","HR: 0.57","HR: 0.57",NA,NA,NA,NA,"Investigator assessment","Clinical","1","Yes",0,0,"0",1,1,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2019-04-11,"Efficacy",NA,"Adjuvant NSCLC","NSCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","47","AP","SUPPL",2019-04-11,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for KEYTRUDA, as a single agent, for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC), who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD L1 [Tumor Proportion Score (TPS) ≥1%]",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2019-04-19,"Efficacy",NA,"Pembro plus Axitinib in RCC","RCC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","54","AP","SUPPL",2019-04-19,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication, in combination with axitinib, for the first-line treatment of patients with advanced renal cell carcinoma",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2019-06-10,"Efficacy",NA,"Fulfillment of PMC and new indications in SCCHN","SCCHN",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","52","AP","SUPPL",2019-06-10,"PRIORITY","EFFICACY",NA,NA,NA,"Fulfillment of PMC and new indications in SCCHN",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2019-06-17,"Efficacy",NA,"2nd line SCLC","SCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","53","AP","SUPPL",2019-06-17,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of patients with metastatic small cell lung cancer with disease progression",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2019-07-30,"Efficacy",NA,"Esophageal SCC","Esophageal Squamous Cell Carcinoma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","55","AP","SUPPL",2019-07-30,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 [Combined Positive Score (CPS) ≥10]",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2019-07-30,"Efficacy",NA,"Esophageal SCC","Esophageal Squamous Cell Carcinoma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","56","AP","SUPPL",2019-07-30,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 [Combined Positive Score (CPS) ≥10]",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2019-09-17,"Efficacy",NA,"In combination with lenvatinib for Endometrial 2nd line","Endometrial Carcinoma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","65","AP","SUPPL",2019-09-17,"PRIORITY","EFFICACY",NA,NA,NA,"KEYTRUDA®, in combination with lenvatinib, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-01-08,"Efficacy",NA,"Bladder Cancer","Bladder Cancer",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","66","AP","SUPPL",2020-01-08,"PRIORITY","EFFICACY",NA,NA,NA,"Provides for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-01-09,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","67","AP","SUPPL",2020-01-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy","Yes","Every 6 weeks dosing in Melanoma","Melanoma","44","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","59","AP","SUPPL",2020-04-28,"STANDARD","EFFICACY","44","Pembrolizumab (KEYTRUDA®)","BLA125514","This supplement modifies the previous label for for use at an additional recommended dosage of 400 mg every 6 weeks for all approved adult indications.","The approval was based on pharmacokinetic modeling and exposure-response analyses that compared the predicted exposure of pembrolizumab 400 mg every six weeks to observed exposures of pembrolizumab in patients who received pembrolizumab at 2 mg/kg every three weeks, 200 mg every three weeks, and 10 mg/kg administered every two weeks. The pharmacokinetic modeling were supported by additional exposure-response analyses across the pembrolizumab development program and an interim analysis of pharmacokinetics and overall response rate (ORR) in a cohort of patients (Cohort B) enrolled in Study KEYNOTE-555 (NCT03665597). Cohort B of Study KEYNOTE-555 was an international, single-arm, multi-center study that enrolled 101 patients with advanced or metastatic melanoma who had not received prior PD-1, PD-L1, or CTLA-4 inhibitors (other than CTLA-4 inhibitors in the adjuvant setting). The ORR was 39% (95% CI: 24, 55) in the first 44 patients enrolled in KEYNOTE-555.

Of note, in the label, section 12.2 clearly states that the PK data was based on interim analysis of 41 patients treated with 400 mg every 6 weeks.",NA,"PK","PK","Pharmacokinetic Analysis",6,NA,NA,NA,"",NA,NA,NA,NA,NA,"PK","PK","12","Yes",0,1,"0",0,0,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in HL","HL",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","60","AP","SUPPL",2020-04-28,"STANDARD","EFFICACY",NA,NA,NA,"Every six weeks dosing in HL",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in PMBCL","PMBCL",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","61","AP","SUPPL",2020-04-28,"STANDARD","EFFICACY",NA,NA,NA,"Every six weeks dosing in PMBCL",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in HCC","HCC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","62","AP","SUPPL",2020-04-28,"STANDARD","EFFICACY",NA,NA,NA,"Every six weeks dosing in HCC",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy","Yes","Every 6 weeks dosing in Merkel Cell Carcinoma","MCC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","63","AP","SUPPL",2020-04-28,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in Gastric Cancer","Gastric Cancer",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","64","AP","SUPPL",2020-04-28,"STANDARD","EFFICACY",NA,NA,NA,"Every six weeks dosing in Gastric Cancer",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in NSCLC","NSCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","69","AP","SUPPL",2020-04-28,"STANDARD","EFFICACY",NA,NA,NA,"Every six weeks dosing in NSCLC",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in RCC","RCC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","76","AP","SUPPL",2020-04-28,"PRIORITY","EFFICACY",NA,NA,NA,"Every six weeks dosing in RCC",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in Endometrial Carcinoma","Endometrial Carcinoma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","77","AP","SUPPL",2020-04-28,"PRIORITY","EFFICACY",NA,NA,NA,"Every six weeks dosing in Endometrial Carcinoma",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in Cervical Cancer","Cervical Cancer",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","78","AP","SUPPL",2020-04-28,"PRIORITY","EFFICACY",NA,NA,NA,"Every six weeks dosing in Cervical Cancer",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in Urothelial carcinoma","Urothelial carcinoma",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","79","AP","SUPPL",2020-04-28,"PRIORITY","EFFICACY",NA,NA,NA,"Every six weeks dosing in Urothelial carcinoma",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in SCCHN","SCCHN",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","80","AP","SUPPL",2020-04-28,"PRIORITY","EFFICACY",NA,NA,NA,"Every six weeks dosing in SCCHN",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in SCLC","SCLC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","81","AP","SUPPL",2020-04-28,"PRIORITY","EFFICACY",NA,NA,NA,"Every six weeks dosing in SCLC",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy",NA,"Every six weeks dosing in Esophageal cancer","Esophageal cancer",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","82","AP","SUPPL",2020-04-28,"PRIORITY","EFFICACY",NA,NA,NA,"Every six weeks dosing in Esophageal cancer",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-04-28,"Efficacy","Yes","Every 6 weeks dosing in MSI-H tumors","Agnostic",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","83","AP","SUPPL",2020-04-28,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-06-16,"Efficacy","Yes","Tumor Mutation Burden-High solid tumors","Agnostic","102","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","71","AP","SUPPL",2020-06-16,"PRIORITY","EFFICACY","102","Pembrolizumab (KEYTRUDA®)","BLA125514","This supplement modifies the previous label for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options",NA,NA,"Objective Response Rate
Duration of Response","Coprimary","Objective Response Rate & Duration of Response",4,NA,"0.28999999999999998",NA,"RR: 29%",NA,"RR: 29%",NA,"21","39","Modified RECIST","mRECIST","7","Yes",0,1,"1",0,0,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-06-16,"Efficacy","Yes","Every 6 weeks dosing in TMB-H tumors","Agnostic",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","90","AP","SUPPL",2020-06-16,"PRIORITY","EFFICACY",NA,NA,NA,"Provides for an alternate dose/schedule of 400 mg every 6 weeks for adult patients with unresectable or metastatic TMB-H [≥10 mutations/megabase (mut/Mb)] solid tumors",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-06-24,"Efficacy","Yes","r/mCSCC","SCC","105","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","68","AP","SUPPL",2020-06-24,"STANDARD","EFFICACY","105","Pembrolizumab (KEYTRUDA®)","BLA125514","This Prior Approval supplemental biologics application adds a new indication for KEYTRUDA, for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation",NA,NA,"Objective Response Rate","ORR","Objective Response Rate",0,"RR diff","34.3 vs. 15","34.299999999999997","RR:34.3%",NA,"RR:34.3%","15","25.2","44.2","Modified RECIST","mRECIST","7","Yes",0,1,"1",0,0,"Yes","No","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy","No",NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-06-24,"Efficacy","Yes","Every 6 weeks dosing for CSCC","SCC",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","92","AP","SUPPL",2020-06-24,"PRIORITY","EFFICACY",NA,NA,NA,"This Prior Approval supplemental biologics license application provides for an alternate dosage regimen of 400 mg every 6 weeks for adult patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No","Yes","0","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-06-29,"Efficacy",NA,"First line colon cancer","Colon Cancer",NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","84","AP","SUPPL",2020-06-29,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for pembrolizumab for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-10-02,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","70","AP","SUPPL",2020-10-02,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-10-14,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","85","AP","SUPPL",2020-10-14,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-11-10,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","48","AP","SUPPL",2020-11-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2020-11-13,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","88","AP","SUPPL",2020-11-13,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-02-10,"Manufacturing (CMC)",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","98","AP","SUPPL",2021-02-10,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-03-16,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","91","AP","SUPPL",2021-03-16,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-03-16,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","93","AP","SUPPL",2021-03-16,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-03-22,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","96","AP","SUPPL",2021-03-22,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-03-30,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","106","AP","SUPPL",2021-03-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-05-05,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","97","AP","SUPPL",2021-05-05,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-06-28,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","108","AP","SUPPL",2021-06-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-07-01,"Efficacy","Yes","laCSCC","SCC","54","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","100","AP","SUPPL",2021-07-01,"STANDARD","EFFICACY","54",NA,NA,"A new indication for pembrolizumab for locally advanced cSCC that is not curable by surgery or radiation",NA,NA,"Objective Response Rate","ORR","Objective Response Rate",0,NA,NA,NA,"RR: 50%",NA,"RR: 50%",NA,"36","64","Modified RECIST","mRECIST","7","Yes",NA,NA,NA,NA,0,"Yes","No",NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-07-21,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","105","AP","SUPPL",2021-07-21,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-07-26,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","114","AP","SUPPL",2021-07-26,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-07-26,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","89","AP","SUPPL",2021-07-26,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-08-03,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","104","AP","SUPPL",2021-08-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-08-10,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","102","AP","SUPPL",2021-08-10,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-08-31,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","117","AP","SUPPL",2021-08-31,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-08-31,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","118","AP","SUPPL",2021-08-31,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-10-13,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","121","AP","SUPPL",2021-10-13,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-10-13,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","122","AP","SUPPL",2021-10-13,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-11-17,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","113","AP","SUPPL",2021-11-17,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-12-03,"Efficacy","Yes","Adjuvant Stage IIB and IIC Melanoma","Melanoma","969","PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","112","AP","SUPPL",2021-12-03,"PRIORITY","EFFICACY","969|(T=509|C=502)","Pembrolizumab (KEYTRUDA®)","BLA125514","The adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection",NA,"A multicenter, randomized (1:1), double-blind, placebo-controlled trial in patients with completely resected stage IIB or IIC melanoma","Relapse-Free Survival","RFS","Relapse-Free Survival",1,"HR",NA,NA,"HR: 0.65","HR: 0.65",NA,NA,NA,NA,"Investigator Assessment","Clinical","1","Yes",NA,NA,"0",1,1,"Yes","No","1","PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2021-12-17,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","120","AP","SUPPL",2021-12-17,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2022-02-04,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","125","AP","SUPPL",2022-02-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2022-02-04,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","95","AP","SUPPL",2022-02-04,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2022-03-21,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","110","AP","SUPPL",2022-03-21,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2022-05-20,"Efficacy",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","123","AP","SUPPL",2022-05-20,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"PEMBROLIZUMAB","KEYTRUDA","BLA125514",2022-06-21,"Labeling",NA,NA,NA,NA,"PEMBROLIZUMAB","PEMBROLIZUMAB","Merck Sharp & Dohme LLC","Prescription","No","001","SOLUTION","INTRAVENOUS","100MG/4ML (25MG/ML)","131","AP","SUPPL",2022-06-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-1 Ab","PD-1 Targeted Antibody","Immunotherapy",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2012-01-23,"Type 1 - New Molecular Entity","Yes","Actinic Keratoses","AK","1005","NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","1","AP","ORIG",2012-01-23,"STANDARD","TYPE 1","1005|
(H/N|
T=277|
C=270
|
T/E|
T=226|
C=232)","Ingenol Mebutate (PICATO®)","NDA202833","Picato® gel is an inducer of cell death indicated for the topical treatment of actinic keratosis.","N comes from adding up both Head and Neck studies as well as the Trunk and Extremity studies","In two double-blind, vehicle-controlled, clinical trials, 547 adult subjects with AK on the face or scalp were randomized to treatment with either Picato® gel, 0.015% or vehicle gel for 3 consecutive days, followed by an 8 week follow-up period","Complete Clearance Rate","CCR","Complete Clearance Rate",5,"RR diff","H/N: 42% (117/277) vs. 4% (10/270)
T/E: 34% (77/226) v s. 5% (11/232)","38% (H/N) | 29% (T/E)","CCR: 37% (Study 1 Head and Neck) |
CCR: 47% (Study 2 Head & Neck) |
CCR: 28% (Study 3 Trunk & Extremities) |
CCR: 42% (Study 4 Trunk & Extremities)",NA,"CCR: 37% (Study 1 Head and Neck) |
CCR: 47% (Study 2 Head & Neck) |
CCR: 28% (Study 3 Trunk & Extremities) |
CCR: 42% (Study 4 Trunk & Extremities)",NA,NA,NA,"Investigator Assessment of 25 cm2 area","Clinical","1","Yes",1,0,"1",1,1,"Yes","No","1","Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2014-03-12,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","2","AP","SUPPL",2014-03-12,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2015-02-03,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","3","AP","SUPPL",2015-02-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2015-10-06,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","5","AP","SUPPL",2015-10-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2015-11-19,"Efficacy","Yes","Describing response to a repeat course","AK",NA,"NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","4","AP","SUPPL",2015-11-19,"STANDARD","EFFICACY",NA,"Ingenol Mebutate (PICATO®)","NDA202833","Updated labeling describing response to a repeat course of Picato Gel, 0.015% on the face or scalp if an incomplete response is observed at a follow-up examination","Sample Size came from the BJD article (Garbe et al 2016). It is not on the label and therefore we are not including it","In this phase III, randomized, double-blind study in patients","Complete Clearance Rate","CCR","Complete Clearance Rate",5,NA,NA,NA,"",NA,NA,NA,NA,NA,"Investigator Assessment","Clinical","1","Yes",0,0,"1",1,1,"Yes","No","1","Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2016-04-15,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","6","AP","SUPPL",2016-04-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2016-09-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","7","AP","SUPPL",2016-09-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2017-01-26,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","8","AP","SUPPL",2017-01-26,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2020-02-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","11","AP","SUPPL",2020-02-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2020-12-17,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","12","AP","SUPPL",2020-12-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"INGENOL MEBUTATE","PICATO","NULL",2021-03-19,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","GEL","TOPICAL","0.015%, 0.05%","13","AP","SUPPL",2021-03-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytotoxic Agent","Cytotoxic Agent","Cytotoxic Agent",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2013-02-08,"Type 1 - New Molecular Entity",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","1","AP","ORIG",2013-02-08,"PRIORITY","TYPE 1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2013-10-03,"Manufacturing (CMC)",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","1","AP","SUPPL",2013-10-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2013-11-15,"REMS",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","2","AP","SUPPL",2013-11-15,"N/A","REMS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2014-03-13,"Labeling",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","3","AP","SUPPL",2014-03-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2014-09-12,"REMS",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","4","AP","SUPPL",2014-09-12,"N/A","REMS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2015-04-23,"Labeling",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","5","AP","SUPPL",2015-04-23,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2015-04-23,"Efficacy",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","6","AP","SUPPL",2015-04-23,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2015-04-23,"Labeling",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","8","AP","SUPPL",2015-04-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2015-09-14,"REMS",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","9","AP","SUPPL",2015-09-14,"N/A","REMS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2015-10-27,"REMS",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","10","AP","SUPPL",2015-10-27,"N/A","REMS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2015-12-01,"REMS",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","11","AP","SUPPL",2015-12-01,"N/A","REMS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2016-04-22,"REMS",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","13","AP","SUPPL",2016-04-22,"N/A","REMS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2016-06-30,"Labeling",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","12","AP","SUPPL",2016-06-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2016-06-30,"Labeling",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","14","AP","SUPPL",2016-06-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2017-06-27,"REMS",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","16","AP","SUPPL",2017-06-27,"N/A","REMS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2017-11-30,"Labeling",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","18","AP","SUPPL",2017-11-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2017-12-29,"Labeling",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","19","AP","SUPPL",2017-12-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2018-03-20,"Labeling",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","17","AP","SUPPL",2018-03-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2019-10-30,"Labeling",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","21","AP","SUPPL",2019-10-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2020-05-14,"Efficacy","Yes","Treatment of adult patients with AIDS-related Kaposi sarcoma","KS","28","POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","23","AP","SUPPL",2020-05-14,"PRIORITY","EFFICACY","28|
(HIV+=18|
HIV-=10)","Pomalidomide (POMALYST®)","NDA204026","New indication for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART)",NA,"An open label, single center, single arm clinical study that evaluated the safety and efficacy of POMALYST in patients with Kaposi sarcoma (KS).","Objective Response Rate","ORR","Objective Response Rate",0,NA,NA,NA,"RR: 67%",NA,"RR: 67%",NA,"41","87","ACTG","ACTG","10","yes",0,1,"1",0,0,"No","Yes","0","Immunomodulatory","Cereblon Inhibitor","Imid","No",NA
"POMALIDOMIDE","POMALYST","NDA204026",2020-05-14,"Efficacy","Yes","Treatment of Kaposi’s Sarcoma in patients who are HIV-negative","KS","28","POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","24","AP","SUPPL",2020-05-14,"PRIORITY","EFFICACY","28|
(HIV+=18|
HIV-=10)","Pomalidomide (POMALYST®)","NDA204026","Treatment of Kaposi’s Sarcoma in patients who are HIV-negative",NA,"An open label, single center, single arm clinical study that evaluated the safety and efficacy of POMALYST in patients with Kaposi sarcoma (KS).","Objective Response Rate","ORR","Objective Response Rate",0,NA,NA,NA,"RR: 80%",NA,"RR: 80%",NA,"44","98","ACTG","ACTG","10","yes",0,1,"1",0,0,"No","Yes","0","Immunomodulatory","Cereblon Inhibitor","Imid","No",NA
"POMALIDOMIDE","POMALYST","NDA204026",2020-11-20,"Efficacy",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","27","AP","SUPPL",2020-11-20,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2020-12-03,"Labeling",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","28","AP","SUPPL",2020-12-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"POMALIDOMIDE","POMALYST","NDA204026",2021-08-05,"REMS",NA,NA,NA,NA,"POMALIDOMIDE","POMALIDOMIDE","Celgene Corporation","Prescription","Yes","003","CAPSULE","ORAL","1 MG, 2 MG, 3 MG, 4 MG","29","AP","SUPPL",2021-08-05,"N/A","REMS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Immunomodulatory","Cereblon Inhibitor","Imid",NA,NA
"MOGAMULIZUMAB-KPKC","POTELIGEO","BLA761051",2018-08-08,"Type 1 - New Molecular Entity","Yes","Relapsed/Refractory Mycosis Fungoides or Sezary Syndrome - Second Line","CTCL","372","MOGAMULIZUMAB","MOGAMULIZUMAB-KPKC","Kyowa Kirin, Inc.","Prescription","TBD","001","INJECTABLE","INJECTION","20MG/5ML","1","AP","ORIG",2018-08-08,"PRIORITY","TYPE 1","372|
(T=186|
C=186)","Mogamulizumab-KPKC (POTELIGEO®)","BLA761051","POTELIGEO is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy",NA,"A randomized, open-label, multicenter trial (Study 0761-010; NCT01728805) of POTELIGEO vs. vorinostat","Progression Free Survival (Prim)
ORR (Sec)","PFS","Progression-Free Survival",2,"HR","7.6 vs 3.1 mo","0.53","HR: 0.53","HR: 0.53",NA,NA,NA,NA,"Global Response Criteria","GRS","9","Yes",1,0,"0",0,1,"Yes","No","1","CCR4 Ab","CCR4 Targeted Antibody & ADCC Inducer","Immunotherapy",NA,NA
"MOGAMULIZUMAB-KPKC","POTELIGEO","BLA761051",2021-07-08,"Labeling",NA,NA,NA,NA,"MOGAMULIZUMAB","MOGAMULIZUMAB-KPKC","Kyowa Kirin, Inc.","Prescription","TBD","001","INJECTABLE","INJECTION","20MG/5ML","11","AP","SUPPL",2021-07-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CCR4 Ab","CCR4 Targeted Antibody & ADCC Inducer","Immunotherapy",NA,NA
"MOGAMULIZUMAB-KPKC","POTELIGEO","BLA761051",2022-03-30,"Labeling",NA,NA,NA,NA,"MOGAMULIZUMAB","MOGAMULIZUMAB-KPKC","Kyowa Kirin, Inc.","Prescription","TBD","001","INJECTABLE","INJECTION","20MG/5ML","15","AP","SUPPL",2022-03-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CCR4 Ab","CCR4 Targeted Antibody & ADCC Inducer","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",1992-05-05,"Type 1 - New Molecular Entity",NA,"Metastatic Renal Cell Carcinoma","RCC",NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","1","AP","ORIG",1992-05-05,"UNKNOWN","TYPE 1",NA,"Aldesleukin (PROLEUKIN®)","BLA103293",NA,"Original BLA is NOT a skin cancer",NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",1998-01-09,"Efficacy",NA,"Unconfirmed",NA,NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","1019","AP","SUPPL",1998-01-09,"UNKNOWN","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",1998-01-09,"Efficacy","Yes","Metastatic Melanoma","Melanoma","270","ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","1021","AP","SUPPL",1998-01-09,"PRIORITY","EFFICACY","270","Aldesleukin (PROLEUKIN®)","BLA103293","Proleukin is indicated for the treatment  of adults with metastatic melanoma","The supplement category on the FDA website is ""supplement', but it is clearly a New Indication supplement for Melanoma, so we'll keep it","Two hundred seventy patients with metastatic melanoma were treated with single agent Proleukin in 8 clinical studies conducted at 22 institutions","Objective Response Rate","ORR","Objective Response Rate",0,NA,"ORR: 16% (43/270); CR 6% (17/270)",NA,"RR: 15.9%",NA,"RR: 15.9%",NA,"11.8","20.8","Sum of 2D tumor Measurements","2D Measurement","2","Yes",0,1,"1",0,0,"Yes","No","1","Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",2000-06-27,"Labeling",NA,NA,NA,NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","1029","AP","SUPPL",2000-06-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",2009-04-08,"Labeling",NA,NA,NA,NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","5087","AP","SUPPL",2009-04-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",2010-03-17,"Labeling",NA,NA,NA,NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","5088","AP","SUPPL",2010-03-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",2010-07-06,"Labeling",NA,NA,NA,NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","5099","AP","SUPPL",2010-07-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",2011-07-19,"Labeling",NA,NA,NA,NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","5114","AP","SUPPL",2011-07-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",2011-12-16,"Labeling",NA,NA,NA,NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","5123","AP","SUPPL",2011-12-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",2012-07-30,"Labeling",NA,NA,NA,NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","5130","AP","SUPPL",2012-07-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",2015-05-06,"Labeling",NA,NA,NA,NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","5139","AP","SUPPL",2015-05-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"ALDESLEUKIN","PROLEUKIN","BLA103293",2019-05-17,"Labeling",NA,NA,NA,NA,"ALDESLEUKIN","ALDESLEUKIN","Clinigen Group PLC","Prescription","No","001","VIAL",NA,"22MIU/VIAL","5146","AP","SUPPL",2019-05-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"INTERFERON ALFA-2A","ROFERON","BLA103145",1988-11-21,"Efficacy","Yes","AIDS-Related Kaposi's Sarcoma","KS","350","INTERFERON ALFA-2A","INTERFERON ALFA-2A",NA,NA,NA,NA,NA,NA,NA,"1000",NA,"SUPPL",NA,NA,"EFFICACY","350","Interferon alfa-2a (ROFERON® A)","BLA103145","Roferon-A is indicated for the treatment of chronic hepatitis C, hairy cell leukemia and AIDS-related Kaposi's sarcoma in patients 18 years of age or older. In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis).","PI found on internet; 350 patients noted in indication. The RR was calculated from Table 2, this only contained a portion of the patietns (167/350).",NA,"Response Rate","ORR","Response Rate",0,NA,"There are two piecies of data here: 
One product label states best RR was at 36 MIU (25.5% = 13.3% CR, 12.2% PR) |
The Other:
20.95% (35/167), which comes from the below:
83 * 0.72 = 6 (CD4 Count 0-200)
51 * 0.275 = 14 (201-400 CD4 cells) 
33 * .454 = 15 (>400 T cells)",NA,"RR: 25.5% (35 MIU)",NA,"RR: 25.5% (35 MIU)",NA,"15.1","27.9",NA,NA,NA,"Yes",0,1,"1",0,0,"Yes","No","1","Cytokine","Cytokine","Immunotherapy",NA,"Original indication; hairly cell leukemia; BLA revoked(withdrawn) May 9, 2014"
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2000-10-16,"Type 3 - New Dosage Form","Yes","Actinic Keratoses","AK","427","DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","1","AP","ORIG",2000-10-16,"STANDARD","TYPE 3","427|
(T=213|
C=214)","Diclofenac Sodium 3% Gel (SOLARAZE®)","NDA021005","Solaraze™ (diclofenac sodium) Gel is indicated for the topical treatment of actinic keratoses (AK).",NA,"Clinical trials were conducted involving a total of 427 patients (213 treated with SolarazeÔ and 214 with gel vehic","Complete Clearance Rate at 30 days after completion of Tx","CCR","Complete Clearance Rate",5,"RR diff","CLNS 32.2% (67/208) vs. 13.2% (28/212)","19","CCR: 47% (Study 1 90d Tx) |
CCR: 34% (Study 2 90d Tx) |
CCR: 31% (Study 3 60d Tx) |
CCR: 14% (Study 3 30d Tx)",NA,"CCR: 47% (Study 1 90d Tx) |
CCR: 34% (Study 2 90d Tx) |
CCR: 31% (Study 3 60d Tx) |
CCR: 14% (Study 3 30d Tx)",NA,NA,NA,"Investigator Assessment","Clinical","1","Yes",0,0,"1",1,1,"Yes","No","1","NSAID","NSAID","NSAID",NA,"Labels here tend to quote ITT pop vs PPP used in efficacy tables: The label states that 427 patients were studied, but I only have data for 420 in my calculations"
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2001-08-17,"Labeling",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","1","AP","SUPPL",2001-08-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2001-10-02,"Manufacturing (CMC)",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","2","AP","SUPPL",2001-10-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2002-02-19,"Manufacturing (CMC)",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","3","AP","SUPPL",2002-02-19,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2002-05-20,"Manufacturing (CMC)",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","4","AP","SUPPL",2002-05-20,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2002-12-13,"Manufacturing (CMC)",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","5","AP","SUPPL",2002-12-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2003-04-29,"Labeling",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","6","AP","SUPPL",2003-04-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2004-03-18,"Manufacturing (CMC)",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","7","AP","SUPPL",2004-03-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2004-07-23,"Manufacturing (CMC)",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","9","AP","SUPPL",2004-07-23,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2007-06-01,"Manufacturing (CMC)",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","10","AP","SUPPL",2007-06-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2011-12-08,"Labeling",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","13","AP","SUPPL",2011-12-08,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2015-03-30,"Manufacturing (CMC)",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","15","AP","SUPPL",2015-03-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2016-05-09,"Labeling",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","16","AP","SUPPL",2016-05-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2016-05-16,"Manufacturing (CMC)",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","17","AP","SUPPL",2016-05-16,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2021-04-28,"Labeling",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","22","AP","SUPPL",2021-04-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"DICLOFENAC SODIUM","SOLARAZE","NDA021005",2022-04-05,"Labeling",NA,NA,NA,NA,"DICLOFENAC SODIUM","DICLOFENAC SODIUM","c(""E. Fougera & Co. a division of Fougera Pharmaceuticals Inc."", ""PharmaDerm a division of Fougera Pharmaceuticals Inc."")","Discontinued","Yes","001","GEL","TOPICAL","3%","23","AP","SUPPL",2022-04-05,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NSAID","NSAID","NSAID",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1955-04-27,"Type 2 - New Active Ingredient","Yes","Mycosis Fungoides","CTCL",NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","1","AP","ORIG",1955-04-27,"STANDARD","TYPE 2",NA,"Hydrocortisone sodium succinate (SOLU-CORTEF®)","NDA009866","Mycosis Fungoides","DESI Drug; efficacy not confirmed",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","Injectable solution; PI available and reviewed 12-16-18"
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1979-06-18,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","43","AP","SUPPL",1979-06-18,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1979-09-24,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","44","AP","SUPPL",1979-09-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1980-04-14,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","45","AP","SUPPL",1980-04-14,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1981-12-15,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","46","AP","SUPPL",1981-12-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1981-12-15,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","47","AP","SUPPL",1981-12-15,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1985-07-24,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","51","AP","SUPPL",1985-07-24,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1987-07-02,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","54","AP","SUPPL",1987-07-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1987-07-23,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","52","AP","SUPPL",1987-07-23,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1988-05-13,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","55","AP","SUPPL",1988-05-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1989-03-22,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","50","AP","SUPPL",1989-03-22,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1990-01-16,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","57","AP","SUPPL",1990-01-16,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1990-03-29,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","56","AP","SUPPL",1990-03-29,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1991-04-01,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","59","AP","SUPPL",1991-04-01,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1993-12-28,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","61","AP","SUPPL",1993-12-28,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1994-03-25,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","65","AP","SUPPL",1994-03-25,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1994-09-15,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","67","AP","SUPPL",1994-09-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1994-12-06,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","62","AP","SUPPL",1994-12-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",1999-11-25,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","70","AP","SUPPL",1999-11-25,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2000-04-04,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","71","AP","SUPPL",2000-04-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2002-10-21,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","72","AP","SUPPL",2002-10-21,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2009-09-01,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","77","AP","SUPPL",2009-09-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2009-09-01,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","79","AP","SUPPL",2009-09-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2010-06-16,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","80","AP","SUPPL",2010-06-16,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2013-09-27,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","97","AP","SUPPL",2013-09-27,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2013-11-08,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","96","AP","SUPPL",2013-11-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2014-03-28,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","99","AP","SUPPL",2014-03-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2014-04-04,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","95","AP","SUPPL",2014-04-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2014-06-09,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","102","AP","SUPPL",2014-06-09,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2014-06-24,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","103","AP","SUPPL",2014-06-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2014-07-03,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","104","AP","SUPPL",2014-07-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2014-07-22,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","101","AP","SUPPL",2014-07-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2014-09-06,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","92","AP","SUPPL",2014-09-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2015-09-23,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","90","AP","SUPPL",2015-09-23,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2016-02-25,"Manufacturing (CMC)",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","108","AP","SUPPL",2016-02-25,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2016-09-08,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","105","AP","SUPPL",2016-09-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2016-09-08,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","98","AP","SUPPL",2016-09-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2019-11-21,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","113","AP","SUPPL",2019-11-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"HYDROCORTISONE SODIUM SUCCINATE","SOLU-CORTEF","NDA009866",2021-05-27,"Labeling",NA,NA,NA,NA,"HYDROCORTISONE SODIUM SUCCINATE","HYDROCORTISONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","003","INJECTABLE","INJECTION","EQ 100MG BASE/VIAL, EQ 250MG BASE/VIAL, EQ 500MG BASE/VIAL, EQ 1GM BASE/VIAL","115","AP","SUPPL",2021-05-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1959-05-18,"Type 2 - New Active Ingredient","Yes","Mycosis Fungoides","CTCL",NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","1","AP","ORIG",1959-05-18,"STANDARD","TYPE 2",NA,"Methylprednisolone Sodium Succinate (SOLU-MEDROL®)","NDA011856","Mycosis Fungoides","DESI drug; data confirming efficacy as part of DESI has not been identified yet",NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid","Y","IV formulation"
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1979-11-13,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","43","AP","SUPPL",1979-11-13,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1980-04-28,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","46","AP","SUPPL",1980-04-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1980-09-30,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","47","AP","SUPPL",1980-09-30,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1981-02-20,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","50","AP","SUPPL",1981-02-20,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1981-08-11,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","44","AP","SUPPL",1981-08-11,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1981-10-16,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","49","AP","SUPPL",1981-10-16,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1983-05-03,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","54","AP","SUPPL",1983-05-03,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1985-02-27,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","53","AP","SUPPL",1985-02-27,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1985-03-28,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","57","AP","SUPPL",1985-03-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1986-01-23,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","61","AP","SUPPL",1986-01-23,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1986-01-31,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","60","AP","SUPPL",1986-01-31,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1986-02-14,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","59","AP","SUPPL",1986-02-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1986-12-08,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","58","AP","SUPPL",1986-12-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1986-12-08,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","62","AP","SUPPL",1986-12-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1989-03-22,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","55","AP","SUPPL",1989-03-22,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1989-07-11,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","68","AP","SUPPL",1989-07-11,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1989-10-02,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","67","AP","SUPPL",1989-10-02,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1990-04-24,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","69","AP","SUPPL",1990-04-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1990-12-07,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","73","AP","SUPPL",1990-12-07,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1991-09-04,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","77","AP","SUPPL",1991-09-04,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1993-11-05,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","78","AP","SUPPL",1993-11-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1994-03-25,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","81","AP","SUPPL",1994-03-25,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1994-04-06,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","84","AP","SUPPL",1994-04-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1994-04-22,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","72","AP","SUPPL",1994-04-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1994-09-15,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","87","AP","SUPPL",1994-09-15,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1998-02-26,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","91","AP","SUPPL",1998-02-26,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",1999-03-16,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","92","AP","SUPPL",1999-03-16,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2000-04-03,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","93","AP","SUPPL",2000-04-03,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2002-10-21,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","94","AP","SUPPL",2002-10-21,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2010-06-24,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","107","AP","SUPPL",2010-06-24,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2011-10-20,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","103","AP","SUPPL",2011-10-20,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2011-10-20,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","104","AP","SUPPL",2011-10-20,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2014-03-28,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","119","AP","SUPPL",2014-03-28,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2014-04-04,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","116","AP","SUPPL",2014-04-04,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2014-06-09,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","122","AP","SUPPL",2014-06-09,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2014-07-03,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","123","AP","SUPPL",2014-07-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2014-07-22,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","121","AP","SUPPL",2014-07-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2015-08-06,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","127","AP","SUPPL",2015-08-06,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2016-09-08,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","124","AP","SUPPL",2016-09-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2016-09-08,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","126","AP","SUPPL",2016-09-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2018-03-28,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","131","AP","SUPPL",2018-03-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2018-07-24,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","133","AP","SUPPL",2018-07-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2021-05-27,"Labeling",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","136","AP","SUPPL",2021-05-27,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"METHYLPREDNISOLONE SODIUM SUCCINATE","SOLU-MEDROL","NDA011856",2021-10-27,"Manufacturing (CMC)",NA,NA,NA,NA,"METHYLPREDNISOLONE SODIUM SUCCINATE","METHYLPREDNISOLONE SODIUM SUCCINATE","Pharmacia & Upjohn Company LLC","Prescription","Yes","006","INJECTABLE","INJECTION","EQ 125MG BASE/VIAL, EQ 125MG BASE/VIAL, EQ 50MG BASE/VIAL, EQ 1GM BASE/VIAL, EQ 2GM BASE/VIAL","139","AP","SUPPL",2021-10-27,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2001-01-19,"Type 1 - New Molecular Entity",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","1","AP","ORIG",2001-01-19,"STANDARD","TYPE 1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2001-08-07,"Efficacy",NA,"PEG-Intron with Ribavirin","HCV ",NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5002","AP","SUPPL",2001-08-07,"PRIORITY","EFFICACY",NA,NA,NA,"PEG-Intron with Ribavirin",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2002-07-17,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5032","AP","SUPPL",2002-07-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2002-11-21,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5030","AP","SUPPL",2002-11-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2003-03-14,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5041","AP","SUPPL",2003-03-14,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2004-03-05,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5070","AP","SUPPL",2004-03-05,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2004-09-23,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5061","AP","SUPPL",2004-09-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2004-10-01,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5086","AP","SUPPL",2004-10-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2004-10-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5087","AP","SUPPL",2004-10-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2004-10-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5088","AP","SUPPL",2004-10-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2005-05-04,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5099","AP","SUPPL",2005-05-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2005-07-22,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5105","AP","SUPPL",2005-07-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2005-11-03,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5077","AP","SUPPL",2005-11-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2006-10-10,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5118","AP","SUPPL",2006-10-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2006-12-22,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5124","AP","SUPPL",2006-12-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2007-05-31,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5135","AP","SUPPL",2007-05-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2008-03-26,"Efficacy",NA,"Unavailable","Unavailable",NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5123","AP","SUPPL",2008-03-26,"STANDARD","EFFICACY",NA,NA,NA,"Unavailable",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2008-12-11,"Efficacy",NA,"Expansion of label in CHC","HCV",NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5171","AP","SUPPL",2008-12-11,"PRIORITY","EFFICACY",NA,NA,NA,"Expand the indication for PegIntron™ (peginterferon alfa-2b), given in combination with REBETOL(ribavirin, USP), to include the treatment of pediatrc patients 3-17 years of age with chronic hepatitis C (CHC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2008-12-11,"Supplement",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5174","AP","SUPPL",2008-12-11,NA,"S",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2009-03-10,"Efficacy",NA,"Expansion of label in CHC","HCV",NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5125","AP","SUPPL",2009-03-10,"STANDARD","EFFICACY",NA,NA,NA,"Expand the indication to include retreatment of chronic hepatitis C patients who failed to respond or relapsed after treatment with combination alpha intereron/ribavirin therapy. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2009-05-08,"Efficacy",NA,"Updated label in CHC ","HCV",NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5172","AP","SUPPL",2009-05-08,"STANDARD","EFFICACY",NA,NA,NA,"Update the package insert with the results of the IDEAL study, P03471, which includes adding a two-step dose reduction scheme for PegIntron™ and increasing the dose of REBETOL® to 1200 mg/day for patients who weigh between 81 and 85 kilograms",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2009-05-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5175","AP","SUPPL",2009-05-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2009-08-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5183","AP","SUPPL",2009-08-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2010-01-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5184","AP","SUPPL",2010-01-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2010-07-21,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5199","AP","SUPPL",2010-07-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2011-02-01,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5201","AP","SUPPL",2011-02-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2011-03-29,"Efficacy","Yes","Adjuvant Melanoma","Melanoma","1256","NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5153","AP","SUPPL",2011-03-29,"PRIORITY","EFFICACY","1256|
(T=627|
C=629)","Pegylated Inteferon-alfa-2b (SYLATRON™)","BLA103949","SYLATRON is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy",NA,"The safety and effectiveness of SYLATRON were evaluated in an open-label, multicenter, randomized (1:1) study conducted in 1256 patients with surgically resected, AJCC Stage III melanoma within 84 days of regional lymph node dissection","RFS","RFS","Relapse-Free Survival",1,"HR","RFS 34.8 vs. 25.5 mo","0.82","HR: 0.82","HR: 0.82",NA,NA,NA,NA,"Investigator assessment","Clinical","1","Yes",0,0,"0",0,1,"Yes","No","1","Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2011-05-06,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5203","AP","SUPPL",2011-05-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2011-05-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5211","AP","SUPPL",2011-05-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2011-06-06,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5204","AP","SUPPL",2011-06-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2011-12-22,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5217","AP","SUPPL",2011-12-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2011-12-22,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5222","AP","SUPPL",2011-12-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2012-06-04,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5231","AP","SUPPL",2012-06-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2012-07-02,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5232","AP","SUPPL",2012-07-02,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2012-12-26,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5252","AP","SUPPL",2012-12-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2013-05-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5263","AP","SUPPL",2013-05-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2013-11-15,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5273","AP","SUPPL",2013-11-15,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2013-12-09,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5248","AP","SUPPL",2013-12-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2013-12-18,"Efficacy",NA,"New pen injector","Non-specific",NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5259","AP","SUPPL",2013-12-18,"STANDARD","EFFICACY",NA,NA,NA,"Provides for a new single-use, dualchamber pre-filled pen injector, PegIntron® Selectdose™ (peginterferon alfa-2b)",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2014-07-31,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5295","AP","SUPPL",2014-07-31,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2014-08-11,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5288","AP","SUPPL",2014-08-11,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2014-08-14,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5285","AP","SUPPL",2014-08-14,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2014-08-30,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5287","AP","SUPPL",2014-08-30,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2014-10-09,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5296","AP","SUPPL",2014-10-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2014-11-17,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5293","AP","SUPPL",2014-11-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2015-05-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5298","AP","SUPPL",2015-05-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2015-05-21,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5297","AP","SUPPL",2015-05-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2015-09-16,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5299","AP","SUPPL",2015-09-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2017-05-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5304","AP","SUPPL",2017-05-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2017-10-02,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5305","AP","SUPPL",2017-10-02,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2017-10-02,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5307","AP","SUPPL",2017-10-02,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2017-10-03,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5306","AP","SUPPL",2017-10-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2018-05-04,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5310","AP","SUPPL",2018-05-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2018-05-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5311","AP","SUPPL",2018-05-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2018-12-21,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5312","AP","SUPPL",2018-12-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"PEGINTERFERON ALFA-2B","PEGINTRON","BLA103949",2019-01-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Prescription","No","008","SYRINGE",NA,"50UG/0.5ML, 80UG/0.5ML, 120UG/0.5ML, 150UG/0.5ML, 50UG/0.5ML, 80UG/0.5ML, 150UG/0.5ML, 120UG/0.5ML, 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL, 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL","5313","AP","SUPPL",2019-01-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cytokine","Cytokine","Immunotherapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2013-05-29,"Type 1 - New Molecular Entity","Yes","Single agent, first-line in advanced BRAF-mutated melanoma","Melanoma","250","DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","1","AP","ORIG",2013-05-29,"STANDARD","TYPE 1","250|
(T=187|
C=63)","Dabrafenib (TAFINLAR®)","NDA202806","TAFINLAR is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test",NA,"A single arm, open-label, two-cohort, multi-center trial  (Trial 2)","Progression-Free Survival","PFS","Progression-Free Survival",2,"HR","5.1 vs. 2.7 mo","0.33","HR: 0.33","HR: 0.33",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",1,0,"0",0,1,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2013-12-26,"Labeling",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","1","AP","SUPPL",2013-12-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2014-01-09,"Efficacy","Yes","Accelerated approval for Dab/Tram in advanced BRAF mutant melanoma","Melanoma","162","DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","2","AP","SUPPL",2014-01-09,"PRIORITY","EFFICACY","162|
(DT2=55|
DT1=54|
D=53)","Dabrafenib (TAFINLAR®) In Combination with Trametinib (MEKINIST®)","NDA202806","A new indication for Tafinlar (dabrafenib), in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test","There is confusion re: Primary endpoints. In short the Label says ORR, which is what we are putting in table 1. However, You need to look into the Approval package for Dabrafenib to find that a co-primary endpoint was used, as the label makes it look like ORR was the primary endpoint. 
Look at page 289 or 290 of the 505 page review","Trial 2 was a multicenter, open-label, randomized (1:1:1) dose-ranging trial designed to evaluate the clinical activity and safety of TAFINLAR in combination with trametinib (at two different doses) and to compare the safety with TAFINLAR as a single agent in patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma","Objective Response Rate (ORR)
PFS","Coprimary","Objective Response Rate",4,"RR diff","76% (41/54) vs. 54% (29/54) : 9.4 vs 5.8 mo","22","RR: 76%",NA,"RR: 76%",NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"1",0,1,"No","Yes","0","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,"AA aproval, later converted to RA"
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2014-08-25,"Manufacturing (CMC)",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","3","AP","SUPPL",2014-08-25,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2015-11-20,"Efficacy","Yes","Regular approval for Dab/Tram in advanced BRAF mutant melanoma","Melanoma","1127","DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","4","AP","SUPPL",2015-11-20,"UNKNOWN","EFFICACY","1127|
(Trial 2|
DT=211|
DP=212
|
Trial 3|
DT=352|
Vem=352)","Dabrafenib (TAFINLAR®) In Combination with Trametinib (MEKINIST®)","NDA202806","Regular approval of dabrafenib, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test and to remove the statement from the currently approved indication `The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib`.","Unable to validate ODAC, Fast Track","The safety and efficacy of TAFINLAR administered with trametinib were evaluated in two  international, randomized, active-controlled trials: one double-blind trial (Trial 2) and one open label trial (Trial 3).","Overall Survival","OS","Overall Survival",3,"HR","25.1 vs. 18.7 mo (Trial 2) 
NR vs. 17.2 mo (Trial 3)","0.71
0.69","HR: 0.71 (Trial 2) | 
HR: 0.69 (Trial 3)","HR: 0.71 (Trial 2) | 
HR: 0.69 (Trial 3)",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"0",1,1,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2016-06-16,"Labeling",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","5","AP","SUPPL",2016-06-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2017-06-16,"Labeling",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","7","AP","SUPPL",2017-06-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2017-06-22,"Efficacy",NA,"New indication for NSCLC","NSCLC",NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","6","AP","SUPPL",2017-06-22,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for Taflinar, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2018-04-20,"Labeling",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","9","AP","SUPPL",2018-04-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2018-04-30,"Efficacy","Yes","Adjuvant BRAF Mutant Melanoma In Combination with Trametinib","Melanoma","870","DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","8","AP","SUPPL",2018-04-30,"PRIORITY","EFFICACY","870|
(T=438|
C=432)","Dabrafenib (TAFINLAR®) In Combination With Trametinib (MEKINIST®)","NDA202806","TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",NA,"COMBI-AD (NCT 01682083) was an international, multi-center, randomized, double-blind, placebo-controlled trial that enrolled patients with Stage III melanoma with BRAF V600E or V600K mutations","Relapse-Free Survival","RFS","Relapse-Free Survival",1,"HR","NE vs. 16.6 mo","0.47","HR: 0.47","HR: 0.47",NA,NA,NA,NA,"Investigator assessment","Clinical","1","Yes",0,0,"0",1,1,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2018-05-04,"Efficacy",NA,"New indication for ATC","ATC",NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","10","AP","SUPPL",2018-05-04,"PRIORITY","EFFICACY",NA,NA,NA,"A new indication for TAFINLAR in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2019-07-16,"Labeling",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","13","AP","SUPPL",2019-07-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2019-10-06,"Efficacy","Yes","Updates label in regards to brain mets for melanoma","Melanoma","121","DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","12","AP","SUPPL",2019-10-06,"STANDARD","EFFICACY","121","Dabrafenib (TAFINLAR®) In Combination With Trametinib (MEKINIST®)","NDA202806","Updates to the CLINICAL STUDIES (14.2) section in the TAFINLAR United States Prescribing Information (USPI) adding the results of Study BRF117277 (Novartis study code CDRB436B2204; “the COMBI-MB study”), a non-randomized, open-label, multi-center, multi-cohort trial of dabrafenib plus trametinib in subjects with BRAF mutation-positive melanoma that has metastasized to the brain",NA,"The COMBI-MB study -  non-randomized, open-label, multi-center, multi-cohort trial","Overall Response Rate","ORR","Overall Response Rate",0,NA,NA,NA,"RR: 50%",NA,"RR: 50%",NA,"40","60","Modified RECIST","mRECIST","7","Yes",0,1,"1",0,0,NA,"No",NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2020-04-09,"Labeling",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","15","AP","SUPPL",2020-04-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2021-05-07,"Labeling",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","17","AP","SUPPL",2021-05-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2021-12-03,"Labeling",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","20","AP","SUPPL",2021-12-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2022-01-28,"Efficacy",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","19","AP","SUPPL",2022-01-28,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2022-02-04,"Manufacturing (CMC)",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","21","AP","SUPPL",2022-02-04,"N/A","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2022-05-27,"Efficacy",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","23","AP","SUPPL",2022-05-27,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"DABRAFENIB MESYLATE","TAFINLAR","NDA202806",2022-06-22,"Efficacy",NA,NA,NA,NA,"DABRAFENIB MESYLATE","DABRAFENIB","Novartis Pharmaceuticals Corporation","Prescription","Yes","002","CAPSULE","ORAL","EQ 75MG BASE; EQ 50MG BASE","22","AP","SUPPL",2022-06-22,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"BEXAROTENE","TARGRETIN","NDA021055",1999-12-29,"Type 1 - New Molecular Entity","Yes","Refractory Cutaneous T-Cell Lymphoma","CTCL","152","BEXAROTENE","BEXAROTENE","c(""Oceanside Pharmaceuticals"", ""Bausch Health US, LLC"")","Prescription","Yes","001","CAPSULE","ORAL","75MG","1","AP","ORIG",1999-12-29,"PRIORITY","TYPE 1","152","Bexarotene (TARGRETIN®)","NDA021055","Targretin® (bexarotene) capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.","The FDA concludes that the results of one-armed studies are exploratory and that conclusions should be based on clinical judgement.","Targretin® capsules were evaluated in 152 patients with advanced and early stage cutaneous T-cell lymphoma (CTCL) in two pivotal, open-label  historically controlled clinical studies conducted in the U.S., Canada, Europe, and Australia","Response Rate","ORR","Response Rate",0,"RR diff","RR 32% (20/62) (20.9, 0.45) vs. 5% (HC)","27","RR: 32.2%",NA,"RR: 32.2%","5","20.9","45.3","Composite (CAILS)","Composite","6","Yes",1,1,"1",0,0,"Yes","No","1","Retinoid","Retinoid","Retinoid",NA,"200 patietns were enrolled in 3 studies, 2 studies were pivotal and 152 were used for the efficacy analyses; Study 1069-23 evaluated stages I-IIa and 1069-24 evaluated stage IIB-IVB; 62 patients were assessed at the approved dose of 300 mg/m2 and that's where the efficacy data comes from"
"BEXAROTENE","TARGRETIN","NDA021055",2001-02-14,"Manufacturing (CMC)",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Oceanside Pharmaceuticals"", ""Bausch Health US, LLC"")","Prescription","Yes","001","CAPSULE","ORAL","75MG","1","AP","SUPPL",2001-02-14,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021055",2002-01-29,"Manufacturing (CMC)",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Oceanside Pharmaceuticals"", ""Bausch Health US, LLC"")","Prescription","Yes","001","CAPSULE","ORAL","75MG","4","AP","SUPPL",2002-01-29,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021055",2003-04-21,"Labeling",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Oceanside Pharmaceuticals"", ""Bausch Health US, LLC"")","Prescription","Yes","001","CAPSULE","ORAL","75MG","2","AP","SUPPL",2003-04-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021055",2003-04-21,"Labeling",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Oceanside Pharmaceuticals"", ""Bausch Health US, LLC"")","Prescription","Yes","001","CAPSULE","ORAL","75MG","3","AP","SUPPL",2003-04-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021055",2011-05-16,"Labeling",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Oceanside Pharmaceuticals"", ""Bausch Health US, LLC"")","Prescription","Yes","001","CAPSULE","ORAL","75MG","6","AP","SUPPL",2011-05-16,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021055",2012-01-06,"Labeling",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Oceanside Pharmaceuticals"", ""Bausch Health US, LLC"")","Prescription","Yes","001","CAPSULE","ORAL","75MG","8","AP","SUPPL",2012-01-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021055",2014-12-02,"Manufacturing (CMC)",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Oceanside Pharmaceuticals"", ""Bausch Health US, LLC"")","Prescription","Yes","001","CAPSULE","ORAL","75MG","9","AP","SUPPL",2014-12-02,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021055",2015-07-29,"Efficacy",NA,"Incorporate study results from Study E7273-G000-401",NA,NA,"BEXAROTENE","BEXAROTENE","c(""Oceanside Pharmaceuticals"", ""Bausch Health US, LLC"")","Prescription","Yes","001","CAPSULE","ORAL","75MG","10","AP","SUPPL",2015-07-29,"STANDARD","EFFICACY",NA,NA,NA,NA,"This 'Prior Approval' supplemental new drug application revises the Clinical Trials section of the prescribing information to incorporate study results from Study E7273-G000-401 entitled 'Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Patients with Refractory Cutaneous T-Cell Lymphoma.'",NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021055",2015-09-14,"Manufacturing (CMC)",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Oceanside Pharmaceuticals"", ""Bausch Health US, LLC"")","Prescription","Yes","001","CAPSULE","ORAL","75MG","11","AP","SUPPL",2015-09-14,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021056",2000-06-28,"Type 3 - New Dosage Form","Yes","Refractory Stage IA and IB Cutaneous T-Cell Lymphoma","CTCL","50","BEXAROTENE","BEXAROTENE","c(""Bausch Health US, LLC"", ""Oceanside Pharmaceuticals"")","Prescription","Yes","001","GEL","TOPICAL","1%","1","AP","ORIG",2000-06-28,"PRIORITY","TYPE 3","50","Bexarotene gel 1% (TARGRETIN®)","NDA021056","Targretin® (bexarotene) gel 1% is indicated for the topical treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.","117 patients were studied in the program, 50 patients in the phase III","One multi-center, open-label, historically-controlled clinical trial program (dose-seeking trials with different response criteria than the multicenter trial). N= 117","Response Rate","ORR","Response Rate",0,"RR diff","26% (13/50) (14.6, 40.3) vs. 5% (HC)","21","RR: 26%",NA,"RR: 26%","5","14.6","40.299999999999997","Composite (CAILS)","Composite","6","Yes",0,1,"1",0,0,"Yes","No","1","Retinoid","Retinoid","Retinoid",NA,"The Gel was not taken to ODAC, but the capsules were"
"BEXAROTENE","TARGRETIN","NDA021056",2002-03-14,"Manufacturing (CMC)",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Bausch Health US, LLC"", ""Oceanside Pharmaceuticals"")","Prescription","Yes","001","GEL","TOPICAL","1%","1","AP","SUPPL",2002-03-14,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021056",2011-04-08,"Labeling",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Bausch Health US, LLC"", ""Oceanside Pharmaceuticals"")","Prescription","Yes","001","GEL","TOPICAL","1%","3","AP","SUPPL",2011-04-08,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021056",2013-07-22,"Manufacturing (CMC)",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Bausch Health US, LLC"", ""Oceanside Pharmaceuticals"")","Prescription","Yes","001","GEL","TOPICAL","1%","5","AP","SUPPL",2013-07-22,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"BEXAROTENE","TARGRETIN","NDA021056",2015-02-09,"Manufacturing (CMC)",NA,NA,NA,NA,"BEXAROTENE","BEXAROTENE","c(""Bausch Health US, LLC"", ""Oceanside Pharmaceuticals"")","Prescription","Yes","001","GEL","TOPICAL","1%","6","AP","SUPPL",2015-02-09,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Retinoid","Retinoid","Retinoid",NA,NA
"PACLITAXEL","TAXOL","NULL",1992-12-29,"Type 1 - New Molecular Entity",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","1","AP","ORIG",1992-12-29,"PRIORITY","TYPE 1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1993-06-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","1","AP","SUPPL",1993-06-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1993-07-23,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","2","AP","SUPPL",1993-07-23,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1994-03-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","5","AP","SUPPL",1994-03-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1994-04-13,"Efficacy",NA,"Unavailable","Unavailable",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","4","AP","SUPPL",1994-04-13,"STANDARD","EFFICACY",NA,NA,NA,"Unavailable",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1994-04-21,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","7","AP","SUPPL",1994-04-21,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1994-06-22,"Efficacy",NA,"Unavailable","Unavailable",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","3","AP","SUPPL",1994-06-22,"STANDARD","EFFICACY",NA,NA,NA,"Unavailable",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1994-07-22,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","9","AP","SUPPL",1994-07-22,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1994-10-19,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","8","AP","SUPPL",1994-10-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1995-02-15,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","10","AP","SUPPL",1995-02-15,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1995-05-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","11","AP","SUPPL",1995-05-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1996-04-01,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","12","AP","SUPPL",1996-04-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1996-04-03,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","13","AP","SUPPL",1996-04-03,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1996-12-13,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","15","AP","SUPPL",1996-12-13,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1997-03-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","17","AP","SUPPL",1997-03-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1997-04-25,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","19","AP","SUPPL",1997-04-25,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1997-08-04,"Efficacy","Yes","AIDS-Related Kaposi's Sarcoma - Second Line","KS","59","NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","22","AP","SUPPL",1997-08-04,"PRIORITY","EFFICACY","59","Paclitaxel (TAXOL®)","NDA020262","Second-line therapy in patients with AIDS-related Kaposi's sarcoma","Application went to ODAC in 1997; supporting documentation can be found on the internet","Two, open-label, non-comparative studies","Response Rate","ORR","Response Rate",0,NA,"ORR: 59% (35/59) (46%, 72%)",NA,"RR: 59%",NA,"RR: 59%",NA,"45.7","71.900000000000006","Modified ACTG","ACTG","10","Yes",0,1,"1",0,0,"Yes","No","1","Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1997-09-18,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","18","AP","SUPPL",1997-09-18,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1997-12-19,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","25","AP","SUPPL",1997-12-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1998-04-01,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","23","AP","SUPPL",1998-04-01,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1998-04-09,"Efficacy",NA,"Taxol plus Cis in Ovarian Cancer","Ovarian Cancer",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","26","AP","SUPPL",1998-04-09,"PRIORITY","EFFICACY",NA,NA,NA,"Use of Taxol as first-line in advanced carcinoma of the ovary with cisplatin",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1998-04-09,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","27","AP","SUPPL",1998-04-09,"PRIORITY","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1998-04-09,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","28","AP","SUPPL",1998-04-09,"PRIORITY","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1998-06-30,"Efficacy",NA,"Use of Taxol as first-line in NSCLC with cisplatin","NSCLC",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","24","AP","SUPPL",1998-06-30,"STANDARD","EFFICACY",NA,NA,NA,"Use of Taxol as first-line in NSCLC with cisplatin",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1998-11-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","29","AP","SUPPL",1998-11-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1999-01-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","14","AP","SUPPL",1999-01-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1999-01-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","16","AP","SUPPL",1999-01-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1999-01-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","21","AP","SUPPL",1999-01-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1999-01-08,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","31","AP","SUPPL",1999-01-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1999-03-19,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","30","AP","SUPPL",1999-03-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1999-10-25,"Efficacy",NA,"Adjuvant Breast Cancer with Doxorubicin","Breast Cancer",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","33","AP","SUPPL",1999-10-25,"PRIORITY","EFFICACY",NA,NA,NA,"Adjuvant Breast Cancer with Doxorubicin",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",1999-12-10,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","32","AP","SUPPL",1999-12-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2000-06-20,"Efficacy",NA,"3 hour infusion of Taxol","Ovarian Cancer",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","36","AP","SUPPL",2000-06-20,"PRIORITY","EFFICACY",NA,NA,NA,"3 hour infusion of Taxol",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2001-04-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","39","AP","SUPPL",2001-04-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2001-05-23,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","40","AP","SUPPL",2001-05-23,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2002-03-04,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","37","AP","SUPPL",2002-03-04,"PRIORITY","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2002-03-04,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","38","AP","SUPPL",2002-03-04,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2002-08-29,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","35","AP","SUPPL",2002-08-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2002-12-12,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","42","AP","SUPPL",2002-12-12,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2003-03-05,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","41","AP","SUPPL",2003-03-05,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2010-08-13,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","48","AP","SUPPL",2010-08-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2011-05-02,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","49","AP","SUPPL",2011-05-02,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2014-06-27,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","50","AP","SUPPL",2014-06-27,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"PACLITAXEL","TAXOL","NULL",2015-03-03,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","6MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","51","AP","SUPPL",2015-03-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Stabilizer","Microtubule Stabilizer","Cytotoxic Agent",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2016-05-18,"Type 1 - New Molecular Entity",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","1","AP","ORIG",2016-05-18,"PRIORITY","TYPE 1",NA,"Atezolizumab (TECENTRIQ®)","BLA761034",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2017-04-17,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","1","AP","SUPPL",2017-04-17,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2018-03-13,"Labeling",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","5","AP","SUPPL",2018-03-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2018-04-30,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","3","AP","SUPPL",2018-04-30,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2018-06-14,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","8","AP","SUPPL",2018-06-14,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2018-06-19,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","10","AP","SUPPL",2018-06-19,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2018-06-26,"Labeling",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","11","AP","SUPPL",2018-06-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2018-07-02,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","12","AP","SUPPL",2018-07-02,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2018-12-06,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","9","AP","SUPPL",2018-12-06,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2019-03-08,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","18","AP","SUPPL",2019-03-08,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2019-03-18,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","19","AP","SUPPL",2019-03-18,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2019-05-06,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","13","AP","SUPPL",2019-05-06,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2019-05-06,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","14","AP","SUPPL",2019-05-06,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2019-12-03,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","21","AP","SUPPL",2019-12-03,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2020-05-18,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","27","AP","SUPPL",2020-05-18,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2020-05-29,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","25","AP","SUPPL",2020-05-29,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2020-07-30,"Efficacy","Yes","Unresectable or metastatic BRAF-mutated melanoma in combination with cobimetinib and vemurafenib","Melanoma","514","ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","28","AP","SUPPL",2020-07-30,"PRIORITY","EFFICACY","514|
(T=256|
C=258)","Atezolizumab (TECENTRIQ®)","BLA761034","Following completion of a 28 day cycle of cobimetinib and vemurafenib, administer TECENTRIQ 840 mg every 2 weeks with cobimetinib 60 mg orally once daily (21 days on /7 days off) and vemurafenib 720 mg orally twice daily.",NA,"One double-blind, randomized (1:1), placebo-controlled, multicenter trial (IMspire150; NCT02908672) conducted in 514 patients","Progression-Free Survival","PFS","Progression-Free Survival",2,"HR","15.1","0.78","HR: 0.78","HR: 0.78",NA,NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"0",1,1,"Yes","No","1","PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy","No",NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2020-09-30,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","29","AP","SUPPL",2020-09-30,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2020-11-10,"Labeling",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","20","AP","SUPPL",2020-11-10,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2020-12-18,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","31","AP","SUPPL",2020-12-18,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2020-12-18,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","32","AP","SUPPL",2020-12-18,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2021-02-17,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","33","AP","SUPPL",2021-02-17,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2021-02-17,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","34","AP","SUPPL",2021-02-17,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2021-02-17,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","35","AP","SUPPL",2021-02-17,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2021-02-17,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","36","AP","SUPPL",2021-02-17,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2021-02-17,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","37","AP","SUPPL",2021-02-17,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2021-02-17,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","38","AP","SUPPL",2021-02-17,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2021-04-13,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","41","AP","SUPPL",2021-04-13,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2021-10-06,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","44","AP","SUPPL",2021-10-06,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2021-10-15,"Efficacy",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","42","AP","SUPPL",2021-10-15,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"ATEZOLIZUMAB","TECENTRIQ","BLA761034",2022-01-21,"Labeling",NA,NA,NA,NA,"ATEZOLIZUMAB","ATEZOLIZUMAB","Genentech, Inc.","Prescription","No","001","INJECTABLE","INJECTION","1200MG/20ML","43","AP","SUPPL",2022-01-21,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PD-L1 Ab","PD-L1 Targeted Antibody","Immunotherapy",NA,NA
"TRIAMCINOLONE ACETONIDE","TRIVARIS","NDA022220",2008-06-16,"Type 3 - New Dosage Form","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL","8MG/0.1ML (8MG/0.1ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","1","AP","ORIG",2008-06-16,"STANDARD","TYPE 3",NA,"Triamcinolone Acetonide (TRIVARIS®)","NDA022220","Mycosis Fungoides","No efficacy estimates",NA,NA,"Missing",NA,NA,NA,"Not listed in PI",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"Yes",0,NA,NA,NA,NA,"Yes","No","1","Glucocorticoid","Glucocorticoid","Glucocorticoid",NA,"Preservative free injection at 80 mg/ml"
"METHOXSALEN","UVADEX","NDA020969",1999-02-25,"Type 3 - New Dosage Form","Yes","Refractory Cutaneous T-Cell Lymphoma","CTCL","51","METHOXSALEN","METHOXSALEN","Therakos, Inc.","Prescription","Yes","001","INJECTABLE","INJECTION","0.02MG/ML","1","AP","ORIG",1999-02-25,"STANDARD","TYPE 3","51","Methoxsalen Solution (UVADEX®)","NDA020969","UVADEX® (methoxsalen) Sterile Solution is indicated for extracorporeal administration with the THERAKOS® UVAR XTS® or THERAKOS® CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of Cutaneous T-Cell Lymphoma (CTCL) that is unresponsive to other forms of treatment","In the overall ITT population the tx'd group's 95% CI did not exclude the null of 25%, though the Prim Endpoint specifically was for 25% reduction in skin score maintained for at least 25 days and the median response duration was 140 days in CTCL3, the study of intereist for this NDA. The solution was thought to be better tolerated than the oral formulation, and that appeared to be a consideration","Single-arm, multi-center, non-blinded trial","Response Rate","ORR","Response Rate",0,"RR diff","37% (15/51) (24, 52) vs.25% of note, current PI says 17/51 (33) so that's what we are going with","12","RR: 33.3%",NA,"RR: 33.3%","25","20.8","47.9","Composite","Composite","6","Yes",0,1,"1",0,0,"Yes","No","1","Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","UVADEX","NDA020969",2013-06-05,"Manufacturing (CMC)",NA,NA,NA,NA,"METHOXSALEN","METHOXSALEN","Therakos, Inc.","Prescription","Yes","001","INJECTABLE","INJECTION","0.02MG/ML","5","AP","SUPPL",2013-06-05,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","UVADEX","NDA020969",2013-11-01,"Labeling",NA,NA,NA,NA,"METHOXSALEN","METHOXSALEN","Therakos, Inc.","Prescription","Yes","001","INJECTABLE","INJECTION","0.02MG/ML","6","AP","SUPPL",2013-11-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","UVADEX","NDA020969",2018-01-09,"Labeling",NA,NA,NA,NA,"METHOXSALEN","METHOXSALEN","Therakos, Inc.","Prescription","Yes","001","INJECTABLE","INJECTION","0.02MG/ML","10","AP","SUPPL",2018-01-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"METHOXSALEN","UVADEX","NDA020969",2021-03-19,"Labeling",NA,NA,NA,NA,"METHOXSALEN","METHOXSALEN","Therakos, Inc.","Prescription","Yes","001","INJECTABLE","INJECTION","0.02MG/ML","14","AP","SUPPL",2021-03-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Phototoxic","Phototoxic Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","VALCHLOR","NDA202317",2013-08-23,"Type 5 - New Formulation or New Manufacturer","Yes","Refractory Stage IA and IB Cutaneous T-Cell Lymphoma","CTCL","242","MECHLORETHAMINE","MECHLORETHAMINE HYDROCHLORIDE","Helsinn Therapeutics (U.S.), Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.016% BASE","1","AP","ORIG",2013-08-23,"STANDARD","TYPE 5","242|
(T=119|
C=123)","Mechlorethamine HCL (VALCHLOR™)","NDA202317","VALCHLOR is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides‐type cutaneous T‐cell lymphoma in patients who have received prior skin‐directed therapy","Comparator arm was aquaphor formulation base; was not called a placebo","VALCHLOR was assessed in a randomized, multicenter, observer‐blind, active‐controlled, non‐inferiority clinical trial of 260 patients with Stage IA, IB, and IIA mycosis fungoides‐type cutaneous T‐cell lymphoma (CTCL) who had received at least one prior skin‐directed therapy.","Response Rate","ORR","Response Rate",0,"RR diff","59.7% (71/119) vs. 48% (59/123) | Response Ratio 1.24 (0.98, 1.58)","12","RR: 60%",NA,"RR: 60%",NA,NA,NA,"Composite (CAILS)","Composite","6","Yes",0,0,"1",0,1,"Yes","No","1","Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,"This was a non-inferiority trial testing two types of solvents (PG vs. Aquaphor); The study 2005-NMMF-201-US demonstrated non-inferiority in CAILS and SWAT response rates ratio for PG arm versus AP arm with lower 95% confidence limit greater than 0.75."
"MECHLORETHAMINE HYDROCHLORIDE","VALCHLOR","NDA202317",2014-07-08,"Manufacturing (CMC)",NA,NA,NA,NA,"MECHLORETHAMINE","MECHLORETHAMINE HYDROCHLORIDE","Helsinn Therapeutics (U.S.), Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.016% BASE","2","AP","SUPPL",2014-07-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","VALCHLOR","NDA202317",2014-07-09,"Labeling",NA,NA,NA,NA,"MECHLORETHAMINE","MECHLORETHAMINE HYDROCHLORIDE","Helsinn Therapeutics (U.S.), Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.016% BASE","1","AP","SUPPL",2014-07-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","VALCHLOR","NDA202317",2014-10-13,"Manufacturing (CMC)",NA,NA,NA,NA,"MECHLORETHAMINE","MECHLORETHAMINE HYDROCHLORIDE","Helsinn Therapeutics (U.S.), Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.016% BASE","3","AP","SUPPL",2014-10-13,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","VALCHLOR","NDA202317",2015-10-29,"Labeling",NA,NA,NA,NA,"MECHLORETHAMINE","MECHLORETHAMINE HYDROCHLORIDE","Helsinn Therapeutics (U.S.), Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.016% BASE","4","AP","SUPPL",2015-10-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","VALCHLOR","NDA202317",2016-04-08,"Manufacturing (CMC)",NA,NA,NA,NA,"MECHLORETHAMINE","MECHLORETHAMINE HYDROCHLORIDE","Helsinn Therapeutics (U.S.), Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.016% BASE","5","AP","SUPPL",2016-04-08,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","VALCHLOR","NDA202317",2016-12-22,"Manufacturing (CMC)",NA,NA,NA,NA,"MECHLORETHAMINE","MECHLORETHAMINE HYDROCHLORIDE","Helsinn Therapeutics (U.S.), Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.016% BASE","6","AP","SUPPL",2016-12-22,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","VALCHLOR","NDA202317",2020-01-13,"Labeling",NA,NA,NA,NA,"MECHLORETHAMINE","MECHLORETHAMINE HYDROCHLORIDE","Helsinn Therapeutics (U.S.), Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.016% BASE","9","AP","SUPPL",2020-01-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"MECHLORETHAMINE HYDROCHLORIDE","VALCHLOR","NDA202317",2020-05-01,"Labeling",NA,NA,NA,NA,"MECHLORETHAMINE","MECHLORETHAMINE HYDROCHLORIDE","Helsinn Therapeutics (U.S.), Inc.","Prescription","Yes","001","GEL","TOPICAL","EQ 0.016% BASE","10","AP","SUPPL",2020-05-01,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Alkylating Agent","Alkylating Agent","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1965-11-25,"Type 1 - New Molecular Entity","Yes","Mycosis Fungoides","CTCL",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","1","AP","ORIG",1965-11-25,"PRIORITY","TYPE 1",NA,"Vinblastine (VELBAN)","NDA012665","Mycosis Fungoides",NA,NA,NA,"Missing",NA,NA,NA,"Not available",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1965-11-25,"Type 1 - New Molecular Entity","Yes","Kaposi's Sarcoma","KS",NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","1_2","AP","ORIG",1965-11-25,"PRIORITY","TYPE 1",NA,"Vinblastine (VELBAN)","NDA012665","KS","Need to exclude from NDA count as the same NDA as CTCL, thus only use once",NA,NA,"Missing",NA,NA,NA,"Not listed in PI",NA,"",NA,NA,NA,NA,NA,NA,NA,NA,"No",NA,NA,NA,NA,NA,"Yes","No","1","Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,"Same NDA as CTCL"
"VINBLASTINE SULFATE","VELBAN","NDA012665",1978-09-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","8","AP","SUPPL",1978-09-25,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1979-01-10,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","9","AP","SUPPL",1979-01-10,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1980-06-20,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","7","AP","SUPPL",1980-06-20,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1981-07-02,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","10","AP","SUPPL",1981-07-02,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1986-01-15,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","12","AP","SUPPL",1986-01-15,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1986-06-30,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","14","AP","SUPPL",1986-06-30,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1986-11-03,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","11","AP","SUPPL",1986-11-03,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1987-01-07,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","15","AP","SUPPL",1987-01-07,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1987-03-19,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","19","AP","SUPPL",1987-03-19,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1987-05-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","18","AP","SUPPL",1987-05-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1987-08-25,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","20","AP","SUPPL",1987-08-25,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1987-10-16,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","16","AP","SUPPL",1987-10-16,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1988-04-18,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","21","AP","SUPPL",1988-04-18,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1989-06-06,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","22","AP","SUPPL",1989-06-06,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1989-06-06,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","23","AP","SUPPL",1989-06-06,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1990-06-18,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","25","AP","SUPPL",1990-06-18,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1990-08-10,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","24","AP","SUPPL",1990-08-10,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1992-07-31,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","27","AP","SUPPL",1992-07-31,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1992-12-16,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","28","AP","SUPPL",1992-12-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1993-09-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","29","AP","SUPPL",1993-09-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1995-07-05,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","30","AP","SUPPL",1995-07-05,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1995-11-06,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","32","AP","SUPPL",1995-11-06,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1996-10-21,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","33","AP","SUPPL",1996-10-21,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1996-12-20,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","31","AP","SUPPL",1996-12-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1997-09-02,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","35","AP","SUPPL",1997-09-02,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",1999-03-04,"Manufacturing (CMC)",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","38","AP","SUPPL",1999-03-04,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",2000-08-24,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","39","AP","SUPPL",2000-08-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",2007-12-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","13","AP","SUPPL",2007-12-07,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",2007-12-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","17","AP","SUPPL",2007-12-07,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",2007-12-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","26","AP","SUPPL",2007-12-07,NA,"LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",2007-12-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","34","AP","SUPPL",2007-12-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",2007-12-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","36","AP","SUPPL",2007-12-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",2007-12-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","37","AP","SUPPL",2007-12-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"VINBLASTINE SULFATE","VELBAN","NDA012665",2007-12-07,"Labeling",NA,NA,NA,NA,"NULL","NULL","NULL","Discontinued","Yes","001","INJECTABLE","INJECTION","10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**","40","AP","SUPPL",2007-12-07,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Microtubule Inhibitor","Microtubule Inhibitor","Cytotoxic Agent",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2011-03-25,"Type 1 - New Molecular Entity","Yes","Unresectable or Metastatic Melanoma","Melanoma","676","IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","1","AP","ORIG",2011-03-25,"PRIORITY","TYPE 1","676|
(I=137|
IGP=403|
GP=136)","Ipilimumab (YERVOY®)","BLA125377","YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older).",NA,"The safety and efficacy of YERVOY were investigated in a randomized (3:1:1), double-blind, double-dummy trial (MDX010-20, NCT00094653) that included 676 randomized patients with unresectable or metastatic melanoma previously treated with one or more of the following: aldesleukin, dacarbazine, temozolomide, fotemustine, or carboplatin","Overall Survival","OS","Overall Survival",3,"HR","10 vs. 6 mo","0.66","HR: 0.66","HR: 0.66",NA,NA,NA,NA,"Investigator Assessment","Clinical","1","Yes",1,0,"0",0,1,"Yes","No","1","CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2011-07-28,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","8","AP","SUPPL",2011-07-28,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2012-02-16,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","16","AP","SUPPL",2012-02-16,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2012-10-26,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","33","AP","SUPPL",2012-10-26,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2013-05-22,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","44","AP","SUPPL",2013-05-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2013-12-05,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","55","AP","SUPPL",2013-12-05,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2015-03-16,"REMS",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","71","AP","SUPPL",2015-03-16,"N/A","REMS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2015-03-19,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","72","AP","SUPPL",2015-03-19,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2015-08-17,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","74","AP","SUPPL",2015-08-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2015-10-28,"Efficacy","Yes","Adjuvant Melanoma","Melanoma","951","IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","73","AP","SUPPL",2015-10-28,"STANDARD","EFFICACY","951|
(T=475|
C=476)","Ipilimumab (YERVOY®)","BLA125377","YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy","Unable to validate ODAC, Fast Track or Breakthrough (though friends of cancer has no BTD for ipi form melanoma)","A randomized (1:1), double-blind, placebo-controlled trial in patients with resected Stage IIIA (>1 mm nodal involvement), IIIB, and IIIC (with no in-transit metastases) histologically confirmed cutaneous melanoma","Relapse-Free Survival (Prim End)
DMFS/OS(Sec End)","RFS","Relapse-Free Survival",1,"HR","26 vs. 17 mo","0.75","HR: 0.75","HR: 0.75",NA,NA,NA,NA,"Investigator Assessment","Clinical","4","Yes",0,0,"0",1,1,"Yes","No","1","CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2017-03-03,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","84","AP","SUPPL",2017-03-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2017-07-21,"Efficacy","Yes","Unresectable or Metastatic Melanoma - patients 12 years and older","Melanoma","45","IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","87","AP","SUPPL",2017-07-21,"STANDARD","EFFICACY","45","Ipilimumab (YERVOY®)","BLA125377","This Prior Approval supplemental biologics application provides for an expansion of  the indication  for the treatment of unresectable or metastatic melanoma to include pediatric patients (12 years and older)
","Unable to verify the number in the popPK study (though corroborated by ASCO post article); on 09-16-2020 DMM changed Tool of PopPK to PK b/c I'm not sure there is a difference and I don't want to draw a distinction bt PK and PopPK.",NA,"PK","PK","Pharmacokinetic Analysis",6,NA,NA,NA,"",NA,NA,NA,NA,NA,"PK","PK","12","Yes",0,1,"0",0,0,"Yes","No","1","CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2017-10-20,"Efficacy",NA,"Adjuvant Melanoma - fulfillment of PMC","Melanoma",NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","86","AP","SUPPL",2017-10-20,"STANDARD","EFFICACY",NA,"Ipilimumab (YERVOY®)","BLA125377","Label update to  include overall survival data obtained from Study CA184029 to fulfill postmarketing commitment (PMC) 2972-2","Fulfillment of PMC, so I'm not including Ns","A randomized (1:1), double-blind, placebo-controlled trial","Overall Survival","OS","Overall Survival",3,NA,NA,NA,"",NA,NA,NA,NA,NA,"RECIST","RECIST","3","Yes",0,0,"0",1,1,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2017-12-13,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","91","AP","SUPPL",2017-12-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2018-02-08,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","93","AP","SUPPL",2018-02-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2018-04-16,"Efficacy",NA,"A new indication for the use of ipilimumab, in combination with nivolumab, for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).","RCC",NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","94","AP","SUPPL",2018-04-16,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2018-07-10,"Efficacy",NA,"A new indication for YERVOY, in combination with nivolumab, is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer","Colon Cancer",NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","96","AP","SUPPL",2018-07-10,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2019-05-08,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","102","AP","SUPPL",2019-05-08,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2019-09-20,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","104","AP","SUPPL",2019-09-20,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2020-03-10,"Efficacy",NA,"A new indication for Yervoy in combination with nivolumab, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib","HCC",NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","108","AP","SUPPL",2020-03-10,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2020-05-15,"Efficacy",NA,"A new indication for Yervoy in combination with nivolumab, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test with no EGFR or ALK genomic tumor aberrations","NSCLC",NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","109","AP","SUPPL",2020-05-15,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2020-05-26,"Efficacy",NA,"A new indication for the use of ipilimumab, in combination with nivolumab and 2 cycles of platinum-based chemotherapy, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations","NSCLC",NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","110","AP","SUPPL",2020-05-26,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2020-06-29,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","106","AP","SUPPL",2020-06-29,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2020-08-13,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","111","AP","SUPPL",2020-08-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2020-09-18,"Efficacy",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","112","AP","SUPPL",2020-09-18,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2020-10-02,"Efficacy",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","115","AP","SUPPL",2020-10-02,"PRIORITY","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2020-11-13,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","119","AP","SUPPL",2020-11-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2021-05-25,"Efficacy",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","121","AP","SUPPL",2021-05-25,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2022-02-25,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","126","AP","SUPPL",2022-02-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2022-02-25,"Labeling",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","127","AP","SUPPL",2022-02-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2022-05-11,"Efficacy",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","124","AP","SUPPL",2022-05-11,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"IPILIMUMAB","YERVOY","BLA125377",2022-05-27,"Efficacy",NA,NA,NA,NA,"IPILIMUMAB","IPILIMUMAB","E.R. Squibb & Sons, L.L.C.","Prescription","No","001","INJECTABLE","INJECTION","3MG","122","AP","SUPPL",2022-05-27,"STANDARD","EFFICACY",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CTLA-4 Ab","CTLA-4 Targeted Antibody","Immunotherapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2011-08-17,"Type 1 - New Molecular Entity","Yes","Unresectable or Metastatic Melanoma","Melanoma","675","VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","1","AP","ORIG",2011-08-17,"PRIORITY","TYPE 1","675|
(T=337|
C=338)","Vemurafenib (ZELBORAF®)","NDA202429","ZELBORAF™ is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test.","On 09-16-2020 DMM changed the tool for this trial from Clinical/RECIST to just RECIST","The efficacy and safety of ZELBORAF in patients with treatment naive, BRAFV600E mutation-positive unresectable or metastatic melanoma as detected by the cobas® 4800 BRAF V600 Mutation Test were assessed in an international, randomized, open-label trial","Overall Survival
PFS (co-Prim)","Coprimary","Overall Survival & Progression-Free Survival",4,"HR","OS: NR vs. 7.9 mo |      PFS: 5.3 vs. 1.6 mo","0.44 (OS)| 0.26 (PFS)","HR: 0.44 (OS)| 
HR: 0.26 (PFS)","HR: 0.44 (OS)| 
HR: 0.26 (PFS)",NA,NA,NA,NA,"Clinical Assessment/RECIST","RECIST","3","Yes",1,0,"0",0,1,"Yes","No","1","Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2013-07-03,"Labeling",NA,NA,NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","2","AP","SUPPL",2013-07-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2013-07-03,"Labeling",NA,NA,NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","3","AP","SUPPL",2013-07-03,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2014-02-06,"Labeling",NA,NA,NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","5","AP","SUPPL",2014-02-06,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2014-03-19,"Efficacy",NA,"Update label on various fronts; not new indication or usage",NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","4","AP","SUPPL",2014-03-19,"STANDARD","EFFICACY",NA,NA,NA,"This Prior Approval supplemental new drug application proposes to revise the package insert to: update the Trial 1 median overall survival results in the CLINICAL STUDIES section; update the WARNINGS AND PRECAUTIONS, QT Prolongation section to monitor for QT prolongation prior to and following treatment initiation or after dose modification; relocate the Cardiac Electrophysiology subsection to the CLINICAL PHARMACOLOGY Pharmacodynamics section; include information regarding hypersensitivity, severe dermatologic reactions, ophthalmologic reactions, hepatotoxicity and embryo-fetal toxicity in the PATIENT COUNSELING INFORMATION section; and to update the Medication Guide.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2014-09-23,"Manufacturing (CMC)",NA,NA,NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","7","AP","SUPPL",2014-09-23,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2014-11-25,"Labeling",NA,NA,NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","6","AP","SUPPL",2014-11-25,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2015-08-11,"Labeling",NA,NA,NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","8","AP","SUPPL",2015-08-11,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2016-05-09,"Labeling",NA,NA,NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","10","AP","SUPPL",2016-05-09,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2016-08-31,"Efficacy",NA,"To include data on efficacy in patients with brain metastases","Melanoma","146","VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","9","AP","SUPPL",2016-08-31,"STANDARD","EFFICACY","146","Vemurafenib (ZELBORAF®)","NDA202429","To include information from Study MO25743 on the anti-tumor activity of vemurafenib in the treatment of patients with BRAF V600E mutation-positive melanoma with brain
metastases",NA,"The activity of ZELBORAF for the treatment of BRAF V600E mutation-positive melanoma, metastatic to the brain was evaluated in an open-label, multicenter, single-arm, two cohort trial (Trial 3).","Overall Response Rate","ORR","Overall Response Rate",0,NA,NA,NA,"",NA,NA,NA,NA,NA,"RECIST","RECIST","3","Yes",0,1,"1",0,0,NA,"No",NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2017-04-17,"Labeling",NA,NA,NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","12","AP","SUPPL",2017-04-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2017-09-13,"Efficacy",NA,"This Prior Approval supplemental new drug application proposes to update the Pediatric Use (8.4) section of the package insert (PI).",NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","14","AP","SUPPL",2017-09-13,"STANDARD","EFFICACY",NA,NA,NA,"This Prior Approval supplemental new drug application proposes to update the Pediatric Use (8.4) section of the package insert (PI).",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2017-09-13,"Labeling",NA,NA,NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","15","AP","SUPPL",2017-09-13,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2017-11-06,"Efficacy",NA,"A New Indication for Erdheim-Chester Disease","Erdheim-Chester Disease",NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","16","AP","SUPPL",2017-11-06,"PRIORITY","EFFICACY",NA,NA,NA,"A new drug application provides for the use of Zelboraf® for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VEMURAFENIB","ZELBORAF","NDA202429",2020-05-18,"Labeling",NA,NA,NA,NA,"VEMURAFENIB","VEMURAFENIB","Genentech, Inc.","Prescription","Yes","001","TABLET","ORAL","240MG","19","AP","SUPPL",2020-05-18,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kinase Inhibitor","Kinase Inhibitor","Targeted Therapy",NA,NA
"VORINOSTAT","ZOLINZA","NDA021991",2006-10-06,"Type 1 - New Molecular Entity",NA,NA,NA,NA,"VORINOSTAT","VORINOSTAT","Merck Sharp & Dohme LLC","Prescription","Yes","001","CAPSULE","ORAL","100MG","1","AP","ORIG",2006-10-06,"PRIORITY","TYPE 1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","Targeted Therapy",NA,NA
"VORINOSTAT","ZOLINZA","NDA021991",2008-07-22,"Labeling",NA,NA,NA,NA,"VORINOSTAT","VORINOSTAT","Merck Sharp & Dohme LLC","Prescription","Yes","001","CAPSULE","ORAL","100MG","1","AP","SUPPL",2008-07-22,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","Targeted Therapy",NA,NA
"VORINOSTAT","ZOLINZA","NDA021991",2009-09-23,"Efficacy",NA,"Labeling changes concerning QTc effects.",NA,NA,"VORINOSTAT","VORINOSTAT","Merck Sharp & Dohme LLC","Prescription","Yes","001","CAPSULE","ORAL","100MG","4","AP","SUPPL",2009-09-23,"STANDARD","EFFICACY",NA,NA,NA,"This supplemental new drug application provides for labeling changes concerning QTc effects.",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","Targeted Therapy",NA,NA
"VORINOSTAT","ZOLINZA","NDA021991",2011-06-10,"Labeling",NA,NA,NA,NA,"VORINOSTAT","VORINOSTAT","Merck Sharp & Dohme LLC","Prescription","Yes","001","CAPSULE","ORAL","100MG","5","AP","SUPPL",2011-06-10,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","Targeted Therapy",NA,NA
"VORINOSTAT","ZOLINZA","NDA021991",2011-11-14,"Labeling",NA,NA,NA,NA,"VORINOSTAT","VORINOSTAT","Merck Sharp & Dohme LLC","Prescription","Yes","001","CAPSULE","ORAL","100MG","2","AP","SUPPL",2011-11-14,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","Targeted Therapy",NA,NA
"VORINOSTAT","ZOLINZA","NDA021991",2013-04-24,"Labeling",NA,NA,NA,NA,"VORINOSTAT","VORINOSTAT","Merck Sharp & Dohme LLC","Prescription","Yes","001","CAPSULE","ORAL","100MG","6","AP","SUPPL",2013-04-24,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","Targeted Therapy",NA,NA
"VORINOSTAT","ZOLINZA","NDA021991",2015-10-07,"Manufacturing (CMC)",NA,NA,NA,NA,"VORINOSTAT","VORINOSTAT","Merck Sharp & Dohme LLC","Prescription","Yes","001","CAPSULE","ORAL","100MG","7","AP","SUPPL",2015-10-07,"PRIORITY","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","Targeted Therapy",NA,NA
"VORINOSTAT","ZOLINZA","NDA021991",2015-12-17,"Labeling",NA,NA,NA,NA,"VORINOSTAT","VORINOSTAT","Merck Sharp & Dohme LLC","Prescription","Yes","001","CAPSULE","ORAL","100MG","8","AP","SUPPL",2015-12-17,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","Targeted Therapy",NA,NA
"VORINOSTAT","ZOLINZA","NDA021991",2018-12-11,"Labeling",NA,NA,NA,NA,"VORINOSTAT","VORINOSTAT","Merck Sharp & Dohme LLC","Prescription","Yes","001","CAPSULE","ORAL","100MG","9","AP","SUPPL",2018-12-11,"STANDARD","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HDAC Inhibitor","HDAC Inhibitor","Targeted Therapy",NA,NA
"IMIQUIMOD","ZYCLARA","NDA022483",2010-03-25,"Type 5 - New Formulation or New Manufacturer","Yes","Use of 3.75% form for Actinic Keratoses of the Full Face or Balding Scalp","AK","319","IMIQUIMOD","IMIQUIMOD","c(""Bausch Health US, LLC"", ""Oceanside Pharmacueticals"", ""Teva Pharmaceuticals USA, Inc."")","Prescription","Yes","001","CREAM","TOPICAL","2.5%, 3.75%","1","AP","ORIG",2010-03-25,"STANDARD","TYPE 5","319|
(T=160|
C=159)","Imiquimod 3.75% Cream (ZYCLARA®)","NDA022483","ZYCLARA Cream is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the full face or balding scalp in immunocompetent adults.",NA,"In two double-blind, randomized, vehicle-controlled clinical studies, 319 subjects with AK were treated with ZYCLARA Cream, or vehicle cream","Complete Clearance Rate at 8 weeks post treatment","CCR","Complete Clearance Rate",5,NA,"Study 1: 25.9% (21/81) vs. 2.5% (2/80)
Study  2: 45.6% (36/79) vs. 10.1% (8/79)",NA,"CCR: 25.9% (Study 1)|
CCR: 45.6% (Study 2)",NA,"CCR: 25.9% (Study 1)|
CCR: 45.6% (Study 2)",NA,NA,NA,"Investigator Assessment of face or balding scalp","Clinical","1","Yes",0,0,"1",1,1,"Yes","No","1","TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ZYCLARA","NDA022483",2011-03-24,"Efficacy",NA,"New use in genital warts",NA,NA,"IMIQUIMOD","IMIQUIMOD","c(""Bausch Health US, LLC"", ""Oceanside Pharmacueticals"", ""Teva Pharmaceuticals USA, Inc."")","Prescription","Yes","001","CREAM","TOPICAL","2.5%, 3.75%","1","AP","SUPPL",2011-03-24,"STANDARD","EFFICACY",NA,NA,NA,"New drug application provides for the use of Zyclara (imiquimod) Cream, 3.75% for the treatment of external genital and perianal warts/condyloma acuminata in patients 12 years or older",NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ZYCLARA","NDA022483",2011-07-15,"Efficacy","Yes","Use of 2.5% cream for AKs on face and scalp","AK","319","IMIQUIMOD","IMIQUIMOD","c(""Bausch Health US, LLC"", ""Oceanside Pharmacueticals"", ""Teva Pharmaceuticals USA, Inc."")","Prescription","Yes","001","CREAM","TOPICAL","2.5%, 3.75%","3","AP","SUPPL",2011-07-15,"STANDARD","EFFICACY","319|
(T=160|
C=159)","Imiquimod 2.5% Cream (ZYCLARA®)","NDA022483","2.5% imiquimod cream for the topical treatment of clinically typical visible or palpable actinic keratoses of the face or balding scalp in immunocompetent adults","The initial application included both the 3.75% and the 2.5% dosage forms. The sponsor submitted for an initial NDA with the 3.75% cream. And followed up with a supplement for 2.5%. The initial NDA had 319 patients. The updated label has 479 patients. Each submission compared against the patients who received a vehicle. Since there are two different NDA numbers and dates of approval, we've used 319 and 160 respectively so that the total number patients in the studies would be 479, which is reflected in the label.","Vehicle-controlled trial","Complete Clearance Rate","CCR","Complete Clearance Rate",5,NA,"Study 1: 23% (19/81) vs. 2.5% (2/80)
Study  2: 38% (3630/79) vs. 10.1% (8/79)",NA,"CCR: 23% (Study 1)|
CCR: 38% (Study 2)",NA,"CCR: 23% (Study 1)|
CCR: 38% (Study 2)",NA,NA,NA,"Investigator Assessment of face or balding scalp","Clinical","1","Yes",0,0,"1",1,1,"Yes","No",NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ZYCLARA","NDA022483",2011-09-29,"Labeling",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","c(""Bausch Health US, LLC"", ""Oceanside Pharmacueticals"", ""Teva Pharmaceuticals USA, Inc."")","Prescription","Yes","001","CREAM","TOPICAL","2.5%, 3.75%","2","AP","SUPPL",2011-09-29,"UNKNOWN","LABELING",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ZYCLARA","NDA022483",2012-02-14,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","c(""Bausch Health US, LLC"", ""Oceanside Pharmacueticals"", ""Teva Pharmaceuticals USA, Inc."")","Prescription","Yes","001","CREAM","TOPICAL","2.5%, 3.75%","6","AP","SUPPL",2012-02-14,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
"IMIQUIMOD","ZYCLARA","NDA022483",2014-11-24,"Manufacturing (CMC)",NA,NA,NA,NA,"IMIQUIMOD","IMIQUIMOD","c(""Bausch Health US, LLC"", ""Oceanside Pharmacueticals"", ""Teva Pharmaceuticals USA, Inc."")","Prescription","Yes","001","CREAM","TOPICAL","2.5%, 3.75%","7","AP","SUPPL",2014-11-24,"STANDARD","MANUF (CMC)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"TLR Agonist","TLR Agonist","Immunotherapy",NA,NA
